0001048477-20-000029.txt : 20201106 0001048477-20-000029.hdr.sgml : 20201106 20201106125355 ACCESSION NUMBER: 0001048477-20-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 201293435 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 10-Q 1 bmrn-20200930.htm 10-Q bmrn-20200930
false2020Q30001048477--12-31P1YP1Y2.5us-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:OtherAssetsNoncurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:AccountsPayableAndAccruedLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrent00010484772020-01-012020-09-30xbrli:shares00010484772020-10-23iso4217:USD00010484772020-09-3000010484772019-12-31iso4217:USDxbrli:shares0001048477us-gaap:ProductMember2020-07-012020-09-300001048477us-gaap:ProductMember2019-07-012019-09-300001048477us-gaap:ProductMember2020-01-012020-09-300001048477us-gaap:ProductMember2019-01-012019-09-300001048477bmrn:RoyaltyAndOtherMember2020-07-012020-09-300001048477bmrn:RoyaltyAndOtherMember2019-07-012019-09-300001048477bmrn:RoyaltyAndOtherMember2020-01-012020-09-300001048477bmrn:RoyaltyAndOtherMember2019-01-012019-09-3000010484772020-07-012020-09-3000010484772019-07-012019-09-3000010484772019-01-012019-09-300001048477us-gaap:CommonStockMember2020-06-300001048477us-gaap:CommonStockMember2019-06-300001048477us-gaap:CommonStockMember2019-12-310001048477us-gaap:CommonStockMember2018-12-310001048477us-gaap:CommonStockMember2020-07-012020-09-300001048477us-gaap:CommonStockMember2019-07-012019-09-300001048477us-gaap:CommonStockMember2020-01-012020-09-300001048477us-gaap:CommonStockMember2019-01-012019-09-300001048477us-gaap:CommonStockMember2020-09-300001048477us-gaap:CommonStockMember2019-09-3000010484772020-06-3000010484772019-06-3000010484772018-12-310001048477us-gaap:AdditionalPaidInCapitalMember2020-06-300001048477us-gaap:AdditionalPaidInCapitalMember2019-06-300001048477us-gaap:AdditionalPaidInCapitalMember2019-12-310001048477us-gaap:AdditionalPaidInCapitalMember2018-12-310001048477us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001048477us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001048477us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001048477us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300001048477us-gaap:AdditionalPaidInCapitalMember2020-09-300001048477us-gaap:AdditionalPaidInCapitalMember2019-09-300001048477us-gaap:TreasuryStockMember2020-06-300001048477us-gaap:TreasuryStockMember2019-06-300001048477us-gaap:TreasuryStockMember2019-12-310001048477us-gaap:TreasuryStockMember2018-12-310001048477us-gaap:TreasuryStockMember2020-07-012020-09-300001048477us-gaap:TreasuryStockMember2019-07-012019-09-300001048477us-gaap:TreasuryStockMember2020-01-012020-09-300001048477us-gaap:TreasuryStockMember2019-01-012019-09-300001048477us-gaap:TreasuryStockMember2020-09-300001048477us-gaap:TreasuryStockMember2019-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2018-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-07-012020-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-07-012019-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-01-012020-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-01-012019-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2020-09-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2019-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001048477us-gaap:RetainedEarningsMember2020-06-300001048477us-gaap:RetainedEarningsMember2019-06-300001048477us-gaap:RetainedEarningsMember2019-12-310001048477us-gaap:RetainedEarningsMember2018-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-06-300001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-06-300001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001048477srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310001048477us-gaap:RetainedEarningsMember2020-07-012020-09-300001048477us-gaap:RetainedEarningsMember2019-07-012019-09-300001048477us-gaap:RetainedEarningsMember2020-01-012020-09-300001048477us-gaap:RetainedEarningsMember2019-01-012019-09-300001048477us-gaap:RetainedEarningsMember2020-09-300001048477us-gaap:RetainedEarningsMember2019-09-3000010484772019-09-300001048477us-gaap:FairValueInputsLevel1Memberus-gaap:CashMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberbmrn:ForeignGovernmentAndOtherDebtSecuritiesMember2020-09-300001048477us-gaap:FairValueInputsLevel2Member2020-09-300001048477us-gaap:FairValueInputsLevel1Memberus-gaap:CashMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberbmrn:ForeignGovernmentAndOtherDebtSecuritiesMember2019-12-310001048477us-gaap:FairValueInputsLevel2Member2019-12-310001048477srt:MaximumMember2020-01-012020-09-300001048477srt:MaximumMember2019-01-012019-12-310001048477srt:MinimumMember2019-01-012019-12-310001048477srt:MinimumMember2020-01-012020-09-30bmrn:investment0001048477us-gaap:FairValueMeasurementsRecurringMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:StrategicInvestmentMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:StrategicInvestmentMember2019-12-310001048477bmrn:FirdapseMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-310001048477bmrn:FirdapseMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-03-310001048477bmrn:FirdapseMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-03-3100010484772019-04-012019-06-300001048477us-gaap:BuildingAndBuildingImprovementsMember2020-09-300001048477us-gaap:BuildingAndBuildingImprovementsMember2019-12-310001048477us-gaap:EquipmentMember2020-09-300001048477us-gaap:EquipmentMember2019-12-310001048477us-gaap:ComputerEquipmentMember2020-09-300001048477us-gaap:ComputerEquipmentMember2019-12-310001048477us-gaap:LeaseholdImprovementsMember2020-09-300001048477us-gaap:LeaseholdImprovementsMember2019-12-310001048477us-gaap:FurnitureAndFixturesMember2020-09-300001048477us-gaap:FurnitureAndFixturesMember2019-12-310001048477us-gaap:LandImprovementsMember2020-09-300001048477us-gaap:LandImprovementsMember2019-12-310001048477us-gaap:LandMember2020-09-300001048477us-gaap:LandMember2019-12-310001048477us-gaap:ConstructionInProgressMember2020-09-300001048477us-gaap:ConstructionInProgressMember2019-12-310001048477bmrn:PreLaunchValoctocogeneRoxaparvovecMember2020-09-300001048477bmrn:PreLaunchValoctocogeneRoxaparvovecMember2020-07-012020-09-300001048477bmrn:PreLaunchValoctocogeneRoxaparvovecMember2020-01-012020-09-300001048477us-gaap:FairValueInputsLevel1Member2020-09-300001048477us-gaap:FairValueInputsLevel1Member2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2020-09-300001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:RestrictedInvestmentsMember2020-09-300001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:RestrictedInvestmentsMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:RestrictedInvestmentsMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2020-09-300001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:ContingentConsiderationMember2020-09-300001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:ContingentConsiderationMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:ContingentConsiderationMember2020-09-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:RestrictedInvestmentsMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:RestrictedInvestmentsMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:RestrictedInvestmentsMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanLiabilityMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbmrn:ContingentConsiderationMember2019-12-310001048477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbmrn:ContingentConsiderationMember2019-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:ContingentConsiderationMember2019-12-310001048477bmrn:ContingentPaymentMember2019-12-310001048477bmrn:ContingentPaymentMember2020-01-012020-09-300001048477bmrn:ContingentPaymentMember2020-09-300001048477us-gaap:NondesignatedMember2020-01-012020-09-300001048477us-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300001048477us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:ShortMember2020-09-300001048477us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:ShortMember2019-12-310001048477us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:LongMember2020-09-300001048477us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:LongMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2019-12-310001048477us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-09-300001048477us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:OperatingExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:OperatingExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-07-012019-09-300001048477us-gaap:NondesignatedMember2020-07-012020-09-300001048477us-gaap:NondesignatedMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:OperatingExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:OperatingExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-09-300001048477us-gaap:NondesignatedMember2019-01-012019-09-300001048477us-gaap:OperatingExpenseMember2020-07-012020-09-300001048477us-gaap:OperatingExpenseMember2019-07-012019-09-300001048477us-gaap:OperatingExpenseMember2020-01-012020-09-300001048477us-gaap:OperatingExpenseMember2019-01-012019-09-30xbrli:purebmrn:lease0001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member2020-09-300001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member2019-12-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2019-12-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2020-09-300001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2019-12-310001048477bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2020-09-300001048477us-gaap:SubsequentEventMemberbmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember2020-10-152020-10-150001048477us-gaap:SubsequentEventMemberbmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMemberus-gaap:SeniorSubordinatedNotesMember2020-10-15utr:D0001048477us-gaap:ConvertibleDebtMember2020-07-012020-09-300001048477us-gaap:ConvertibleDebtMember2019-07-012019-09-300001048477us-gaap:ConvertibleDebtMember2020-01-012020-09-300001048477us-gaap:ConvertibleDebtMember2019-01-012019-09-300001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Memberus-gaap:SeniorSubordinatedNotesMember2020-05-310001048477bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Memberus-gaap:SeniorSubordinatedNotesMember2020-05-012020-05-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2018-10-310001048477us-gaap:LondonInterbankOfferedRateLIBORMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MinimumMember2018-10-012018-10-310001048477us-gaap:LondonInterbankOfferedRateLIBORMemberbmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MaximumMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MinimumMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMembersrt:MaximumMember2018-10-012018-10-310001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2020-09-300001048477bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember2019-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300001048477bmrn:AccumulatedGainLossFromOtherMember2020-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012020-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2020-07-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-300001048477bmrn:AccumulatedGainLossFromOtherMember2019-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012019-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2019-07-012019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2019-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2019-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2020-01-012020-09-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310001048477bmrn:AccumulatedGainLossFromOtherMember2018-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-09-300001048477bmrn:AccumulatedGainLossFromOtherMember2019-01-012019-09-30bmrn:Segment0001048477country:US2020-07-012020-09-300001048477country:US2019-07-012019-09-300001048477country:US2020-01-012020-09-300001048477country:US2019-01-012019-09-300001048477srt:EuropeMember2020-07-012020-09-300001048477srt:EuropeMember2019-07-012019-09-300001048477srt:EuropeMember2020-01-012020-09-300001048477srt:EuropeMember2019-01-012019-09-300001048477srt:LatinAmericaMember2020-07-012020-09-300001048477srt:LatinAmericaMember2019-07-012019-09-300001048477srt:LatinAmericaMember2020-01-012020-09-300001048477srt:LatinAmericaMember2019-01-012019-09-300001048477bmrn:RestOfWorldMember2020-07-012020-09-300001048477bmrn:RestOfWorldMember2019-07-012019-09-300001048477bmrn:RestOfWorldMember2020-01-012020-09-300001048477bmrn:RestOfWorldMember2019-01-012019-09-300001048477bmrn:ProductFourMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-07-012020-09-300001048477bmrn:ProductFourMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-07-012019-09-300001048477bmrn:ProductFourMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-09-300001048477bmrn:ProductFourMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2020-07-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2019-07-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2020-01-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductThreeMember2019-01-012019-09-300001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-07-012020-09-300001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-07-012019-09-300001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-09-300001048477bmrn:ProductTwoMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSevenMember2020-07-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSevenMember2019-07-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSevenMember2020-01-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductSevenMember2019-01-012019-09-300001048477bmrn:ProductSixMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-07-012020-09-300001048477bmrn:ProductSixMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-07-012019-09-300001048477bmrn:ProductSixMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-09-300001048477bmrn:ProductSixMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-09-300001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-07-012020-09-300001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-07-012019-09-300001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-09-300001048477bmrn:ProductFiveMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-09-300001048477us-gaap:ProductMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-07-012020-09-300001048477us-gaap:ProductMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-07-012019-09-300001048477us-gaap:ProductMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-09-300001048477us-gaap:ProductMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-09-300001048477bmrn:ProductOneMemberus-gaap:SalesChannelThroughIntermediaryMember2020-07-012020-09-300001048477bmrn:ProductOneMemberus-gaap:SalesChannelThroughIntermediaryMember2019-07-012019-09-300001048477bmrn:ProductOneMemberus-gaap:SalesChannelThroughIntermediaryMember2020-01-012020-09-300001048477bmrn:ProductOneMemberus-gaap:SalesChannelThroughIntermediaryMember2019-01-012019-09-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-07-012020-09-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-07-012019-09-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-09-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-09-300001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-07-012020-09-300001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-07-012019-09-300001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-09-300001048477srt:EuropeMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:LatinAmericaMemberbmrn:ProductsExcludingProductOneMember2020-07-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:LatinAmericaMemberbmrn:ProductsExcludingProductOneMember2019-07-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:LatinAmericaMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:LatinAmericaMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-09-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-07-012020-09-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-07-012019-09-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-09-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-07-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-07-012019-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2020-01-012020-09-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingProductOneMember2019-01-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerFourMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerFourMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerFourMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerFourMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001048477us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001048477bmrn:CustomerOneMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-01-012020-09-300001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMemberus-gaap:AccountsReceivableMember2020-01-012020-09-300001048477bmrn:CustomerOneMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001048477us-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001048477bmrn:CustomersMember2020-09-300001048477bmrn:CustomersMember2019-12-310001048477us-gaap:CostOfSalesMember2020-07-012020-09-300001048477us-gaap:CostOfSalesMember2019-07-012019-09-300001048477us-gaap:CostOfSalesMember2020-01-012020-09-300001048477us-gaap:CostOfSalesMember2019-01-012019-09-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-012020-03-310001048477srt:MinimumMemberbmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-012020-03-310001048477srt:MaximumMemberbmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember2020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMembersrt:MinimumMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMembersrt:MaximumMember2020-03-012020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember2020-03-310001048477bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember2020-03-012020-03-310001048477srt:MinimumMemberbmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember2020-03-012020-03-310001048477srt:MaximumMemberbmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember2020-03-012020-03-310001048477country:IE2020-09-300001048477us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001048477us-gaap:EmployeeStockOptionMember2019-07-012019-09-300001048477us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001048477us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2020-07-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2019-07-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2020-01-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2019-01-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-07-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2019-07-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-01-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember2019-01-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2020-07-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2019-07-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2020-01-012020-09-300001048477bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember2019-01-012019-09-300001048477us-gaap:RestrictedStockMember2020-07-012020-09-300001048477us-gaap:RestrictedStockMember2019-07-012019-09-300001048477us-gaap:RestrictedStockMember2020-01-012020-09-300001048477us-gaap:RestrictedStockMember2019-01-012019-09-300001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2020-07-012020-09-300001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2019-07-012019-09-300001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2020-01-012020-09-300001048477bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember2019-01-012019-09-300001048477us-gaap:StockCompensationPlanMember2020-07-012020-09-300001048477us-gaap:StockCompensationPlanMember2019-07-012019-09-300001048477us-gaap:StockCompensationPlanMember2020-01-012020-09-300001048477us-gaap:StockCompensationPlanMember2019-01-012019-09-300001048477bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember2020-09-300001048477bmrn:EarlyStageDevelopmentProgramMemberbmrn:ThirdPartyMember2020-04-012020-06-300001048477bmrn:ThirdPartyMember2020-01-012020-09-300001048477bmrn:ProgramsNoLongerBeingDevelopedMemberbmrn:ThirdPartyMember2020-01-012020-09-300001048477bmrn:ClinicalAndPostMarketingServicesMember2020-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
______________________________________
Form 10-Q 
______________________________________
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
Or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                      .
Commission File Number: 000-26727
______________________________________ 
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)  
______________________________________
Delaware68-0397820
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
770 Lindaro StreetSan RafaelCalifornia94901
(Address of principal executive offices)(Zip Code)
 
(415) 506-6700
(Registrant’s telephone number including area code)
______________________________________

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001BMRNThe Nasdaq Global Select Market
______________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large Accelerated Filer☒Accelerated Filer☐
Non-accelerated Filer☐Smaller Reporting Company☐
Emerging Growth Company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  ☐    No  ☒
Applicable only to corporate issuers:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 181,529,667 shares of common stock, par value $0.001, outstanding as of October 23, 2020.


BIOMARIN PHARMACEUTICAL INC.
TABLE OF CONTENTS
Page

2
Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to “BioMarin,” the “Company,” “we,” “us,” and “our” refer to BioMarin Pharmaceutical Inc. and, where appropriate, its wholly owned subsidiaries.
BioMarin®, Brineura®, Kuvan®, Naglazyme®, Palynziq® and Vimizim® are our registered trademarks. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this report are the property of their respective owners.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under securities laws. Many of these statements can be identified by the use of terminology such as “believes,” “expects,” “intends,” “anticipates,” “plans,” “may,” “will,” “could,” would,” “projects,” “continues,” “estimates,” “potential,” “opportunity” or the negative versions of these terms and other similar expressions. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “Risk Factors,” in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as information provided elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (the SEC) on February 27, 2020. You should carefully consider that information before you make an investment decision.
You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of the Company’s management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, the Company does not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events.
The discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q.
3

PART I. FINANCIAL INFORMATION
Item 1.    Financial Statements
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30, 2020 and December 31, 2019
(In thousands, except share amounts)
September 30,
2020
December 31,
2019 (1)
ASSETS(unaudited) 
Current assets:
Cash and cash equivalents$1,015,675 $437,446 
Short-term investments489,998 316,361 
Accounts receivable, net411,712 377,404 
Inventory700,847 680,275 
Other current assets120,747 130,657 
Total current assets2,738,979 1,942,143 
Noncurrent assets:
Long-term investments265,122 411,978 
Property, plant and equipment, net1,015,062 1,010,868 
Intangible assets, net427,172 456,580 
Goodwill196,199 197,039 
Deferred tax assets1,396,547 549,422 
Other assets119,009 122,009 
Total assets$6,158,090 $4,690,039 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities$480,403 $570,621 
Short-term convertible debt, net374,290 361,882 
Total current liabilities854,693 932,503 
Noncurrent liabilities:
Long-term convertible debt, net1,074,164 486,238 
Long-term contingent consideration54,103 50,793 
Other long-term liabilities121,237 98,124 
Total liabilities2,104,197 1,567,658 
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 181,492,344 and 179,838,114 shares issued and outstanding, respectively.
181 180 
Additional paid-in capital4,937,791 4,832,707 
Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)
(10,756)(9,961)
Accumulated other comprehensive income10,385 20,164 
Accumulated deficit(883,708)(1,720,709)
Total stockholders’ equity4,053,893 3,122,381 
Total liabilities and stockholders’ equity$6,158,090 $4,690,039 
(1)December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
4

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Three and Nine Months Ended September 30, 2020 and 2019
(In thousands, except per share amounts)
(unaudited)
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
 
2020201920202019
REVENUES:
 
Net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
Royalty and other revenues16,043 10,197 39,522 25,147 
Total revenues476,784 461,097 1,408,338 1,249,605 
OPERATING EXPENSES:
Cost of sales188,793 96,949 398,134 263,567 
Research and development147,053 172,963 471,449 542,195 
Selling, general and administrative179,450 170,112 542,157 493,024 
Intangible asset amortization and contingent consideration17,429 17,063 48,018 57,114 
Gain on sale of nonfinancial assets— — (59,495)(15,000)
Total operating expenses532,725 457,087 1,400,263 1,340,900 
INCOME (LOSS) FROM OPERATIONS(55,941)4,010 8,075 (91,295)
Equity in the loss of BioMarin/Genzyme LLC(921)(551)(1,077)(780)
Interest income4,004 5,340 13,539 17,537 
Interest expense(9,597)(2,937)(24,560)(16,530)
Other income, net1,239 3,960 1,886 6,038 
INCOME (LOSS) BEFORE INCOME TAXES(61,216)9,822 (2,137)(85,030)
Benefit from income taxes(846,019)(45,214)(839,138)(46,158)
NET INCOME (LOSS)$784,803 $55,036 $837,001 $(38,872)
NET INCOME (LOSS) PER SHARE, BASIC$4.33 $0.31 $4.63 $(0.22)
NET INCOME (LOSS) PER SHARE, DILUTED$4.01 $0.30 $4.39 $(0.22)
Weighted average common shares outstanding, basic181,142 179,289 180,592 178,873 
Weighted average common shares outstanding, diluted197,674 185,924 194,959 178,873 
COMPREHENSIVE INCOME (LOSS)$765,138 $74,600 $827,222 $(7,140)
 
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
5

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Three and Nine Months Ended September 30, 2020 and 2019
(In thousands)
(unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
 2020201920202019
Shares of common stock, beginning balances (1)
181,148 179,433 179,838 178,253 
Issuances under equity incentive plans344 171 2,172 1,351 
Repurchase of common stock— — (518)— 
Shares of common stock, ending balances181,492 179,604 181,492 179,604 
Total stockholders' equity, beginning balances (1)
$3,236,679 $2,960,954 $3,122,381 $2,967,940 
Common stock:
Beginning balances (1)
181 179 180 178 
Issuances under equity incentive plans, net of tax— 1 1 2 
Ending balance181 180 181 180 
Additional paid-in capital:
Beginning balance (1)
4,885,637 4,744,316 4,832,707 4,669,926 
Issuances under equity incentive plans, net of tax7,319 (1,294)17,601 (19,183)
Stock-based compensation44,757 40,144 136,688 122,212 
Repurchase of common stock— — (50,000)— 
Common stock held by the NQDC78 (250)795 (692)
Accounting impact of NQDC Plan change— — — 10,653 
Ending balance
4,937,791 4,782,916 4,937,791 4,782,916 
Treasury stock:
Beginning balance (1)
— — — — 
Purchase of treasury stock— — (50,000)— 
Retirement of treasury stock— — 50,000 — 
Ending balance— — — — 
Company common stock held by the NQDC:
Beginning balance (1)
(10,678)(10,211)(9,961)(13,301)
Common stock held by the NQDC(78)250 (795)692 
Accounting impact of NQDC Plan change— — — 2,648 
Ending balance(10,756)(9,961)(10,756)(9,961)
Accumulated other comprehensive income:
Beginning balance (1)
30,050 17,439 20,164 5,271 
Other comprehensive income (loss)(19,665)19,564 (9,779)31,732 
Ending balance10,385 37,003 10,385 37,003 
Accumulated Deficit:
Beginning balance (1)
(1,668,511)(1,790,769)(1,720,709)(1,694,134)
Impact of change in accounting principles— — — (2,727)
Net income (loss)784,803 55,036 837,001 (38,872)
Ending balance(883,708)(1,735,733)(883,708)(1,735,733)
Total stockholders' equity, ending balances
$4,053,893 $3,074,405 $4,053,893 $3,074,405 
(1)The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the years ended December 31, 2019 and 2018, respectively, filed with the SEC on February 27, 2020.
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 
6

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30, 2020 and 2019
(In thousands)
(unaudited)
Nine Months Ended September 30,
20202019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)$837,001 $(38,872)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization77,814 79,510 
Non-cash interest expense14,766 9,395 
 Amortization of premium (accretion of discount) on investments175 (1,897)
Stock-based compensation142,125 121,763 
Gain on sale of nonfinancial assets(59,495)(15,000)
Inventory write-off, net of stock-based compensation75,609 — 
Deferred income taxes(854,199)(59,780)
Unrealized foreign exchange loss9,082 784 
Non-cash changes in the fair value of contingent consideration1,352 5,646 
Other388 (18)
Changes in operating assets and liabilities:
Accounts receivable, net(32,915)(61,803)
Inventory(73,310)(52,571)
Other current assets32,848 (13,259)
Other assets(5,543)(7,112)
Accounts payable and accrued liabilities(76,174)21,747 
Other long-term liabilities9,225 2,386 
Net cash provided by (used in) operating activities98,749 (9,081)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment(83,286)(94,241)
Maturities and sales of investments345,224 635,678 
Purchases of available-for-sale securities(369,942)(528,497)
Proceeds from sale of nonfinancial assets67,159 15,000 
Purchase of intangible assets(14,369)(8,323)
Investment in convertible note(8,709)— 
Other(725)(1,747)
Net cash provided by (used in) investing activities(64,648)17,870 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of awards under equity incentive plans60,268 21,768 
Taxes paid related to net share settlement of equity awards(42,667)(40,951)
Payment of contingent acquisition consideration— (57,508)
Repurchase of common stock(50,000)— 
Proceeds from convertible senior subordinated note offering, net585,752 — 
Principal repayments of financing leases(6,080)(2,025)
Net cash provided by (used in) financing activities547,273 (78,716)
Effect of exchange rate changes on cash(3,145)(835)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS578,229 (70,762)
Cash and cash equivalents:
Beginning of period$437,446 $493,982 
End of period$1,015,675 $423,220 
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for income taxes$4,355 $6,088 
Cash paid for interest$5,615 $5,777 
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets$(13,281)$(5,801)
Increase (decrease) in accounts payable and accrued liabilities related to intangible assets$(3,043)$2,053 
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
7
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

(1) NATURE OF OPERATIONS
BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.

(2) BASIS OF PRESENTATION
The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.
On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - Debt, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2020, as compared to the significant accounting policies disclosed in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

8
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(4) RECENT ACCOUNTING PRONOUNCEMENTS
Except as described in Note 2 – Basis of Presentation, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the nine months ended September 30, 2020, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that the Company believes are of significance or potential significance to the Company.


(5) FINANCIAL INSTRUMENTS
All marketable securities were classified as available-for-sale at September 30, 2020 and December 31, 2019.
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:
September 30, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$378,705 $— $— $378,705 $378,705 $— $— 
Level 2:
Money market instruments557,006 — — 557,006 557,006 — — 
Corporate debt securities435,954 4,558 (14)440,498 — 280,000 160,498 
U.S. government agency securities361,336 2,182 (1)363,517 79,964 199,559 83,994 
Asset-backed securities23,430 129 — 23,559 — 3,639 19,920 
Commercial paper6,800 — — 6,800 — 6,800 — 
Foreign and other549 161 — 710 — — 710 
Subtotal1,385,075 7,030 (15)1,392,090 636,970 489,998 265,122 
Total$1,763,780 $7,030 $(15)$1,770,795 $1,015,675 $489,998 $265,122 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments173,100 — — 173,100 173,100 — — 
Corporate debt securities518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other549 145 (1)693 — — 693 
Subtotal901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)    The Company’s short-term marketable securities mature in one year or less.
9
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(2)    The Company’s long-term marketable securities mature between one and five years.
As of September 30, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.
The Company has three investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of September 30, 2020 and December 31, 2019, the fair value of the Company’s strategic investments was $8.0 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Condensed Consolidated Balance Sheets.

(6) GOODWILL AND INTANGIBLE ASSETS
Intangible assets consisted of the following:
September 30,
2020		December 31,
2019
Intangible assets:
Finite-lived intangible assets$638,468 $652,734 
Accumulated amortization(211,296)(196,154)
Net carrying value$427,172 $456,580 
In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. Additionally, the Company recognized a $0.8 million reduction to goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million, as a result of the sale of Firdapse.
During the second quarter of 2019, the Company recorded $15.0 million of gain on sale of intangible assets, reported in Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Comprehensive Income (Loss), due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.

10
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(7) PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, net consisted of the following: 
September 30,
2020		December 31,
2019
Building and improvements$756,479 $725,906 
Manufacturing and laboratory equipment402,357 366,951 
Computer hardware and software187,722 167,554 
Land90,418 90,418 
Leasehold improvements52,479 51,324 
Furniture and equipment39,360 38,569 
Land improvements7,349 7,349 
Construction-in-progress92,581 111,897 
1,628,745 1,559,968 
Accumulated depreciation(613,683)(549,100)
Total property, plant and equipment, net$1,015,062 $1,010,868 
The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.

Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Depreciation expense$22,187 $24,238 $65,749 $67,206 
Depreciation capitalized into inventory$10,883 $9,807 $34,053 $24,894 


11
BIOMARIN PHARMACEUTICAL INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(8) SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventory consisted of the following:
September 30,
2020		December 31,
2019
Raw materials$73,857 $74,442 
Work-in-process296,685 349,978 
Finished goods330,305 255,855 
Total inventory$700,847 $680,275 
Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If the marketing application is rejected, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed to Research and Development (R&D).
In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requested additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $81.2 million to Cost of Sales in the three and nine months ended September 30, 2020.
Accounts Payable and Accrued Liabilities consisted of the following:
September 30,
2020		December 31,
2019
Accounts payable and accrued operating expenses$218,021 $240,981 
Accrued compensation expense137,415 192,467 
Accrued rebates payable65,999 57,163 
Accrued royalties payable20,426 30,797 
Lease liabilities10,930 10,700 
Value added taxes payable7,222 8,395 
Forward foreign currency exchange contracts7,774 10,448 
Deferred revenue3,240 13,037 
Other9,376 6,633 
Total accounts payable and accrued liabilities$480,403 $570,621 


12
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(9) FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2020 and December 31, 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 12 – Debt, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2020 or December 31, 2019.
Fair Value Measurements at September 30, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,902 $— $1,902 
Other assets:
NQDC Plan assets17,652 — 17,652 
Restricted investments (1)
2,987 — 2,987 
Total other assets20,639 — 20,639 
Total assets$22,541 $— $22,541 
Liabilities:
Current liabilities:
NQDC Plan liability$1,902 $— $1,902 
Other long-term liabilities:
NQDC Plan liability17,652 — 17,652 
Contingent consideration— 54,103 54,103 
Total other long-term liabilities17,652 54,103 71,755 
Total liabilities$19,554 $54,103 $73,657 

13
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Fair Value Measurements at December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)    The restricted investments at September 30, 2020 and December 31, 2019 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
There were no transfers between levels during the three and nine months ended September 30, 2020. The following table represents a roll forward of contingent consideration.
Contingent consideration at December 31, 2019$50,793 
Changes in fair value of contingent consideration1,352 
Foreign exchange remeasurement of Euro denominated contingent acquisition consideration1,958 
Contingent consideration at September 30, 2020$54,103 
14
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(10) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as hedging instruments and have maturities up to two and a half years. The Company also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments and have maturities up to three months. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The following table summarizes the aggregate notional amounts for the Company’s derivatives designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$729,998 $820,546 
Purchase$163,116 $212,348 
The following table summarizes the aggregate notional amounts for the Company’s derivatives not designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$41,031 $77,335 
Purchase$30,031 $30,818 
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationSeptember 30, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$13,537 $19,584 
Other assets4,621 13,539 
Subtotal$18,158 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$7,704 $8,184 
Other long-term liabilities4,406 5,493 
Subtotal$12,110 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$16 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$70 $2,264 
Total Derivatives Assets$18,174 $33,592 
Total Derivatives Liabilities$12,180 $15,941 
(1)    For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
15
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income (Loss) for the periods presented.
Three Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$460,741 $2,693 $450,900 $6,196 
Operating expenses as reported$532,725 $(815)$457,087 $(1,388)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$4,166 $(1,286)

Nine Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,368,816 $17,301 $1,224,458 $11,171 
Operating expenses as reported$1,400,263 $(4,274)$1,340,900 $(1,885)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$9,600 $(5,182)
As of September 30, 2020, the Company expected to reclassify unrealized gains of $4.8 million from Accumulated Other Comprehensive Income (AOCI) to earnings as the forecasted revenue and operating expense transactions occur over the next 12 months. For additional discussion of balances in AOCI see Note 13 – Accumulated Other Comprehensive Income.

16
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(11) LEASES
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020: 
Lease ClassificationClassificationSeptember 30,
2020		December 31,
2019
Assets:
OperatingOther Assets$45,764 $49,045 
FinancingOther Assets12,018 10,389 
Total ROU assets$57,782 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$7,813 $7,451 
FinancingAccounts payable and accrued liabilities3,117 3,249 
Noncurrent:
OperatingOther long-term liabilities40,831 44,092 
FinancingOther long-term liabilities4,570 6,708 
Total lease liabilities$56,331 $61,500 
Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
Remainder of 2020$3,460 $940 $4,400 
20219,908 3,080 12,988 
20229,095 2,375 11,470 
20238,055 1,797 9,852 
20246,253 48 6,301 
Thereafter21,714 20 21,734 
Total lease payments58,485 8,260 66,745 
Less: Interest(9,841)(573)(10,414)
Present value of lease liabilities$48,644 $7,687 $56,331 

Lease costs associated with payments under the Company’s leases were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
Lease CostClassification2020201920202019
Operating (1)
Operating Expenses$3,227 $3,535 $8,953 $9,946 
Financing:
AmortizationOperating Expenses841 600 2,307 1,811 
Interest expenseOperating Expenses111 142 352 455 
Total lease costs$4,179 $4,277 $11,612 $12,212 
 (1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
17
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Other InformationSeptember 30,
2020		September 30,
2019
Weighted average remaining lease term (in years):
Operating leases7.18.0
Financing leases2.84.2
Weighted average discount rate:
Operating leases5.1 %5.2 %
Financing leases5.2 %5.4 %
    As of September 30, 2020, one operating lease is expected to commence in the fourth quarter of 2020.
Nine Months Ended September 30,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$7,007 $5,918 
Financing leases$354 $454 
Cash used in financing activities:
Financing leases$6,080 $2,027 
ROU assets obtained in exchange for lease obligations:
Operating leases$3,299 $9,268 
Financing leases$3,941 $72 
 
18
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(12) DEBT
Convertible Notes
As of September 30, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.5 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
September 30,
2020		December 31,
2019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,792)— 
Unamortized deferred offering costs(709)— 
2027 Notes, net586,499 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,470)(6,533)
Unamortized deferred offering costs(1,865)(2,229)
2024 Notes, net487,665 486,238 
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993 374,993 
Unamortized discount(649)(12,078)
Unamortized deferred offering costs(54)(1,033)
2020 Notes, net (1)
374,290 361,882 
Total convertible debt, net$1,448,454 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$590,010 $— 
2024 Notes
517,730 521,839 
2020 Notes
374,997 405,679 
Total fair value of fixed rate convertible debt$1,482,737 $927,518 
(1)    The 2020 Notes are classified as a current liability in the periods presented because they matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
19
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
(2)    The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Interest expense on the Company’s convertible debt consisted of the following: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Accretion of discount on convertible notes$4,696 $4,005 $13,201 $11,860 
Coupon interest expense4,255 2,271 9,443 6,681 
Amortization of debt issuance costs535 508 1,565 1,522 
Total interest expense on convertible debt$9,486 $6,784 $24,209 $20,063 
 
2027 Notes
In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense.
The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.
The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act.
See Note 13 - Debt in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the Company’s convertible debt.
Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and earnings before interest, taxes, depreciation and amortization (EBITDA) for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount
20
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021, at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2020, and December 31, 2019, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility. As of September 30, 2020, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants.

(13) ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019. 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification		Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Gains (losses) on cash flow hedges:
Forward contracts
Net product revenues$2,693 $6,196 $17,301 $11,171 
Forward contracts
Operating expenses(815)(1,388)(4,274)(1,885)
Total gain (loss) on cash flow hedges$1,878 $4,808 $13,027 $9,286 
The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2020 and 2019.
Three Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2020$22,963 $7,087 $— $30,050 
Other comprehensive income (loss) before
     reclassifications
(16,094)(2,201)— (18,295)
Less: net gain (loss) reclassified from AOCI1,878 — — 1,878 
Tax effect— 508 — 508 
Net current-period other comprehensive income (loss)(17,972)(1,693)— (19,665)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 

21
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Three Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2019$14,181 $3,271 $(13)$17,439 
Other comprehensive income (loss) before
     reclassifications		23,973 522 (3)24,492 
Less: gain (loss) reclassified from AOCI4,808 — — 4,808 
Tax effect— (120)— (120)
Net current-period other comprehensive income (loss)19,165 402 (3)19,564 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 


Nine Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2019$16,614 $3,565 $(15)$20,164 
Other comprehensive income (loss) before
     reclassifications		1,404 2,379 15 3,798 
Less: gain (loss) reclassified from AOCI13,027 — 13,027 
Tax effect— (550)— (550)
Net current-period other comprehensive income (loss)(11,623)1,829 15 (9,779)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 

Nine Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
     reclassifications		35,431 7,256 (3)42,684 
Less: gain (loss) reclassified from AOCI9,286 — — 9,286 
Tax effect— (1,666)— (1,666)
Net current-period other comprehensive income (loss)26,145 5,590 (3)31,732 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 


(14) REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
22
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Total revenues by geographic region:
United States$252,948 $201,874 $729,672 $562,217 
Europe121,158 125,485 375,453 369,585 
Latin America44,064 83,799 141,852 164,132 
Rest of world58,614 49,939 161,361 153,671 
Total revenues$476,784 $461,097 $1,408,338 $1,249,605 

The following table disaggregates Net Product Revenues by product. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Net product revenues by product:
Vimizim$147,891 $163,466 $401,789 $411,953 
Kuvan123,993 120,524 368,604 340,771 
Naglazyme76,323 94,408 271,585 279,462 
Palynziq46,092 24,142 121,354 55,250 
Brineura25,455 19,840 75,223 46,815 
Firdapse— 5,668 1,316 16,262 
Total net product revenues marketed by the Company$419,754 $428,048 $1,239,871 $1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 $128,945 $73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
United States$203,892 $175,127 $582,734 $480,330 
Europe115,548 121,363 360,718 358,041 
Latin America44,064 83,799 141,852 164,132 
Rest of world56,250 47,759 154,567 148,010 
Total net product revenues marketed by the Company419,754 428,048 1,239,871 1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 128,945 73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
23
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Customer A16 %16 %15 %17 %
Customer B14 %13 %14 %12 %
Customer C11 %10 %12 %11 %
Customer D1 %12 %3 %6 %
Total42 %51 %44 %46 %

On a consolidated basis, two customers accounted for 33% and 15% of the September 30, 2020 accounts receivable balance, respectively, compared to December 31, 2019, when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of September 30, 2020, and December 31, 2019, the accounts receivable balance for Genzyme included $106.5 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The outbreak of COVID-19 continues to affect economies and business around the world. The Company experienced a modest impact on its global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, in the three and nine months ended September 30, 2020 and the Company anticipates a continued impact on its financial results for the remainder of 2020 and into fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations. See the risk factor related to the impact of the coronavirus pandemic, “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A of this Quarterly Report, for additional details on the impact of the COVID-19 pandemic.
The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.

(15) STOCK-BASED COMPENSATION
The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Cost of sales$10,342 $4,093 $20,381 $12,629 
Research and development15,705 14,261 45,333 43,037 
Selling, general and administrative24,122 20,819 76,411 66,097 
Total stock-based compensation expense$50,169 $39,173 $142,125 $121,763 
Stock-based compensation of $4.9 million and $14.9 million was capitalized into inventory for the three and nine months ended September 30, 2020, respectively. Stock-based compensation of $5.1 million and $13.2 million was capitalized into inventory for the three and nine months ended September 30, 2019, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.
24
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
Restricted Stock Unit Awards with Market Conditions
In March 2020, the Compensation Committee and Board approved the grant of 126,710 RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between 0% and 200% of the base TSR-RSUs, with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the 50th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of $112.12 per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.
Restricted Stock Unit Awards with Performance Conditions
In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year Non-GAAP income target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its current long-range financial plan and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.
In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year strategic goal target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its product candidate development pipeline and planned regulatory activity and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.

(16) INCOME TAXES
In the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s Ex-US regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Condensed Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of September 30, 2020.

(17) NET INCOME (LOSS) PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s Employee Share Purchase Plan (ESPP), unvested RSUs, common stock held by the NQDC and contingent issuances of common stock related to the Company’s convertible debt.
The following table sets forth the computation of basic and diluted earnings per common share (common shares in
25
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Numerator:
Net Income (Loss), basic$784,803 $55,036 $837,001 $(38,872)
Add: Interest on convertible notes7,070 937 18,333 — 
Net Income (Loss), diluted$791,873 $55,973 $855,334 $(38,872)
Denominator:
Weighted-average common shares outstanding, basic181,142 179,289 180,592 178,873 
Effect of dilutive securities:
Options to purchase common stock1,731 1,560 1,728 — 
Common stock issuable under the 2020 notes3,983 — 3,983 — 
Common stock issuable under the 2024 notes3,970 3,970 3,970 — 
Common stock issuable under the 2027 notes4,365 — 2,373 — 
Unvested RSUs1,926 669 1,765 — 
Common stock potentially issuable for ESPP purchases346 231 337 — 
Common shares held by the NQDC211 205 211 — 
Weighted-average common shares outstanding, diluted197,674 185,924 194,959 178,873 
Net Income (Loss) per common share, basic$4.33 $0.31 4.63 (0.22)
Net Income (Loss) per common share, diluted$4.01 $0.30 4.39 (0.22)
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Options to purchase common stock5,172 5,829 5,175 7,388 
Common stock issuable under the 2020 Notes— 3,983 — 3,983 
Common stock issuable under the 2024 Notes— — — 3,970 
Unvested RSUs2,900 3,360 3,060 4,029 
Common stock potentially issuable for ESPP purchases193 222 204 453 
Common stock held by the NQDC— — — 205 
Total number of potentially issuable shares8,265 13,394 8,439 20,028 
The potential effect of the capped call transactions and potential shares issuable under the 2020 Notes were excluded from the calculation of diluted net income (loss) per share in the three and nine months ended September 30, 2020 and 2019, as the Company’s closing price on September 30, 2020 and 2019 did not exceed the conversion price of $94.15 per share. The Company’s 2020 Notes matured on October 15, 2020 and were settled in cash. The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as of September 30, 2020.There is no similar capped call transaction associated with the 2024 Notes or the 2027 Notes. See Note 12 – Debt for additional information on the Company’s 2020 Notes and 2027 Notes. Refer to Note 13 - Debt to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the 2024 Notes and details of the capped call transaction.

(18) COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of
resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these
matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general
26
BIOMARIN PHARMACEUTICAL INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)
practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses
are probable and reasonably estimable.
Contingent Payments
As of September 30, 2020, the Company was subject to contingent payments totaling approximately $622.4 million upon achievement of certain development, regulatory and commercial sales milestones, if they occur before certain dates in the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $70.3 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and $236.0 million related to programs that are no longer being developed.
As of September 30, 2020, the Company recorded a total of $54.1 million of contingent liabilities on its Condensed
Consolidated Balances Sheet. See Note 9 – Fair Value Measurements to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
In the normal course of business, the Company enters into various firm purchase commitments primarily related to active
pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services. As of September 30, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $150.3 million.

27
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risk factor related to the impact of the coronavirus pandemic, “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A in this Quarterly Report on Form 10-Q, amongst the other risk factors. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled “Forward-Looking Statements” that appears at the beginning of this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Condensed Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S GAAP) and are presented in U.S. Dollars (USD).
28
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Overview
We are a global biotechnology company that develops and commercializes innovative therapies for people with serious
and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent
a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a
significant benefit over existing products.
Our portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates. A summary of our major commercial products, as of September 30, 2020, is provided below:
Major Commercial ProductsIndication
U.S. Orphan Drug Exclusivity
Expiration (1)
U.S. Biologic
Exclusivity
Expiration (2)
EU Orphan Drug Exclusivity
Expiration (1)
Aldurazyme (laronidase)
 MPS I (3)
ExpiredExpiredExpired
Brineura (cerliponase alfa)
 CLN2 (4)
202420292027
Kuvan (sapropterin dihydrochloride)
 PKU (5)
ExpiredNot Applicable
2020 (6)
Naglazyme (galsulfase)
 MPS VI (7)
ExpiredExpiredExpired
Palynziq (pegvaliase-pqpz) (8)
 PKU
202520302029
Vimizim (elosulfase alpha)
 MPS IVA (9)
202120262024

(1)See “Government Regulation—Orphan Drug Designation” in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020 (Annual Report) for further discussion
(2)See “Government Regulation— Healthcare Reform” in Part I, Item 1 of our Annual Report for further discussion
(3)For the treatment of Mucopolysaccharidosis I (MPS I)
(4)For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
(5)For the treatment of phenylketonuria (PKU)
(6)Kuvan, a small molecule therapy, has been granted orphan drug status in the European Union (EU), which together with pediatric exclusivity, confers 12 years of market exclusivity in the EU that expires in December 2020
(7)For the treatment of Mucopolysaccharidosis VI (MPS VI)
(8)For adult patients with PKU
(9)For the treatment of Mucopolysaccharidosis IV Type A (MPS IVA)
A summary of our ongoing major development programs, as of September 30, 2020, is provided below:
Major Product Candidates
in Development		Target
Indication		U.S. Orphan
Designation		EU Orphan
Designation		Stage
Valoctocogene roxaparvovecSevere Hemophilia AYesYesClinical Phase 3
VosoritideAchondroplasiaYesYesClinical Phase 3
BMN 307PKUYesYesClinical Phase 1/2

Uncertainty Relating to the COVID-19 Pandemic
The outbreak of novel coronavirus disease (COVID-19) continues to affect economies and business around the world. We experienced a modest impact on our global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and our overall business operations during the three and nine months ended September 30, 2020. We anticipate a continued impact due to COVID-19 on our financial results for the remainder of 2020 and into fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor related to the impact of the coronavirus pandemic, “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A of this
29
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Quarterly Report, for additional details on the impact of the COVID-19 pandemic.
Business Developments
We continued to grow our commercial business and advance our product candidate pipeline during 2020. We believe that the combination of our internal research programs, acquisitions and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Below is a summary of recent key business developments:
Continued Emphasis on Research and Development
•Valoctocogene roxaparvovec - We are working with the U.S. Food and Drug Administration (FDA) to align on steps forward to obtain marketing approval following the August 18, 2020 Complete Response Letter (CRL) to our Biologics License Application (BLA) for valoctocogene roxaparvovec gene therapy for severe hemophilia A. The FDA recommended that we complete the Phase 3 study and submit two-year follow-up safety and efficacy data on all study participants. The Phase 3 study was fully enrolled in November 2019 and will complete one-year of follow-up in November 2020. We intend to share the one-year top-line Phase 3 data in the first quarter of 2021.
Additionally, the European Medicines Agency (EMA) recently requested the 52-week results from the full Phase 3 study cohort of 134 subjects to inform their benefit-risk assessment. To facilitate this submission within the EMA regulatory framework, we recently withdrew the Marketing Authorization Application (MAA) and plan to resubmit the MAA with these data in the second quarter of 2021.

•Vosoritide - Marketing applications for vosoritide were validated and accepted by the EMA and FDA, respectively, in the third quarter of 2020. The Committee for Medicinal Products for human use (CHMP) opinion is expected in Europe in the second half of 2021. The U.S. New Drug Application (NDA) for Vosoritide is under Standard review by the FDA with Prescription Drug User Fee Act (PDUFA) Target Action Date of August 20, 2021. Vosoritide is an investigational, once daily injection of an analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. Vosoritide has Orphan Drug designation from the FDA and EMA.

•Palynziq - In October 2020 we announced that the FDA approved our supplemental BLA (sBLA) to increase the maximum allowable dose of Palynziq Injection for treatment of adults with PKU to 60 mg daily. Previously, the maximum dose was 40 mg daily. In the Phase 3 PRISM studies, 19% of study participants required a 60 mg dose to achieve adequate response to Palynziq.

•BMN 307 - In September 2020, we announced that we began dosing participants in PHEARLESS, the Phase 1/2 study of BMN 307 our gene therapy candidate for PKU, which has been granted fast track designation by the FDA. All subjects participating in the PHEARLESS study will receive product made at commercial scale from our gene therapy manufacturing facility. In January 2020, both the FDA and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom granted BMN 307 Investigational New Drug (IND) status and approved our Clinical Trial Application (CTA), respectively. Both the FDA and EMA have granted BMN 307 Orphan Drug Status.
•BMN 331 - In July 2020, we began Investigational New Drug (IND)-enabling studies for our third gene therapy product candidate, BMN 331, for the treatment of hereditary angioedema.
•Gene therapy manufacturing facility - In January 2020, we announced that significant improvements in productivity at our gene therapy facility had increased capacity for up to 10,000 patients per year, depending on dose and product mix.
30
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Financial Highlights
Key components of our results of operations include the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Total revenues$476.8 $461.1 $1,408.3 $1,249.6 
Cost of sales$188.8 $96.9 $398.1 $263.6 
Research and development (R&D) expense$147.1 $173.0 $471.4 $542.2 
Selling, general and administrative (SG&A) expense$179.5 $170.1 $542.2 $493.0 
Intangible asset amortization and contingent consideration$17.4 $17.1 $48.0 $57.1 
Gain on sale of nonfinancial assets$— $— $(59.5)$(15.0)
Provision for (benefit from) income taxes$(846.0)$(45.2)$(839.1)$(46.2)
Net Income (Loss)$784.8 $55.0 $837.0 $(38.9)
The increase in Net Income for the three months ended September 30, 2020 as compared to the three months ended September 30, 2019 was primarily due to the following:

•an increase in the benefit from income taxes of $800.8 million primarily due to the completion of an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where our Ex-US regional headquarters are located and we have significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates, resulting in a tax benefit of $835.1 million based on the fair value of the transferred intellectual property rights; and
•decreased R&D expense primarily resulting from decreasing clinical manufacturing costs for BMN 307 and lower clinical activity spend for valoctocogene roxaparvovec; partially offset by

•an increase in Cost of Sales resulting from an $81.2 million inventory charge related to pre-launch valoctocogene roxaparvovec inventory reserves due to regulatory responses received requesting additional data extending anticipated regulatory approvals timelines; and
•higher SG&A expense primarily related to pre-commercialization activities related to valoctocogene roxaparvovec.
We recognized Net Income for the nine months ended September 30, 2020 as compared to a Net Loss for the nine months ended September 30, 2019, primarily due to the following:
•an increase in the benefit from income taxes of $792.9 million primarily due to the completion of an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where our Ex-US regional headquarters are located and we have significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates, resulting in a tax benefit of $835.1 million based on the fair value of the transferred intellectual property rights;
•increased Total Revenues driven primarily by Palynziq and Aldurazyme Net Product Revenues; and
•decreased R&D expense primarily due to lower clinical manufacturing costs and a decrease in clinical study activities; partially offset by
•an increase in Cost of Sales resulting from an $81.2 million inventory charge related to pre-launch valoctocogene roxaparvovec inventory reserves due to regulatory responses received requesting additional data extending anticipated regulatory approval timelines; and
•increased SG&A expense primarily due to pre-commercialization activities related to valoctocogene roxaparvovec.
See “Results of Operations” below for additional information related to the Net Income/(Loss) fluctuations presented above.
31
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Our cash, cash equivalents and investments totaled approximately $1.8 billion as of September 30, 2020, which includes net proceeds of $535.8 million from our May 2020 convertible debt offering, compared to $1.2 billion as of December 31, 2019. We have historically financed our operations primarily through our cash flows from operating activities and the issuance of common stock and convertible debt. We will be highly dependent on our net product revenues to supplement our current liquidity and fund our operations for the foreseeable future. We may in the future elect to supplement this with further debt or equity offerings or commercial borrowing. Further, depending on market conditions, our financial position and performance and other factors, we may in the future choose to use a portion of our cash, cash equivalents or investments to repurchase our convertible debt or other securities. See “Financial Position, Liquidity and Capital Resources” below for a further discussion of our liquidity and capital resources.

Critical Accounting Policies, Estimates and Judgments
In preparing our Condensed Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions.
The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, our estimates may change materially in future periods.
Except as detailed in Note 2 to our accompanying Condensed Consolidated Financial Statements, there have been no significant changes to our critical accounting policies, estimates and judgments during the nine months ended September 30, 2020, compared to the critical accounting policies, estimates and judgments disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Recent Accounting Pronouncements
See Note 4 to our accompanying Condensed Consolidated Financial Statements for a description of recent accounting pronouncements and our expectation of their impact on our results of operations and financial condition.

32
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Results of Operations
Revenues
Net Product Revenues consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Net product revenues by product:
Vimizim$147.9 $163.5 $(15.6)$401.8 $412.0 $(10.2)
Kuvan124.1 120.6 3.5 368.7 340.8 27.9 
Naglazyme76.3 94.4 (18.1)271.6 279.5 (7.9)
Palynziq46.1 24.1 22.0 121.4 55.2 66.2 
Brineura25.4 19.8 5.6 75.2 46.8 28.4 
Firdapse— 5.7 (5.7)1.2 16.3 (15.1)
Total net product revenues marketed by the Company$419.8 $428.1 $(8.3)$1,239.9 $1,150.6 $89.3 
Aldurazyme net product revenues marketed by Sanofi Genzyme40.9 22.8 18.1 128.9 73.9 55.0 
Total net product revenues$460.7 $450.9 $9.8 $1,368.8 $1,224.5 $144.3 
Net Product Revenues include revenues generated from our approved products. In the U.S., our commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program, and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., our commercial products are sold to authorized distributors or directly to government purchasers or hospitals, which act as the end-users. In certain countries, such as in Latin America, governments place large periodic orders for Naglazyme and Vimizim. The timing of these large government orders can be inconsistent and can create significant quarter to quarter variation in our revenues.
The increase in Net Product Revenues for the three months ended September 30, 2020 as compared to the three months ended September 30, 2019 was primarily attributed to the following:
•Palynziq: the increase was primarily driven by a combination of revenue from U.S. patients achieving maintenance dosing and new patients initiating therapy;
•Aldurazyme: the increase was primarily attributed to higher sales volume to Genzyme;
•Brineura: the increase was primarily attributed to strong patient growth in Europe, Middle East, Africa and North America; partially offset by
•Naglazyme and Vimizim: the decreases were primarily attributed to decreased sales volume due to timing of orders placed from Latin America as well as the impact of missed infusions resulting from the COVID-19 pandemic; and
•Firdapse: the decrease was primarily attributed to the divestiture and sale of the Firdapse business in January 2020.
The increase in Net Product Revenues for the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019 was primarily attributed to the following:
•Palynziq: the increase was primarily driven by a combination of revenue from U.S. patients achieving maintenance dosing and new patients initiating therapy;
•Aldurazyme: the increase was primarily attributed to higher sales volume to Genzyme;
•Brineura: the increase was primarily attributed to growth in the number of patients in all regions;
•Kuvan: the increase was primarily driven by growth in the U.S.; partially offset by
•Firdapse: the decrease was primarily attributed to the divestiture and sale of the Firdapse business in January 2020;
33
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
•Vimizim: the decrease was primarily attributed to decreased sales volumes in Latin America and EMEA as well as the impact of missed infusions resulting from the COVID-19 pandemic offset by growth in North America; and
•Naglazyme: the decrease was primarily attributed to the timing of orders received from Latin America as well as the impact of missed infusions resulting from the COVID-19 pandemic.
We anticipate the COVID-19 pandemic will have a continued impact on future Net Product Revenues in the remainder of 2020 and into 2021 as many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Although we are working with our patient community and health care providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from the doses of our products that are missed by patients and the lost revenue from delayed treatment starts for new patients will never be recouped. See the risk factor “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition” in “Risk Factors” included in Part II, Item 1A of this Quarterly Report for additional information.
In October of 2020, we lost U.S market exclusivity for Kuvan. We have been preparing for the loss of exclusivity which will result in a reduction in market share and affect our revenue and results of operations in the remainder of 2020 and into 2021. See the risk factor “The sale of generic versions of Kuvan by generic manufacturers may adversely affect our revenues and results of operations” in “Risk Factors” included in Part II, Item 1A of this Quarterly Report for additional information. Additionally, the responses received from the FDA and EMA requesting additional safety and efficacy data from our valoctocogene roxaparvovec Phase 3 studies have extended our anticipated regulatory approval timelines which will have an impact on Net Product Revenues for remainder of 2020 and 2021.
We face exposure to movements in foreign currency exchange rates and we use foreign currency exchange contracts to hedge a percentage of our foreign currency exposure. The following table shows our Net Product Revenues denominated in USD and foreign currencies:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Sales denominated in USD$302.6 $284.6 $18.0 $846.4 $738.6 $107.8 
Sales denominated in foreign currencies158.1 166.3 (8.2)522.4 485.9 36.5 
Total Net Product Revenues$460.7 $450.9 $9.8 $1,368.8 $1,224.5 $144.3 
The net impact of foreign currency exchange rates on product sales denominated in currencies other than USD during the three and nine months ending September 30, 2020 was unfavorable by $4.0 million and $14.8 million, respectively, driven primarily by weakening of currencies in Latin American markets relative to the USD, such as the Brazilian Real and Colombian Peso. This compares to an unfavorable impact of $6.9 million and $18.6 million for the three and nine months ending September 30, 2019, respectively, which were driven primarily by fluctuations in Euro, partially offset by Brazilian Real.
Royalty and Other Revenues
Royalty and Other Revenues include royalties earned on net sales of products sold, milestones achieved by licensees or sublicensees, manufacturing and transition services for licensees and rental income associated with the tenants in our facilities.
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Royalty and other revenues$16.0 $10.2 $5.8 $39.5 $25.1 $14.4 
The increase in Royalty and Other Revenues for the three and nine months ended September 30, 2020 compared to the same period in 2019 was primarily due to license revenues earned from the third-party that licensed tralesinidase alfa from us and royalties earned on net sales of products sold by our licensees.
We expect to continue to earn royalties from third parties in the future.
Cost of Sales
Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products, as well as inventory valuation reserves. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and internal and external final formulation and packaging costs. Cost of Sales also
34
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
includes royalties payable to third parties based on sales of our products.
The following table summarizes our Cost of Sales and product gross margin:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Total Net Product Revenues$460.7 $450.9 $9.8 $1,368.8 $1,224.5 $144.3 
Cost of Sales$188.8 $96.9 $91.9 $398.1 $263.6 $134.5 
Product gross margin59.0 %78.5 %(19.5)%70.9 %78.5 %(7.6)%
Cost of Sales increased for the three and nine months ended September 30, 2020 compared to the same periods in 2019 primarily due to an $81.2 million inventory reserve related to pre-launch valoctocogene roxaparvovec inventory as a result of anticipated regulatory approval delays. Product gross margin for the three and nine months ended September 30, 2020 compared to the same periods in 2019 decreased primarily due to higher cost of sales and product mix as there were higher sales of lower margin products.
Research and Development
R&D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our approved products. R&D expense primarily includes preclinical and clinical studies, personnel and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs.
We manage our R&D expense by identifying the R&D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.
R&D expense consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Early stage programs$34.5 $21.1 $13.4 $116.7 $57.9 $58.8 
Vosoritide30.7 25.3 5.4 97.8 85.4 12.4 
Valoctocogene roxaparvovec28.4 40.9 (12.5)92.6 144.8 (52.2)
PKU gene therapy (BMN 307)18.6 31.9 (13.3)53.7 73.1 (19.4)
Other approved products14.0 14.1 (0.1)41.8 48.1 (6.3)
Palynziq11.5 17.3 (5.8)35.3 57.3 (22.0)
Brineura5.7 9.2 (3.5)20.4 30.4 (10.0)
Tralesinidase alfa0.4 6.8 (6.4)1.0 22.6 (21.6)
Other3.3 6.4 (3.1)12.1 22.6 (10.5)
Total R&D expense$147.1 $173.0 $(25.9)$471.4 $542.2 $(70.8)
The decrease in R&D expense for the three months ended September 30, 2020 as compared to the same period in 2019 was primarily due to the following:
•a decrease in clinical manufacturing costs related to BMN 307, which was manufactured in 2019;
•a decrease in costs related to valoctocogene roxaparvovec due to lower clinical activity spend;
•a decrease in costs related to tralesinidase alfa as the program was licensed to a third-party in the fourth quarter of 2019; and
•a decrease in clinical study costs related to Palynziq due to completion of studies to support European regulatory approval; partially offset by
•an increase in early stage programs costs related primarily to pre-clinical studies for BMN 331 program for the treatment of hereditary angioedema.
35
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
The decrease in R&D expense during the nine months ended September 30, 2020 as compared to the same period in 2019 primarily due to the following:
•a decrease in costs related to valoctocogene roxaparvovec, due to lower clinical activity spend and a regulatory milestone payment made to a third-party in 2019;
•a decrease in clinical study costs related to Palynziq due to completion of studies to support European regulatory approval;
•a decrease in tralesinidase alfa as the program was licensed to a third-party in the fourth quarter of 2019;
•a decrease in clinical manufacturing costs related to BMN 307, which was manufactured in 2019; and
•a decrease in costs related to Brineura due to completion of clinical studies; partially offset by
•an increase in early stage programs primarily related to the $26.3 million payment made for preclinical programs licensed from a third party in the second quarter of 2020 and costs related pre-clinical studies for BMN 311 for the treatment of hereditary angioedema.
We expect R&D expense to be generally flat in future periods, primarily due to increased spending on preclinical activities for early stage development programs, offset by lower development costs on valoctocogene roxaparvovec and Palynziq.
Selling, General and Administrative
Sales and Marketing (S&M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and administrative (G&A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.
Selling, General and Administrative (SG&A) expense consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Selling & Marketing expense$101.1 $93.5 $7.6 $293.0 $264.7 $28.3 
General & Administrative expense78.4 76.6 1.8 249.2 228.3 20.9 
Total SG&A expense$179.5 $170.1 $9.4 $542.2 $493.0 $49.2 

Three Months Ended
September 30,		Nine Months Ended
September 30,
Selling & Marketing expense by product20202019Change20202019Change
PKU Products (Kuvan and Palynziq)$30.0 $32.8 $(2.8)$91.8 $97.3 $(5.5)
Valoctocogene roxaparvovec26.9 12.6 14.3 70.6 28.7 41.9 
MPS Products (Aldurazyme, Naglazyme and Vimizim)25.4 28.5 (3.1)78.0 85.2 (7.2)
Brineura8.5 11.3 (2.8)27.3 31.0 (3.7)
Other10.3 8.3 2.0 25.3 22.5 2.8 
Total Selling & Marketing expense$101.1 $93.5 $7.6 $293.0 $264.7 $28.3 
The increase in S&M expense for the three and nine months ended September 30, 2020 as compared to the same periods in 2019 was primarily a result of an increase in pre-commercialization activities related to valoctocogene roxaparvovec partially offset by decreases in MPS Products, PKU Products and Brineura as well as lower travel expenses due to the COVID-19 pandemic.
G&A expense for the three months ended September 30, 2020 as compared to 2019 was generally flat.
The increase in G&A expense for the nine months ended September 30, 2020 as compared to the same period in 2019 was primarily due to the impact of revaluation of non-USD denominated assets and liabilities and employee-related expenses.
We expect SG&A expense to increase in future periods as a result of the continued global expansion of Palynziq and pre-commercialization efforts related to vosoritide.
Contingent Consideration, Intangible Asset Amortization and Gain on Sale of Nonfinancial Assets
36
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Changes during the periods presented for Intangible Asset Amortization and Contingent Consideration include:
Three Months Ended
September 30,		Nine Months Ended
September 30,
20202019Change20202019Change
Changes in the fair value of contingent consideration$1.9 $0.8 $1.1 $1.4 $19.9 $(18.5)
Amortization of intangible assets15.5 16.3 (0.8)46.6 37.2 9.4 
Total intangible asset amortization and contingent consideration$17.4 $17.1 $0.3 $48.0 $57.1 $(9.1)
Gain on sale of nonfinancial assets$— $— $— $59.5 $15.0 $44.5 
Fair value of contingent consideration – there was no significant change in the fair value of the contingent consideration for the three and nine months ended September 30, 2020 and the three months ended September 30, 2019. The changes in the fair value of the contingent consideration for the nine months ended September 30, 2019 were attributable to changes in the estimated probability of achieving development milestones, primarily related to the Palynziq program’s European MAA which was approved in the second quarter of 2019.
Amortization of intangible assets – The increase in the nine months ended September 30, 2020 was primarily due to the Palynziq acquired in-process research and development assets that were placed into service following EU marketing approval in May 2019.
Gain on Sale of Nonfinancial Assets – we recognized a gain of $59.5 million in the nine months ended September 30, 2020 due to the divestiture and sale of Firdapse compared to a gain of $15.0 million in the nine months ended September 30, 2019 due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset. See Note 6 to our accompanying Condensed Consolidated Financial Statements for additional discussion on this transaction.
Interest Income
We invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk. Interest income was comprised of the following:
Three Months Ended September 30,Nine Months Ended September 30,
20202019Change20202019Change
Interest income$4.0 $5.3 $(1.3)$13.5 $17.5 $(4.0)
The decrease in interest income for the three and nine months ended September 30, 2020 compared to 2019 was primarily due to lower interest rates.
We expect interest income to be lower over the next 12 months due to lower interest rates and yields on our cash equivalents and investments.
Interest Expense
We incur interest expense on our convertible debt. Interest expense for the periods presented consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
20202019Change20202019Change
Total interest expense$9.6 $2.9 $6.7 $24.6 $16.5 $8.1 
The interest expense on convertible debt for the three and nine months ended September 30, 2020 compared to 2019 was higher due primarily to the issuance of the 2027 Notes in the second quarter of 2020.
We expect interest expense to be lower over the next 12 months due to the settlement of the 2020 Notes, partially offset by increased interest expense for the 2027 Notes.
37
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
See Note 12 to our accompanying Condensed Consolidated Financial Statements for additional information related to our convertible debt. 
Benefit from Income Taxes
The following table summarizes our income tax benefit:
Three Months Ended September 30,Nine Months Ended September 30,
20202019Change20202019Change
Benefit from income taxes$846.0 $45.2 $800.8 $839.1 $46.2 $792.9 
Tax benefit was computed using a forecasted annual effective tax rate for the three and nine months ended September 30, 2020 and 2019. Provision for income taxes for the three and nine months ended September 30, 2020 and 2019 consisted of state, federal and foreign current tax expense which was offset by tax benefits related to stock option exercises and deferred tax benefits from federal orphan drug credits and R&D credits.
In the third quarter of 2020, we completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where our Ex-US regional headquarters are located and we have significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, our Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, we recognized a deferred tax asset of $835.1 million, and related tax benefit on our Condensed Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. We expect to be able to realize the deferred tax asset resulting from this transaction and have not recorded a valuation allowance as of September 30, 2020.
On March 27, 2020, The Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law which lifts certain limitations originally imposed by the Tax Cuts and Jobs Act of 2017. The CARES Act allows taxpayers to now carryback net operating losses (NOLs) to the prior five years for NOLs originating during 2018 through 2020 and eliminates the 80% limitation allowing taxpayers to fully offset 100% of taxable income in 2018, 2019 or 2020. The CARES Act also allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the full amount rather than over a period of years. Taxpayers may generally deduct interest up to 50% of adjusted taxable income plus business interest income which was previously limited to 30% for tax years beginning January 1, 2019 and 2020. The CARES Act also raises the charitable deduction limit to 25% of taxable income and reinstates qualified improvement property eligible for 15-year classification and 100% bonus depreciation. On June 29, 2020, California enacted legislative changes (AB 85) which suspended California net operating loss utilization for years 2020 through 2022. In addition, an annual cap of $5 million was imposed on the amount of business incentive tax credits companies can utilize. The enactment of both the CARES Act and California AB 85 did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our net deferred tax assets as of September 30, 2020.
In the first quarter of 2020, it came to our attention that certain historical transactions may be interpreted to be subject to withholding tax regulation. We recorded a reserve as of June 30, 2020 to reflect the uncertain tax position.

Financial Position, Liquidity and Capital Resources
As of September 30, 2020, we had approximately $1.8 billion in cash, cash equivalents and investments which includes net proceeds of $535.8 million from our May 2020 convertible debt offering. We expect to fund our operations with our net product revenues from our commercial products, cash, cash equivalents and investments, supplemented as may become necessary by proceeds from equity or debt financings and loans, or collaborative agreements with corporate partners. We may require additional financing to fund the repayment of our convertible debt, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The timing and mix of our funding options could change depending on many factors, including how much we elect to spend on our development programs, potential licenses and acquisitions of complementary technologies, products and companies or if we elect to settle all or a portion of our convertible debt in cash. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the ongoing COVID-19
38
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
pandemic.
In managing our liquidity needs in the U.S., we do not rely on unrepatriated earnings as a source of funds and we have not provided for U.S. federal or state income taxes on these undistributed foreign earnings. We do not record U.S. tax expense on the undistributed earnings of our controlled foreign subsidiaries as these earnings are intended to be indefinitely reinvested offshore. As of September 30, 2020, $244.8 million of our $1.8 billion balance of cash, cash equivalents, and investments was held in foreign subsidiaries, a significant portion of which is required to fund the liquidity needs of these foreign subsidiaries. For additional discussion regarding income taxes, see Note 18 to our Condensed Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.
We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We sell our products in certain countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to be unable to pay for our products. We will continue to monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.
Our liquidity and capital resources as of September 30, 2020 and December 31, 2019 were as follows:
September 30, 2020December 31, 2019Change
Cash and cash equivalents$1,015.7 $437.4 $578.3 
Short-term investments490.0 316.4 173.6 
Long-term investments265.1 412.0 (146.9)
Cash, cash equivalents and investments$1,770.8 $1,165.8 $605.0 
Total convertible debt, net$1,448.5 $848.1 $600.4 
Our cash flows for the nine months ended September 30, 2020 and 2019 are summarized as follows:
20202019Change
Cash and cash equivalents at the beginning of the period$437.4 $494.0 $(56.6)
Net cash provided by (used in) operating activities98.7 (9.1)107.8 
Net cash provided by (used in) investing activities(64.6)17.9 (82.5)
Net cash provided by (used in) financing activities547.3 (78.7)626.0 
Foreign exchange impact(3.1)(0.9)(2.2)
Cash and cash equivalents at the end of the period$1,015.7 $423.2 $592.5 
Short-term and long-term investments755.1 729.4 25.7 
Cash, cash equivalents and investments$1,770.8 $1,152.6 $618.2 
Cash Provided by (Used in) Operating Activities
Cash provided by operating activities increased by $107.8 million to $98.7 million in the nine months ended September 30, 2020, compared to $9.1 million cash used operating activities in the nine months ended September 30, 2019. The increase is primarily attributed to the timing of cash receipts from our customers, licensees and sublicensees partially offset by timing of payments to vendors and higher inventory levels.
Cash Provided by (Used in) Investing Activities
Net cash used in investing activities in the nine months ended September 30, 2020 increased by $82.5 million to $64.6 million, compared to $17.9 million cash provided by investing activities during the nine months ended September 30, 2019. The increase is primarily attributable to higher net purchases of available-for-sale debt securities offset by the receipt of $67.2 million in cash due to the divestiture and sale of Firdapse assets to a third party. 
Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities in the nine months ended September 30, 2020 increased by $626.0 million to $547.3 million compared to $78.7 million cash used in financing activities during the nine months ended September 30, 2019 due primarily to the proceeds from the issuance of the 2027 Notes and an increase in proceeds from the exercise of awards under our equity incentive plans, partially offset by the repurchase of our common stock.
39
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Other Information
Our $1.5 billion (undiscounted) of total convertible debt as of September 30, 2020 will impact our liquidity due to the semi-annual cash interest payments. As of September 30, 2020, our indebtedness consisted of the 2020 Notes, the 2024 Notes and the 2027 Notes (collectively, the Notes), which, if not converted, will be required to be repaid in cash at maturity in October 2020, August 2024 and May 2027 respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.
Subsequent to quarter-end, our 2020 Notes matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as our share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period and the capped call transaction, which was entered into concurrently with the issuance of notes, was not triggered. We used a portion of the net proceeds we received from the issuance of the 2027 Notes to repay the principal balance of the 2020 Notes. We incurred no gain or loss upon the extinguishment of the 2020 Notes. See Note 12 to our accompanying Condensed Consolidated Financial Statements for additional discussion.
In October 2018, we entered into an unsecured revolving credit facility of $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is also intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at our option, at a rate equal to either (a) the LIBOR rate, or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Our obligations under the Credit Facility are guaranteed by our direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable. The 2018 Credit Facility contains financial covenants requiring us to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2020, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility.
For additional information related to our convertible debt see Note 12 to our accompanying Condensed Consolidated Financial Statements and Note 13 - Debt included in our Annual Report on Form 10-K for the year ended December 31, 2019.
Funding Commitments
We cannot estimate with certainty the cost to complete any of our product development programs. Additionally, we cannot precisely estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see “Risk Factors” included in Part II, Item 1A of this Quarterly Report on Form 10-Q, for a discussion of the reasons we are unable to estimate such information, and in particular the following risk factors:
•The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations, and financial condition;
•If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase;
•    If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program;
•    If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected; and
•    If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
40
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Our investment in our product development programs and continued development of our existing commercial products has a major impact on our operating performance. Our R&D expenses for the period since inception as of September 30, 2020 were as follows:
Since Program Inception
Palynziq$724.7 
Valoctocogene roxaparvovec$686.4 
Vosoritide$537.7 
Brineura$346.9 
PKU gene therapy$161.0 
Other approved products$1,156.9 
We may need or elect to increase our spending above our current long-term plans to be able to achieve our long-term goals. This may increase our capital requirements, including: costs associated with the commercialization of our products; additional clinical trials; investments in the manufacturing of our commercial products; preclinical studies and clinical trials for our product candidates; potential licenses and other acquisitions of complementary technologies, products and companies; and general corporate purposes.
Our future capital requirements will depend on many factors, including, but not limited to:
•our ability to successfully market and sell our products;
•the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities;
•the progress and success of our preclinical studies and clinical trials (including the manufacture of materials for use in such preclinical studies and clinical trials);
•the timing, number, size and scope of our preclinical studies and clinical trials;
•the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities; and
•the progress of research programs carried out by us.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our consolidated financial position or results of operations.

41
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)
Contractual and Commercial Obligations
We have contractual and commercial obligations under our convertible debt, leases and other obligations related to R&D activities, purchase commitments, licenses and sales royalties with annual minimums. Our contractual obligations as of September 30, 2020 are presented in the table below.
Payments Due Within
Remainder of 2020>1 -3
Years		> 3 - 5
Years		More
Than 5
Years		Total
2027 Notes and related interest (1)
$3.8 $15.0 $22.5 $611.3 $652.6 
2024 Notes and related interest— 5.9 500.9 — 506.8 
2020 Notes and related interest (1)
377.8 — — — 377.8 
R&D and purchase commitments110.8 39.5 — — 150.3 
Leases4.4 24.4 22.8 15.2 66.8 
Total$496.8 $84.8 $546.2 $626.5 $1,754.3 
(1)    Our 2027 Notes were issued in May 2020 and our 2020 Notes matured and settled in cash on October 15, 2020. Refer to Note 12 to our accompanying Condensed Consolidated Financial Statements for additional discussion of our convertible debt.
As of September 30, 2020, we were also subject to contingent payments totaling approximately $622.4 million upon achievement of certain development and regulatory activities and commercial sales milestones if they occur before certain dates in the future. Of this amount, $235.0 million related to early stage development programs licensed from a third party in the second quarter of 2020, $70.3 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from Merck Serono and $236.0 million related to programs that are no longer being developed.
As of September 30, 2020, we recorded $54.1 million of contingent consideration on our Condensed Consolidated Balance Sheets, all of which was long-term.
See Note 18 to our accompanying Condensed Consolidated Financial Statements for additional discussion on our commitments.


42
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Our market risks during the nine months ended September 30, 2020 have not materially changed from those discussed in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2019.

Item 4.    Controls and Procedures
(a) Controls and Procedures
An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this report.
Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2020.
In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management must apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure controls system are met.
(b) Change in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We are utilizing the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control. We believe that our ability to maintain an effective internal control environment has not been impacted by the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.
43
PART II. OTHER INFORMATION
Item 1.    Legal Proceedings
On September 25, 2020, a purported shareholder class action lawsuit was filed against us, our Chief Executive Officer, our President of Worldwide Research and Development and our Executive Vice President and Chief Financial Officer in the United States District Court in the Northern District of California, alleging violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made materially false or misleading statements regarding the clinical trials and Biologics License Application (BLA) for valoctocogene roxaparvovec by purportedly failing to disclose that differences between the Company’s Phase 1/2 and Phase 3 clinical studies limited the ability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect and, as a result, that it was foreseeable that the Food and Drug Administration (FDA) would not approve the BLA without additional data. The complaint seeks an unspecified amount of damages, pre-judgment and post-judgment interest, attorneys’ fees, expert fees, and other costs. We believe that the claims have no merit and we intend to vigorously defend this action.

Item 1A.    Risk Factors
An investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.
We have marked with an asterisk (*) those risk factors below that include a substantive change from or update to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 27, 2020.
Risks Related to Our Business
*The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations, and financial condition.
On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic has resulted in travel restrictions, quarantines, “work-from-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world, including in many countries in which we operate. We experienced a modest impact on our product revenues in the third quarter of 2020 from the COVID-19 pandemic, and we expect that the outbreak may continue to adversely impact our financial results and our business generally. Ongoing and future effects of the COVID-19 pandemic (or any future pandemic) on all aspects of our business and operations, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, and the duration of such effects, are highly uncertain and difficult to predict. We anticipate that the COVID-19 pandemic will likely continue to have an adverse impact on our business, results of operations, and financial condition.
The continued spread of COVID-19 has adversely affected and will likely continue to adversely impact our product development programs, including preclinical study and clinical trial operations. We have been, and will likely continue to be, unable to initiate or continue conducting clinical trials as originally planned due to the prioritization of hospital resources toward the outbreak, difficulty in recruiting and retaining healthcare providers and staff due to their diversion toward treating COVID-19 patients or their heightened exposure to COVID-19, potential unwillingness of patients to enroll or continue in trials for fear of exposure to COVID-19 at sites, or the inability of patients to comply with clinical trial protocols as quarantines or travel restrictions impede patient movement or otherwise interrupt healthcare services. For example, we experienced delays in certain clinical trials and have had to reevaluate expected timelines for those trials. In addition, we rely on independent clinical investigators, contract research organizations (CROs) and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. Additionally, the COVID-19 pandemic has delayed, and may continue to postpone, necessary interactions with regulators regarding our products in development, which could delay review or approval of our regulatory submissions.
44
COVID-19 could adversely affect our ability to source materials and supplies and successfully manufacture and distribute our product candidates and products. The outbreak could result in reduced operations of third-party suppliers of raw materials and supplies upon whom we rely or otherwise limit our ability to obtain sufficient materials and supplies necessary for production of our therapies. Our manufacturing facilities and those of our contract manufacturers are located in areas impacted by the COVID-19 pandemic, which may result in delays or disruptions in our ability to produce product candidates and products. If we or any third party in our supply or distribution chain are adversely impacted by the COVID-19 pandemic, including as a result of required closures, staffing shortages, production slowdowns and disruptions in delivery systems, our operations may be disrupted, limiting our ability to manufacture and distribute our product candidates for clinical trials and research and development operations and our products for commercial sales.
Our commercial operations have also been, and will likely continue to be, adversely impacted by the COVID-19 pandemic. Many of our products are administered via infusions in a clinic or hospital setting and/or by a healthcare professional. Treating COVID-19 patients has become the priority for many healthcare facilities and workers, so it has become, and may continue to be, difficult for some of our patients to receive our therapies that are administered by infusion. Although we are working with our patient community and healthcare providers to find alternative arrangements where necessary, such as providing infusions at home, the revenue from doses of our products that are missed by patients and the lost revenue from delayed treatment starts for new patients will never be recouped. Moreover, some patients may choose to skip infusions because they do not want to risk exposure to COVID-19 by having a healthcare provider administer the therapy at a healthcare facility or at home. The pandemic has also hindered our ability to find new patients and start treating newly found patients, and it has limited our sales force’s ability to promote our products to distributors, hospitals, clinics, doctors and pharmacies, which could adversely affect our revenues and results of operations. In addition, the COVID-19 pandemic could adversely affect our workforce and the employees of companies with which we do business, thereby disrupting our business operations. We have implemented work-from-home policies for employees whose jobs do not require them to be onsite. Increased reliance by us and the companies with which we do business on personnel working from home may negatively impact productivity, increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations. For our employees whose jobs require them to be onsite, we have taken precautions to avoid the spread of COVID-19 among our employees, but we cannot guarantee our workforce will not face an outbreak that could adversely impact our operations.
While the long-term economic impact and the duration of the COVID-19 pandemic may be difficult to predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and convertible notes. In addition, a recession, further market correction or depression resulting from the COVID-19 pandemic could materially adversely affect our business and the value of our common stock and convertible notes.
To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this Risk Factors section, such as those relating to our conducting a significant amount of our sales and operations outside of the United States (U.S.), exposure to changes in foreign exchange rates, our substantial indebtedness, our need to generate sufficient cash flows to service our indebtedness and finance our operations, our ability to comply with the covenants contained in the agreements that govern our indebtedness and the volatility of our stock price.
*If we fail to obtain and maintain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.
We must obtain and maintain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain FDA approval for each product candidate that we intend to commercialize, and in Europe we must obtain approval from the European Medicines Agency (EMA). The FDA and EMA approval processes are typically lengthy and expensive, and approval is never certain. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory agency will mean that other agencies will also approve the same product candidate. Similarly, regulatory authorities may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.
45
We have had fewer interactions with regulatory authorities outside the U.S. and the European Union (EU) as compared to our interactions with the FDA and EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EMA approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EMA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA or EMA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA or EMA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.
Because of the risks and uncertainties in pharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. We also rely on independent third-party CROs to file some of our foreign marketing applications and important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.
Although the FDA and the EMA have programs to facilitate expedited development and accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. In addition, the FDA, the EMA and other international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy to grant approval and may require additional data. Moreover, if original FDA approval for one of our product candidates is granted via the accelerated approval pathway, we may be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of the FDA’s marketing approval for a product candidate. If we fail to obtain and maintain regulatory approval for our product candidates, we will be unable to market and sell those product candidates, which would have a negative effect on our business and financial condition.
With respect to valoctocogene roxaparvovec, we may experience challenges specific to gene therapy that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials, the FDA has only approved a very small number of vector-based gene therapy products thus far. Moreover, there are very few approved gene therapy products outside the U.S. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for valoctocogene roxaparvovec in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. For example, in October 2020, it was reported that the Director of the Center for Biologics Evaluation and Research, the center of the FDA responsible for reviewing marketing applications for gene therapies, stated that the FDA will assess the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Regulatory review agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our treatment candidate or lead to significant post-approval studies, limitations or restrictions. For example, on August 18, 2020 the FDA issued a Complete Response Letter (CRL) to our BLA for valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for additional data from our ongoing Phase 3 study of valoctocogene roxaparvovec that will not be available until November 2021. Continued delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring valoctocogene roxaparvovec to market could have a negative effect on our business and financial condition. Even if we do obtain regulatory approval, ethical, social and legal concerns about gene therapy arising in the future could result in additional regulations restricting or prohibiting sale of our product.
46
In addition, some of our product candidates are intended to be used in combination with a delivery device, such as an injector or other delivery system. Medical products containing a combination of new drugs, biological products or medical devices may be regulated as “combination products” in the U.S. A combination product generally is defined as a product consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). Each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Our product candidates intended for use with such devices, or expanded indications that we may seek for our products used with such devices, may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug or biologic product and device is sought under a single application, the increased complexity of the review process may delay approval. The FDA review process and criteria are not well-established areas, which could also lead to delays in the approval process. In addition, because these delivery devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.
From time to time during the development and regulatory approval process for our products and product candidates, we engage in discussions with the FDA and comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory agencies globally, but we do not always follow such guidance. This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. For example, although we designed our Phase 3 study of vosoritide in a manner that we believe can demonstrate efficacy and safety of the product candidate for the target patient population, the FDA may ultimately disagree. Moreover, sometimes different regulatory agencies provide different or conflicting advice. While we attempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other non-U.S. regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.
Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.
Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim have received regulatory approval to be commercially marketed and sold in the U.S., the EU and certain other countries, and Palynziq has received regulatory approval to be commercially marketed in the U.S. and the EU. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.
An example of the ongoing regulatory requirements our products are subject to is the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., Palynziq is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:
•prescribers must be certified by enrolling in the REMS program and completing training;
•prescribers must prescribe auto-injectable epinephrine with Palynziq;
•pharmacies must be certified with the REMS program and must dispense Palynziq only to patients who are authorized to receive it;
•patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq; and
•patients must have auto-injectable epinephrine available at all times while taking Palynziq.
47
Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of Palynziq. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the Palynziq REMS program, or whether the FDA will permit modifications to the Palynziq REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute Palynziq in the U.S., impair the safety profile of Palynziq, disrupt continuity of care for Palynziq patients and/or negatively affect sales of Palynziq.
Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product's approved labeling. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.
In addition, the FDA often requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient.
Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:
•restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
•restrictions on product manufacturing processes;
•restrictions on the marketing of a product;
•restrictions on product distribution;
•requirements to conduct post-marketing clinical trials;
•untitled or warning letters or other adverse publicity;
•withdrawal of the products from the market;
•refusal to approve pending applications or supplements to approved applications that we submit;
•recall of products;
•refusal to permit the import or export of our products;
•product seizure;
•fines, restitution or disgorgement of profits or revenue;
•injunctions; or
•imposition of civil or criminal penalties.
If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory agency withdraws its approval of a product, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.
If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.
48
As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. In the EU, orphan drug designation is available if a sponsor can establish: that the medicine is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, which is equivalent to around 250,000 people or fewer or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the medicinal product in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity (extendable to twelve years for medicines that have complied with an agreed pediatric investigation plan pursuant to Regulation 1901/2006) is available. Orphan drug marketing exclusivity may be lost in the EU if a manufacturer is unable to supply sufficient quantities and marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this medicinal product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug exclusivity for our products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.
Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor product’s orphan drug exclusivity period expires. Moreover, with respect to certain biologics and gene therapies, it is uncertain how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidates’ orphan drug exclusivities. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.
We may face competition from biosimilars approved through an abbreviated regulatory pathway.
Our Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act (the FDC Act) and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated approval of biological products that are demonstrated to be “biosimilar” or “interchangeable” with an FDA-approved biological product. A similar abridged marketing authorization process is available to biosimilar products in the EU. In order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of exclusivity for reference products. In Europe, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or Marketing Authorization Applications (MAAs) in Europe, as well as products in development that may be approved under those regimes in the future, could be reference products for biosimilar marketing applications.
To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.
49
As part of the drug development process we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early stage product candidates, we may need to perform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial will be favorable. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials, such as the data we have announced from the GENEr-8-1 study for valoctocogene roxaparvovec. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.
Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.
Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:
•slow or insufficient patient enrollment;
•slow recruitment of, and completion of necessary institutional approvals at, clinical sites;
•budgetary constraints or prohibitively high clinical trial costs;
•longer treatment time required to demonstrate efficacy;
•lack of sufficient supplies of the product candidate;
•adverse medical events or side effects in treated patients, including immune reactions;
•lack of effectiveness of the product candidate being tested;
•availability of competitive therapies to treat the same indication as our product candidates;
•regulatory requests for additional clinical trials or preclinical studies;
•deviations in standards for Good Clinical Practice (GCP); and
•disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services reportable to the FDA or other regulatory authority. If the FDA or other regulatory authority concludes that a financial relationship between us and a principal investigator has created a conflict of interest, the FDA or other regulatory authority may question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.
Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional development and treatment risks in relation to our other, more traditional drug development programs.
50
In addition to the risks set forth in this Risk Factors section associated with developing more traditional pharmaceutical drugs, there are additional, unique development and treatment risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. The goal of gene therapy is to be able to correct an inborn genetic defect through one-time administration of therapeutic genetic material containing non-defective gene copies. The gene copies are designed to reside permanently in a patient, allowing the patient to produce an essential protein or ribonucleic acid (RNA) molecule that a healthy person would normally produce. There is a risk, however, that the new gene copies will produce too little or too much of the desired protein or RNA. Although a one-time administration of a gene therapy product like our product candidate valoctocogene roxaparvovec is intended to correct an inborn genetic defect for the entire lifetime of a patient, there is a risk that the therapeutic effect will not be durable and production of the desired protein or RNA will decrease over time or cease entirely. Because the treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential overproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Furthermore, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed.
As compared to our other, more traditional products, our gene therapy product candidate valoctocogene roxaparvovec, if approved, may present additional problems with respect to the pricing, coverage, and reimbursement and acceptance of the product candidate.
In addition to the risks set forth in this Risk Factors section associated with commercializing more traditional pharmaceutical drugs, there are additional, unique commercial risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec. Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we face uncertainty with respect to the pricing, coverage and reimbursement of valoctocogene roxaparvovec, if approved. In order to recover our research and development costs and commercialize this one-time treatment on a profitable basis, we expect the cost of a single administration of valoctocogene roxaparvovec to be substantial. Therefore, we expect that coverage and reimbursement by governments and other third-party payers will be essential for the vast majority of patients to be able to afford valoctocogene roxaparvovec. Accordingly, sales of valoctocogene roxaparvovec, if approved, will depend substantially, both domestically and internationally, on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of valoctocogene roxaparvovec.
We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. Even if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product candidate in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of valoctocogene roxaparvovec until the product candidate has been on the market for a certain amount of time. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, valoctocogene roxaparvovec
We have implemented a data access plan for valoctocogene roxaparvovec, which restricts our management’s review of emerging data from these trials. Without access to ongoing data, management does not have the ability to adjust the trials based on such emerging data, which could adversely impact the ultimate outcome of these trials.
In order to preserve the scientific integrity of the valoctocogene roxaparvovec trials and to allow us to only report on data at intervals that we believe will be meaningful to investors, we have implemented a data access plan related to the ongoing open label trials, which is designed to significantly mirror blinded trials. Pursuant to this plan, the ongoing emerging data are generally not collected by us, with the exception that certain specific data points are collected and reviewed by a small group of medical personnel monitoring and managing the trial, and then, only to the extent necessary to allow them to perform their monitoring responsibilities. As we disclose and publicly discuss prior data from these trials, such discussions do not incorporate any of the currently emerging data that are being collected and reviewed by personnel monitoring the trial and, accordingly, this prior data may differ significantly from more recent data that are only available to such personnel. Further, because our management does not have access to any of the ongoing data and does not have the ability to adjust the trials based on such emerging data, the data access plan could adversely impact the ultimate outcome of the trials.
If we continue to incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.
51
Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for each year since our inception, with the exception of 2008 and 2010. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we fail to become profitable or are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.
*If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.
As of September 30, 2020, we had cash, cash equivalents and investments totaling $1.8 billion and debt obligations of $1.5 billion (undiscounted), which consisted of our 1.50% senior subordinated convertible notes due in 2020 (the 2020 Notes), our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes) and our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes). We settled or repaid in cash all outstanding 2020 Notes at maturity in October 2020. The 2024 Notes and the 2027 Notes (collectively, the Notes), if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.
In January 2016, we terminated our License and Commercialization Agreement with Ares Trading, S.A. (Merck Serono). Pursuant to the Termination and Transition Agreement related to Kuvan and the Termination Agreement related to Palynziq, we are obligated to make certain payments to Merck Serono if sales and development milestones are achieved. The remaining milestone payments that may become payable include up to a maximum of €60 million, in cash, if future sales milestones are met with respect to Kuvan and Palynziq.
We may require additional financing to fund the repayment of the Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.
We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:
•our ability to successfully market and sell our products;
•the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);
•the timing, number, size and scope of our preclinical studies and clinical trials;
•the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;
•the progress of research programs carried out by us;
•our possible achievement of development and commercial milestones under agreements with third parties, such as the Kuvan and Palynziq milestones under the termination agreements with Merck Serono;
•any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;
•Sanofi Genzyme’s (Genzyme) ability to continue to successfully commercialize Aldurazyme; and
•whether our convertible debt is converted to common stock in the future.
Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:
•additional licenses and collaborative agreements;
•additional contracts for product manufacturing; and
•additional financing facilities or arrangements.
52
We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.
*We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.
As of September 30, 2020, we had $1.5 billion (undiscounted) principal amount of indebtedness, including $375.0 million (undiscounted) principal amount of indebtedness under the 2020 Notes, $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes and $600.0 million (undiscounted) principal amount of indebtedness under the 2027 Notes. We settled or repaid in cash all outstanding 2020 Notes at maturity in October 2020. In October 2018, we also entered into an unsecured credit agreement (the 2018 Credit Facility) with Bank of America, N.A., as the administrative agent, swingline lender and a lender, Citibank N.A. as letter of credit issuer and each of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citibank, N.A. and Wells Fargo Securities, LLC as joint lead arrangers and joint bookrunners, providing up to $200.0 million in revolving loan commitments. Our indebtedness may:
•limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;
•limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;
•require us to use a substantial portion of our cash flow from operations to make debt service payments;
•limit our flexibility to plan for, or react to, changes in our business and industry;
•place us at a competitive disadvantage compared to our less leveraged competitors; and
•increase our vulnerability to the impact of adverse economic and industry conditions.
In addition, the 2018 Credit Facility contains, and any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full. If we default under the 2018 Credit Facility, the outstanding borrowings thereunder could become immediately due and payable, the 2018 Credit Facility lenders could refuse to permit additional borrowings under the facility, or it could lead to defaults under agreements governing our current or future indebtedness, including the indentures governing the Notes. If we default under any of the Notes, such Notes could become immediately due and payable and it could lead to defaults under the other Notes and/or the 2018 Credit Facility.
*In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.
Our outstanding indebtedness consists primarily of the 2024 Notes and 2027 Notes, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon maturity of the Notes, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.
In addition, we also may borrow up to $200.0 million in revolving loans under the 2018 Credit Facility, which would be required to be repaid in cash at maturity on October 19, 2021.
53
If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.
Before we can begin commercial manufacture of our products, regulatory authorities must approve marketing applications that identify manufacturing facilities operated by us or our contract manufacturers that have passed regulatory inspection and manufacturing processes that are acceptable to the regulatory authorities. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced inspection by the FDA and international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facility in the U.S. has been approved by the FDA for the manufacture of Palynziq, and it has been approved by the FDA, the European Commission (EC), and health agencies in other countries for the manufacture of Aldurazyme, Brineura, Naglazyme and Vimizim. Our manufacturing facility in Shanbally, Cork, Ireland has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Vimizim, and it has been approved by the FDA and the EMA as a formulated bulk drug substance manufacturing and quality control facility for Brineura. In addition, our third-party manufacturers’ facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.
Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal or international regulatory inspection.
If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.
If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.
Due to the complexity of manufacturing our product candidates and products, we may not be able to manufacture sufficient quantities. Our inability to produce enough of our product candidate at acceptable costs may result in the delay or termination of development programs. With respect to our commercial portfolio, we may not be able to manufacture our products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins.
The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.
With respect to valoctocogene roxaparvovec, gene therapy products are relatively novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the valoctocogene roxaparvovec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all, or commercializing valoctocogene roxaparvovec on a profitable basis, if at all.
Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.
Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of
54
internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs, including Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim, have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.
We have entered into contractual relationships with third-party manufacturers to produce active ingredients in Kuvan and Palynziq. If those manufacturers are unwilling or unable to fulfill their contractual obligations, we may be unable to meet demand for Kuvan and Palynziq, or sell these products at all, we may lose potential revenue, and we may be forced to terminate a program. We have contracts for the production of final product for Kuvan and Palynziq. We also currently rely on third parties for portions of the manufacture of Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.
In addition, our manufacturing processes subject us to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.
Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.
We depend on single-source suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:
•timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;
•labor interruptions;
•changes in our sources for manufacturing;
•the timing and delivery of shipments;
•our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; and
•conditions affecting the cost and availability of raw materials.
If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.
Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.
With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.
55
Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve profitability.
All of our products target diseases with small patient populations. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve profitability. For Brineura, Naglazyme and Vimizim in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.
If we fail to obtain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.
The course of treatment for patients using our products is expensive. We expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenue and gross margins will be adversely affected.
Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.
Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.
Reimbursement in the EU and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.
For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margins may be adversely affected.
56
A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenue in these countries.
We make a significant portion of our international sales of Naglazyme and Vimizim through special access or “named patient” programs, which do not require full product approval, and we expect a significant portion of our international sales of Brineura will also be through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained for each patient. The approval normally requires an application or a lawsuit accompanied by evidence of medical need. Generally, the approvals for each patient must be renewed from time to time.
These programs are not well defined in some countries and are subject to changes in requirements and funding levels. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.
Without the special access programs, we would need to seek full product approval to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek and maintain a full product approval, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.
If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected.
Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely) or commercialize their products before we do. With respect to valoctocogene roxaparvovec, if the product candidate is approved, we will face a highly developed and competitive market for hemophilia A treatments. As we commercialize valoctocogene roxaparvovec, if approved, we may face intense competition from large pharmaceutical companies with extensive resources and established relationships in the hemophilia A community. If we do not compete successfully, our revenue would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.
Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenue and results of operations.
We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has recently come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.
International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected.
57
We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenue and results of operations.
*Government healthcare reform could increase our costs and adversely affect our revenue and results of operations.
Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. There remain judicial and congressional challenges to certain aspects of the PPACA, as well as efforts by the U.S. Presidential administration to repeal or replace certain aspects of the PPACA, and we expect there will be additional challenges and amendments to the PPACA in the future. Since January 2017, the U.S. President has signed several Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed legislation repealing the PPACA in its entirety, it has enacted laws that modify certain provisions of the PPACA such as removing penalties for not complying with the PPACA’s individual mandate to carry health insurance, eliminating the implementation of certain PPACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the individual mandate was repealed by Congress as part of the Tax Cuts & Jobs Act. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. On March 2, 2020, the U.S. Supreme Court announced that it would review this case. It is unclear how such litigation and other efforts to repeal and replace the PPACA will impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.
We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Recently there has been heightened governmental scrutiny in countries worldwide over the manner in which manufacturers set prices for their marketed products.
In the U.S., there have been several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the U.S. Presidential administration’s budget proposal for the fiscal year 2021 includes a $135.0 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, place limits on pharmaceutical price increases. Moreover, the U.S. Presidential administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On July 24, 2020, the current U.S. President announced four executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals, including, among other things, one that directs the U.S. Department of Health and Human Services (HHS) to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for plans, pharmacies, and pharmaceutical benefit managers The FDA also recently released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Although a number of these and other measures may require additional authorization to become effective, Congress and the U.S. Presidential administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.
58
Likewise, in many EU countries, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU countries and other foreign countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. Moreover, in order to obtain reimbursement for our products in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our products to other available therapies.
Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
For more information regarding government healthcare reform, see “Government Regulation - Health Reform” in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.
Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.
*If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.
We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase, order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers.
Federal and state false claims laws, including the civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
In addition, recent healthcare reform legislation has strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.
59
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and foreign laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation, including a November 2020 California ballot measure that passed and will substantially expand the requirements of the CCPA. These new regulations could increase our potential liability, increase our compliance costs and adversely affect our business.
The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EU Member State implementing legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Potential pecuniary fines for noncompliant companies may be up to the greater of €20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with the new EU data protection rules.
The GDPR and other European data protection laws generally restrict the transfer of personal information from Europe, including the European Economic Area, United Kingdom (U.K.) and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from Europe has been the European Commission’s Standard Contractual Clauses. However, the Court of Justice issued a decision that called into question whether the Standard Contractual Clauses can lawfully be used for transfers of personal information from Europe to the United States or most other countries. At present, there are few, if any, viable alternatives to the Standard Contractual Clauses, on which we have relied for personal information transfers from Europe to the United States and other countries. Authorities in the U.K. and Switzerland may similarly question the viability of the Standard Contractual Clauses, as a mechanism for the lawful transfer of personal information from those countries to the United States. Furthermore, it is unclear whether transfer of personal information from Europe to the U.K. will remain lawful after the post-Brexit transition period ends on December 31, 2020 and what if any transfer mechanisms will be available for such transfers. If we are unable to implement sufficient safeguards to ensure that our transfers of personal information from Europe are lawful, we will face increased exposure to regulatory actions, substantial fines, and injunctions against processing personal information from Europe. In addition, we may be required to increase our data processing capabilities in Europe at significant expense. Inability to import personal information from Europe may also restrict our clinical trials activities in Europe and limit our ability to collaborate with contract research organizations, service providers, contractors and other companies subject to European data protection laws. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of operating our business.

60
Substantial new laws and regulations affecting compliance have also been adopted in the U.S. and certain foreign countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians (including certain other healthcare professionals) and teaching hospitals, as well as investment and ownership interests held by such physicians and their immediate family members during the preceding calendar year. Effective January 1, 2022, manufacturers will also be required to report on payments or transfers of value, and ownership and investment interests held, during the previous year to physician assistants, nurse practitioners or clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many foreign countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted foreign legislation creates reporting obligations on payments, gifts and benefits made to these professionals; however, implementing regulations enacting such laws are still pending and subject to varying interpretations by courts and government agencies. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.
Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement agencies in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to significant criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.
We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenue and results of operations.
A significant portion of the sales of Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim are generated from countries other than the U.S. Similarly, we expect a significant portion of the sales of Palynziq to be generated from countries other than the U.S. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:
•the increased complexity and costs inherent in managing international operations;
•diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;
•political and economic instability;
•diminished protection of intellectual property in some countries outside of the U.S.;
•trade protection measures and import or export licensing requirements;
•difficulty in staffing and managing international operations;
•differing labor regulations and business practices;
•potentially negative consequences from changes in or interpretations of tax laws;
•changes in international medical reimbursement policies and programs;
•financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by foreign governments;
•regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ and service providers’ activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); and
•rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.
Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations.
61
As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenue and profitability.
*The U.K.’s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could adversely affect our revenue and results of operations.
In June 2016, a majority of the eligible members of the electorate in the U.K. voted to withdraw from the EU in a national referendum (Brexit). On March 29, 2017, the U.K.’s Prime Minister formally delivered the notice of withdrawal. After significant negotiation between the U.K. and the EU, the withdrawal of the U.K. from the EU took effect on January 31, 2020. There is now a transition period while the U.K. and EU negotiate additional arrangements, including their future trading terms. The U.K. has stated that it wants the transition period to expire, and the future trading terms to be agreed, by December 31, 2020. No agreement has yet been reached between the U.K. and the EU and it may be the case that no formal customs and trading agreement will be reached prior to the expiration of the transition period on December 31, 2020.
The uncertainties regarding the U.K.’s future relationship with the EU, have had and may continue to have an adverse effect on global economic conditions and the stability of global financial markets. In particular, depending on what terms are agreed between the U.K. and the EU, if any, it could lead to a period of considerable uncertainty in relation to global financial and banking markets, as well as on regulatory processes in Europe and the EEA. Lack of clarity about future U.K. laws and regulations as the U.K. determines which EU rules and regulations to replace or replicate, including financial laws and regulations, tax and free trade agreements, intellectual property rights, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws, could decrease foreign direct investment in all markets, increase costs, depress economic activity and restrict access to capital.
If the U.K. and the EU are unable to negotiate acceptable future trading terms or if other EU countries pursue withdrawal, barrier-free access between the U.K. and other EU or EEA countries could be diminished or eliminated, which could make our doing business in the EU more difficult. As a result of Brexit, we may face disruptions in our supply chain, inventory management, manufacturing process and product distribution network, which could adversely affect our business and results of operations. Moreover, Brexit may also lead to new regulatory costs and challenges that could have a material adverse effect on our operations. The EMA has issued guidance to marketing authorization holders of centrally authorized medicinal products regarding certain requirements that need to be considered as part of Brexit, such as the requirement for the marketing authorization holder of a product centrally approved by the EC to be established in the EU, and the requirement for some activities relating to centrally approved products, such as batch release and pharmacovigilance, be performed in the EU. Furthermore, there are few indications of the effect Brexit will have on the pathway to obtaining marketing approval for any of our product candidates in the U.K.
U.S. export control and economic sanctions may adversely affect our business, financial condition and operating results. Moreover, compliance with such regulatory requirements may increase our costs and negatively impact our ability to sell our products and collect cash from customers.
Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or hinder our ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. If we fail to comply with these laws and regulations, we could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges and fines.
We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, be renewed in the future or that we will remain in compliance. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
Moreover, U.S. export control and economic sanctions may make operating in certain countries more difficult and expensive. For example, we may be unable to find distributors or financial institutions willing to facilitate the sale of our products and collection of cash from such sales in a cost-effective manner, if at all.
62
Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.
We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the United States, the U.K. Bribery Act and other similar laws in other countries in which we do business. We operate in a number of countries that are recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to foreign officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered foreign officials for purposes of applicable anti-corruption laws.
Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.
Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products
Changes in funding for the FDA, the EMA and other government agencies or government shutdowns could hinder the ability of such agencies to hire and retain key leadership and other personnel or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
Changes in funding levels of government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA to timely review and approve INDs or marketing authorizations for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.
Government shutdowns could also impact the ability of government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory agencies, such as the FDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Our international operations pose currency risks, which may adversely affect our operating results and net income.
A significant and growing portion of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the Great British Pound, the Canadian Dollar and several other currencies, changes in those currencies relative to the U.S. Dollar (USD) will impact our revenues and expenses. If the USD were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the USD were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. In addition, because our financial statements are reported in USD, changes in currency exchange rates between the USD and other currencies have had, and will continue to have, an impact on our results of
63
operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.
We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.
*If we are unable to protect our intellectual property, we may not be able to compete effectively.
Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.
The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of Aldurazyme, Naglazyme and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in Kuvan) has also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.
We own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:
•With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.
•Patents have limited duration and expire. For example, certain of our patents related to Aldurazyme expired in November 2019 and the other patents related to Aldurazyme expire by November 2020.
•Competitors may interfere with our patent process in a variety of ways. Competitors may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, a competitor could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent.
•Generic manufacturers may use litigation and regulatory means to obtain approval for generic versions of our products notwithstanding our filed patents or patent applications.
•Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs.
•Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.
•The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a “first-to-invent” system to a “first-to-file” system, and the implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.
It is also unclear whether our trade secrets are adequately protected. Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.
64
Under policies recently adopted in the EU, clinical trial data submitted to the EMA in MAAs that were traditionally regarded as confidential commercial information are now subject to public disclosure. Subject to our ability to review and redact a narrow sub-set of confidential commercial information, the new EU policies will result in the EMA’s public disclosure of certain of our clinical study reports, clinical trial data summaries and clinical overviews for recently completed and future MAA submissions. The move toward public disclosure of development data could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, and enabling competitors to use our data to gain approvals for their own products.
If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenue and financial results generally.
Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.
Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, such as valoctocogene roxaparvovec, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. If someone else claims we infringe its intellectual property, we would face a number of issues, including the following:
•Defending a lawsuit takes significant executive resources and can be very expensive.
•If a court decides that our product infringes a competitor’s intellectual property, we may have to pay substantial damages.
•With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.
•We may need to redesign our product so it does not infringe the intellectual property rights of others.
•Redesigning our product so it does not infringe the intellectual property rights of competitors may not be possible or could require substantial funds and time.
We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations.
If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.
If our Manufacturing, Marketing and Sales Agreement with Genzyme were terminated, we could be prevented from continuing to commercialize Aldurazyme or our ability to successfully commercialize Aldurazyme would be delayed
65
or diminished.
Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Genzyme and us related to Aldurazyme for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.
If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to Aldurazyme and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to Aldurazyme will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to Aldurazyme is to be sold to the highest bidder, with the proceeds to be split between Genzyme and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.
If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to Aldurazyme exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offeree’s interest in Aldurazyme and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating party’s interest in Aldurazyme and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to Aldurazyme. The Amended and Restated Collaboration Agreement between us and Genzyme will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.
If we were obligated or given the option to buy out Genzyme’s interest in Aldurazyme and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to Aldurazyme, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Genzyme’s interest, we may be held in breach of the agreement and may lose any claim to the rights to Aldurazyme and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing Aldurazyme. If this happened, not only would our product revenues decrease, but our share price would also decline.
If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.
Our future growth and development depend in part on our ability to successfully develop new products from our research and development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals, are inherently uncertain and may not result in the commercialization of any products.
Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as Aldurazyme, Kuvan and Naglazyme. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which may target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.
66
Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.
*The sale of generic versions of Kuvan by generic manufacturers may adversely affect our revenue and results of operations.
The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, permits the FDA to approve abbreviated new drug applications (ANDAs) for generic versions of branded drugs. We refer to this process as the ANDA process. The ANDA process permits competitor companies to obtain marketing approval for a drug with the same active ingredient as a branded drug, but does not generally require the conduct and submission of clinical efficacy studies for the generic product. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product is bioequivalent to the branded product.
Pursuant to the Hatch-Waxman Act, companies were permitted to file ANDA applications for proposed generic versions of Kuvan at any time after December 2011. We own several patents that cover Kuvan, and we have listed those patents in conjunction with that product in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). The Hatch-Waxman Act requires an ANDA applicant seeking FDA approval of its proposed generic product prior to the expiration of our Orange Book-listed patents to certify that the applicant believes that our patents are invalid or will not be infringed by the manufacture, use or sale of the drug for which the application has been submitted (a paragraph IV certification) and notify us of such certification (a paragraph IV notice). Upon receipt of a paragraph IV notice, the Hatch-Waxman Act allows us, with proper basis, to bring an action for patent infringement against the ANDA filer, asking that the proposed generic product not be approved until after our patents expire. If we commence a lawsuit within 45 days from receipt of the paragraph IV notice, the Hatch-Waxman Act provides a 30-month stay, during which time the FDA cannot finally approve the generic’s application. If the litigation is resolved in favor of the ANDA applicant during the 30-month stay period, the stay is lifted and the FDA may approve the ANDA if it is otherwise ready for approval. The discovery, trial and appeals process in such a lawsuit is costly, time consuming, and may result in generic competition if the ANDA applicant prevails.
Between 2014 and 2016 we received paragraph IV notice letters from two pharmaceutical companies notifying us that each had filed ANDAs seeking approval of proposed generic versions of Kuvan. We filed lawsuits alleging patent infringement against each company, and between 2015 and 2017 we entered into settlement agreements with the companies that resolved the patent litigation in the U.S. The settlement agreements granted the companies non-exclusive licenses to our Kuvan-related patents to allow them to market generic versions of sapropterin dihydrochloride in the U.S. for the indications approved for Kuvan beginning on October 1, 2020, or earlier under certain circumstances. Generic versions of Kuvan first became available in the U.S. in October 2020.
Any future ANDA or related legal proceeding could have an adverse impact on our stock price, and litigation to enforce our patents has, and is likely to continue to, cost a substantial amount and require significant management attention. If the patents covering Kuvan and its use are not upheld in litigation, or if any ANDA filer we bring suit against is found to not infringe our asserted patents, the resulting generic competition following the expiration of regulatory exclusivity would have a material adverse effect on our revenue and results of operations. Moreover, generic competition following the settlements described above could have a material adverse effect on our revenue and results of operations.
We also face potential generic competition for Kuvan in certain foreign countries, and there is a process equivalent to the ANDA process under Article 10 of Directive 2001/83/EC in the EU. Our ability to successfully market and sell Kuvan in many countries in which we operate is based upon patent rights or certain regulatory forms of exclusivity, or both. The scope of our patent rights and regulatory exclusivity for Kuvan vary from country to country and are dependent on the availability of meaningful legal remedies in each country. If our patent rights and regulatory exclusivity for Kuvan are successfully challenged, expire, or otherwise terminate in a particular country, the resulting generic competition could have a material adverse effect on our revenue and results of operations.
If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
67
For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
We depend upon our key personnel and our ability to attract and retain employees.
Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of any member of our senior management or the inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results.
Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officers’ ability to compete with us after their employment is terminated. The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. Due to this intense competition, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. If we are unsuccessful in our recruitment and retention efforts, our business may be harmed.
Our success depends on our ability to manage our growth.
Product candidates that we are currently developing or may license or acquire in the future may be intended for patient populations that are significantly larger than any of the patient populations we currently target. In order to continue development and marketing of these products, if approved, we will need to significantly expand our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory and corruption risks and our management may be unable to manage successfully future market opportunities or our relationships with customers and other third parties.
Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.
Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as Aldurazyme, Naglazyme, and Vimizim in MPS diseases, could be greatly reduced. Moreover, if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will still depend, in part, on the acceptance of physicians, patients and healthcare payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost effective and safe. Changes in treatment method can be caused by the introduction of other companies’ products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.
If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.
We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercialization of our product
68
programs.
We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively and have a material adverse effect on our business, reputation, financial condition, and results of operations.
We rely significantly on our information technology systems to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively. Our ability to manage and maintain our operations, inventory and internal reports, to manufacture and ship our products to customers and timely invoice them depends significantly on our enterprise resource planning, production management and other information systems. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access of these systems, may affect our ability to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations.
As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties for which we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees or contractors or malware, hacking, business email compromise, phishing or other cyberattacks directed by third parties. While we have implemented measures to protect our information and data, our efforts may not be successful.
We have experienced and may continue to experience cybersecurity incidents. Although to our knowledge we have not experienced any material incident or interruption to date, if such an event were to occur it could result in a material disruption of our development programs and commercial operations, including due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information. Moreover, the costs to us to investigate and mitigate cybersecurity incidents could be significant. For example, the loss of clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security breach that results in the unauthorized access, use or disclosure of personal data may require us to notify individuals, governmental authorities, credit reporting agencies, or other parties pursuant to privacy and security laws and regulations or other obligations. Such a security compromise could harm our reputation, erode confidence in our information security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, proprietary or personal information, we could be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims, litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.
If a natural disaster, terrorist or criminal activity or other unforeseen event caused significant damage to our facilities or those of our third-party manufacturers and suppliers or significantly disrupted our operations or those of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.
The occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair the ability for us or our third-party manufacturers to manufacture our products and product candidates. Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for Aldurazyme, Naglazyme and Palynziq and is one of two manufacturing facilities for Brineura and Vimizim. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support valoctocogene roxaparvovec clinical development activities and the anticipated commercial demand for valoctocogene roxaparvovec, if approved. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely,
69
impaired, and our commercialization efforts and revenue could be seriously impaired.
Moreover, other unforeseen events, such as power outages, could significantly disrupt our operations or those of our third-party manufacturers and suppliers, which could result in significant delays in the manufacture of our products and adversely impact our commercial operations and revenues. Pacific Gas and Electric Company, the electric utility in the San Francisco Bay Area where many of our facilities are located, commenced widespread blackouts during the fall of 2019 to avoid and contain wildfires sparked during strong wind events by downed power lines or equipment failures. While we have not experienced damage to our facilities or material disruption to our operations as a result of these power outages, ongoing blackouts, particularly if prolonged or frequent, could impact our business going forward. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.
*Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business and financial condition.
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (TCJA), enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, the application of certain tax credits (including a reduction of tax credits under the Orphan Drug Act), the deductibility of expenses, the utilization of net operating losses (NOLs) and other deferred tax assets, and the taxation of foreign earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, enacted on March 27, 2020, modified certain provisions of the TCJA, including provisions relating to NOL utilization. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the CARES Act, or any newly enacted federal tax legislation. The impact of changes under the TCJA, the CARES Act, or future reform legislation could increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.
Moreover, changes in the tax laws of foreign jurisdictions could arise, including as a result of the base erosion and profit shifting (BEPS) project that was undertaken by the Organization for Economic Co-operation and Development (OECD), or other initiatives led by the European Commission. The OECD, which represents a coalition of member countries including the United States and other countries in which we have operations, made several recommendations with the aim of addressing tax avoidance and ensuring that profits are taxed where economic activities generating the profits are performed and where value is created. These changes, as adopted by countries, may increase tax uncertainty and may adversely affect our provision for income taxes, results of operations and cash flows. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm's length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities successfully challenge our transfer prices as not reflecting arm's length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, resulting in a higher tax liability. In addition, if a country from which income is reallocated does not agree with the reallocation, both that country and the other country to which the income was allocated could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our business, financial condition, results of operations and cash flows.
Our business is affected by macroeconomic conditions.
Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counter parties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.
We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenue would be adversely affected.
70
Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.
Risks Related to Ownership of Our Securities
*Our stock price may be volatile, and an investment in our stock could suffer a decline in value.
Our valuation and stock price may have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock will fluctuate due to factors including:
•product sales and profitability of our products;
•manufacturing, supply or distribution of our product candidates and commercial products;
•progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;
•results of clinical trials, announcements of technological innovations or new products by us or our competitors;
•generic competition to Kuvan tablets and powder relating to our settlements with the two pharmaceutical companies described above in this Risk Factors section or potential generic competition from future competitors;
•government regulatory action affecting our product candidates, our products or our competitors’ product candidates and products in both the U.S. and non-U.S. countries;
•developments or disputes concerning patent or proprietary rights;
•general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;
•economic conditions in the U.S. or abroad;
•negative publicity about us or the pharmaceutical industry;
•changes in the structure of healthcare payment systems;
•cybersecurity incidents experienced by us or others in our industry;
•broad market fluctuations in the U.S., the EU or in other parts of the world;
•actual or anticipated fluctuations in our operating results, including due to timing of large orders for our products, in particular in Latin America, where governments place large periodic orders for Naglazyme and Vimizim;
•changes in company assessments or financial estimates by securities analysts;
•acquisitions of products, businesses, or other assets; and
•sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.
Furthermore, the stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In some cases, these fluctuations have been unrelated or disproportionate to the operating performance of those companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. For example, in September 2020, after a substantial drop in our stock price that followed an announcement providing a regulatory update regarding valoctocogene roxaparvovec, we and certain of our officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false and misleading statements. We may be the target of additional litigation of this type in the future as well. Securities litigation against us could result in substantial costs and divert our management’s time and attention from other business concerns, which could harm our business.
In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.
*Conversion of the Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress the price of our common stock.
71
The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.
Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.
We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholders’ meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.
The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take us over.
The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of us would trigger options by the respective holders of the applicable Notes to require us to repurchase such Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the Notes.
*Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:
•any derivative action or proceeding brought on our behalf;
•any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of BioMarin to us or our stockholders;
•any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; and
•any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.
This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction, and further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provision, including consent to the personal jurisdiction of the Court of Chancery of the State of Delaware related to any action covered by such provision. While the Delaware courts have determined that such choice of forum provision is facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provision. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provision of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.
72
This exclusive-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
None.


Item 3.    Defaults Upon Senior Securities
None.

Item 4.    Mine Safety Disclosures
Not applicable.

Item 5.    Other Information
On November 4, 2020, we entered into a part-time employment agreement with Dr. Robert A. Baffi, effective January 1, 2021, setting forth the terms under which Dr. Baffi will continue to serve as a Senior Advisor to us on a part-time basis through December 31, 2021 (the Part-Time Agreement). As of January 1, 2021, the Part-Time Agreement terminates Dr. Baffi’s full-time employment agreement with us and entitles Dr. Baffi to an annual salary of $200,000 and continuation of insurance benefit plans and programs for him and his spouse during the term of the Part-Time Agreement.


73
Item 6.    Exhibits
Exhibit NumberDescription
2.1
2.2
2.3
3.1
3.2
31.1*
31.2*
32.1+
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Link Document
104
XBRL tags for the cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, are embedded within the Inline XBRL document.
*    Filed herewith
+    The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act of 1933, as amended, irrespective of any general incorporation language contained in any such filing.
74
Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019, (iii) Condensed Consolidated Statement of Stockholders’ Equity for the three and nine months ended September 30, 2020 and 2019, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019, and (v) Notes to Condensed Consolidated Financial Statements.
75
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BIOMARIN PHARMACEUTICAL INC.
Dated: November 6, 2020By/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President,  
Chief Financial Officer

76
 EX-31.1 2 exhibit311-30sep20x10q.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Jean-Jacques Bienaimé, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 6, 2020
/s/ JEAN-JACQUES BIENAIMÉ
Jean-Jacques Bienaimé
Chief Executive Officer


 EX-31.2 3 exhibit312-30sep20x10q.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Brian R. Mueller, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 6, 2020
/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President, Chief Financial Officer


 EX-32.1 4 exhibit321-30sep20x10q.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
We, Jean-Jacques Bienaimé and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc.
/s/ JEAN-JACQUES BIENAIMÉ
Jean-Jacques Bienaimé
Chief Executive Officer
Date: November 6, 2020
/S/ BRIAN R. MUELLER
Brian R. Mueller
Executive Vice President, Chief Financial Officer
Date: November 6, 2020
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.


 EX-101.SCH 5 bmrn-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2105104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2106105 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2110106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2114107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2417406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 2118108 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2420407 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 2421408 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2122109 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2424409 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2425410 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) link:presentationLink link:calculationLink link:definitionLink 2126110 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2428411 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2429412 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2430413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2431414 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2133111 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2334307 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2436417 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2436417 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2437418 - Disclosure - Leases - Schedule of Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 2438419 - Disclosure - Leases - Schedule of Other Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2140112 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2341308 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2442421 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2443422 - Disclosure - Debt - Summary of Convertible Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2444423 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2145113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2346309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2447424 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) link:presentationLink link:calculationLink link:definitionLink 2448425 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) link:presentationLink link:calculationLink link:definitionLink 2149114 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2451426 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2452427 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) link:presentationLink link:calculationLink link:definitionLink 2453428 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 2454429 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) link:presentationLink link:calculationLink link:definitionLink 2455430 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) link:presentationLink link:calculationLink link:definitionLink 2156115 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2357311 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Stock-Based Compensation - Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2459432 - Disclosure - Stock Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2160116 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2461433 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2162117 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2363312 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2464434 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2465435 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2466436 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2167118 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2468437 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bmrn-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bmrn-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bmrn-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Weighted average discount rate: Weighted Average Discount Rate [Abstract] Weighted average discount rate abstract. Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim Products Excluding Product One [Member] Products excluding product one. Accretion of discount on convertible notes Amortization of Debt Discount (Premium) Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Stock Treasury Stock [Member] Early Stage Development Program Early Stage Development Program [Member] Early Stage Development Program Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Inventory write-off, net of stock-based compensation Inventory Write-down Customer D Customer Four [Member] Customer 4 Supplemental Cash Flow Information Supplemental Cash Flow Lease Information [Abstract] Supplemental cash flow lease information. Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Other current assets Other Current Assets [Member] Debt issuance costs Debt Issuance Costs, Gross Range Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Short-term convertible debt, net Short-term convertible debt, net Convertible Debt, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Third Party Third Party [Member] Third party. Amortization Finance Lease, Right-of-Use Asset, Amortization DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Schedule of Available-for-sale Securities [Line Items] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items] Schedule of cash, cash equivalents and available-for-sale securities. Security Exchange Name Security Exchange Name Liabilities: Lease Liabilities [Abstract] Lease liabilities. Intangible assets, net Net carrying value Intangible Assets, Net (Excluding Goodwill) Proceeds from convertible senior subordinated note offering, net Proceeds from Convertible Debt Weighted average remaining lease term (in years): Weighted Average Remaining Lease Term [Abstract] Weighted average remaining lease term abstract. INCOME (LOSS) FROM OPERATIONS Operating Income (Loss) Total current liabilities Liabilities, Current Amount Reclassified from AOCI Gain (Loss) Reclassification out of Accumulated Other Comprehensive Income [Member] Variable Rate Variable Rate [Domain] Increase (decrease) in accounts payable and accrued liabilities related to intangible assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets Variable Rate Variable Rate [Axis] Total lease payments Finance Lease, Liability, Payment, Due Long-term investments Long-term Marketable Securities Debt Securities, Available-for-sale, Noncurrent Repurchase of common stock Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Furniture and equipment Furniture and Fixtures [Member] Depreciation capitalized into inventory Depreciation Expense Capitalized Into Inventory Depreciation expense capitalized into inventory during the reporting period. Entity Address, State or Province Entity Address, State or Province Operating leases Operating Lease, Payments ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Firdapse Product Five [Member] Product 5 [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Operating Operating Lease, Right-of-Use Asset Debt discount Convertible debt, unamortized discount Debt Instrument, Unamortized Discount REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Concentration Risk And Segment Reporting Disclosure [Text Block] Concentration risk and segment reporting disclosure. Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Summary of Convertible Debt Convertible Debt [Table Text Block] Cash paid for income taxes Income Taxes Paid 2021 Finance Lease, Liability, to be Paid, Year One 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Contingent consideration Contingent Consideration [Member] Contingent consideration. AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Customer Customer [Axis] Credit Concentration Risk Credit Concentration Risk [Member] Fair Value by Liability Class Fair Value by Liability Class [Domain] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Percentage of Annual TSR multiplier on absolute basis Annual Shareholder Return Multiplier On Absolute Basis, Percentage Annual Shareholder Return Multiplier On Absolute Basis, Percentage Hedging Designation Hedging Designation [Domain] Total lease costs Lease, Cost Operating expenses Operating Expenses Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Deferred tax assets Deferred Income Tax Assets, Net Other Payments for (Proceeds from) Other Investing Activities Financing leases Finance Lease, Principal Payments Restricted Stock Unit Awards With Market Conditions Two Thousand Twenty Base Restricted Stock Unit Awards With Market Conditions [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Market Conditions Liability Class Liability Class [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Marketed by Genzyme Sales Channel, Through Intermediary [Member] Inventory Total inventory Inventory, Net Total revenues Net product revenues Revenue from Contract with Customer, Excluding Assessed Tax Fair Value, Measurement Frequency Measurement Frequency [Domain] Total Operating And Finance Lease Liabilities Payments Due [Abstract] Operating and finance lease liabilities payments due. Inventory [Line Items] Inventory [Line Items] Strategic Investment Strategic Investment [Member] Strategic investment. Concentration risk, percentage Concentration Risk, Percentage Business Acquisition Business Acquisition [Axis] Geographical Geographical [Domain] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in measurement of lease liabilities abstract. Debt instrument, conversion ratio Debt Instrument, Convertible, Conversion Ratio Customers Customers [Member] Customers. Inventory [Axis] Inventory [Axis] Statement [Line Items] Statement [Line Items] Long term marketable securities maturity period Long Term Marketable Securities Maturity Period Long-term marketable securities maturity period. Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Other Accounts Payable and Accrued Liabilities Computer hardware and software Computer Equipment [Member] Purchase Long [Member] Schedule Of Interest Expenses [Line Items] Schedule Of Interest Expenses [Line Items] Schedule of interest expenses. Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Statement [Table] Statement [Table] Proceeds from sale of nonfinancial assets Proceeds From Sale Of Nonfinancial Assets Proceeds From Sale Of Nonfinancial Assets Range Statistical Measurement [Axis] IRELAND IRELAND U.S. government agency securities US Government Agencies Debt Securities [Member] Long-term convertible debt, net Convertible Notes, net of unamortized discount and deferred offering costs Convertible Debt, Noncurrent Restricted Investments Restricted Investments [Member] Restricted investments. Cash Flow Hedging Gains (Losses) Reclassified into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Fair value of other current liabilities Other Liabilities Current Fair Value Disclosure Other liabilities current fair value disclosure. Entity Small Business Entity Small Business Other income, net Other Operating Income (Expense), Net Latin America Latin America [Member] Operating Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Cost of sales Cost of Revenue Selling, general and administrative Selling, General and Administrative Expenses [Member] Increase (decrease) in goodwill Goodwill, Period Increase (Decrease) Summary of Derivatives Designated as Hedging Instruments Outstanding Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Amendment Flag Amendment Flag Earnings Per Share [Table] Earnings Per Share [Table] Earnings per share. Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Contingent Consideration Type Contingent Consideration Type [Domain] Liabilities remeasured Contingent consideration at December 31, 2019 Contingent consideration at September 30, 2020 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Leases Lessee, Finance Leases [Text Block] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Purchase commitments and other minimum contractual obligations Purchase Commitment, Remaining Minimum Amount Committed Outstanding amount Long-term Line of Credit SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Effect of dilutive securities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Measurement Frequency Measurement Frequency [Axis] Royalty and other revenues Royalty And Other [Member] Royalty and other. Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Unrealized Gains (Losses) on Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Short-term investments Short-term Marketable Securities Debt Securities, Available-for-sale, Current 1.50% Senior Subordinated Convertible Notes Due in October 2020 One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member] One point five zero percent senior subordinated convertible notes due in October twenty twenty. Derivative Instrument Derivative Instrument [Axis] Fair Value of Financial Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Gains (Losses) Recognized in Earnings Derivative, Gain (Loss) on Derivative, Net Other long-term liabilities Other Noncurrent Liabilities [Member] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Common stock issuable under the 2027 Notes Convertible Senior Notes Due Two Thousand Twenty Seven [Member] Convertible Senior Notes Due Two Thousand Twenty Seven Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Domain] Geographical Geographical [Axis] Total lease payments Operating And Finance Lease Liability Payments Due Operating and finance lease liability payments due. Less: Interest Operating And Finance Lease Liability Undiscounted Excess Amount Operating and finance lease liability undiscounted excess amount. Lease Classification Assets and Liabilities, Lessee [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Foreign and other Foreign Government And Other Debt Securities [Member] Foreign government and other debt securities. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Customer One Customer A Customer One [Member] Customer 1 Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] Schedule of Net Product Revenues by Product Revenue from External Customers by Products and Services [Table Text Block] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location Income Statement Location [Domain] Cash Cash [Member] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general and administrative Selling, General and Administrative Expense Maturity of Lease Liabilities Maturity Of Lease Liabilities [Abstract] Maturity of lease liabilities. Notional amount Derivative, Notional Amount Foreign exchange contracts Foreign Exchange Contract [Member] Schedule of Lease Cost Lease, Cost [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other assets Other Assets, Noncurrent Concentration Risk [Table] Concentration Risk [Table] Financing leases Finance Lease, Interest Payment on Liability Total assets Assets Forward foreign currency exchange contracts Derivative Liability, Current Granted restricted stock units (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Financing Finance Lease, Liability, Payment, Due [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Antidilutive Securities Antidilutive Securities [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Cost of sales Cost of Sales [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Axis] Schedule of Maturities of Finance Lease Liabilities Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Interest expense Total interest expense on convertible debt Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Product and Service Product and Service [Axis] Total liabilities Liabilities ROU assets obtained in exchange for lease obligations: Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract] Right of use assets obtained in exchange for lease obligations abstract. Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Investment Type Investment Type [Axis] Contingent liabilities Contingent Liability Accrual Sales And Licensing Milestones Contingent Liability Accrual Sales And Licensing Milestones Other assets Other Noncurrent Assets [Member] Annual percentage of shares earned, performance metric Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2021 Operating And Finance Lease Liability Payments Due Year One Operating And Finance Lease Liability Payments Due Year One Position Position [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net Income (Loss), basic Net Income (Loss) Available to Common Stockholders, Basic Level 1: Quoted Price in Active Markets For Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Inventory Increase (Decrease) in Inventories Convertible debt, Unamortized deferred offering costs Deferred Offering Costs Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Raw materials Inventory, Raw Materials, Net of Reserves Marketed by Company Sales Channel, Directly to Consumer [Member] Debt Instrument Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Thereafter Finance Lease, Liability, to be Paid, After Year Four Finance Lease, Liability, to be Paid, After Year Four Common stock issuable under the 2020 notes Convertible Notes due 2020 Convertible Senior Notes Due Twenty Twenty [Member] Convertible senior notes due twenty twenty. Contingent Consideration by Type Contingent Consideration by Type [Axis] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block] Schedule of cash, cash equivalents and available-for-sale securities. Rest of world Rest Of World [Member] Rest of world. Asset Class Asset Class [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Interest expense Finance Lease, Interest Expense Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Fair value of other non-current assets Other Assets Noncurrent Fair Value Disclosure Other assets noncurrent fair value disclosure. 2022 Operating And Finance Lease Liability Payments Due Year Two Operating and finance lease liability payments due year two. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total fair value of fixed rate convertible debt Convertible Debt, Fair Value Disclosures Schedule of Goodwill [Table] Schedule of Goodwill [Table] INCOME (LOSS) BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Subsequent Event Subsequent Event [Member] 0.599% Senior Subordinated Convertible Notes Due in August 2024 Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member] Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type Concentration Risk Type [Axis] Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Property, plant and equipment, gross Property, Plant and Equipment, Gross Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) Common Stock Issued, Employee Stock Trust Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating expenses as reported Operating Expenses Operating Expense [Member] Add: Interest on convertible notes Interest on Convertible Debt, Net of Tax Coupon interest expense Interest Expense, Debt, Excluding Amortization Total ROU assets Operating And Finance Lease Right Of Use Asset Operating and finance lease right of use asset. Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive income (loss) Total AOCI Attributable to Parent [Member] Award vesting service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Gain on sale of nonfinancial assets Gain (Loss) on Disposition of Assets Concentration Risk And Geographic Information [Line Items] Concentration Risk And Geographic Information [Line Items] Concentration risk and geographic information. Operating, noncurrent Operating Lease, Liability, Noncurrent Contingent Payment Contingent Payment [Member] Contingent Payment Accrued royalties payable Accrued Royalties, Current Issuances under equity incentive plans (in shares) Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares Stock issued during period value new issues net excess tax benefit tax deficiency, shares. Current assets: Assets, Current [Abstract] Interest income Investment Income, Interest Total lease liabilities Present value of lease liabilities Operating And Finance Lease Liability Operating and finance lease liability. COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2023 Finance Lease, Liability, to be Paid, Year Three Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Cash used in operating activities: Cash Flow, Operating Activities, Lessee [Abstract] Decrease in accounts payable and accrued liabilities related to fixed assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period. Document Period End Date Document Period End Date DEBT Long-term Debt [Text Block] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Accounting impact of NQDC Plan change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Value added taxes payable Sales and Excise Tax Payable, Current Equity in the loss of BioMarin/Genzyme LLC Income (Loss) from Equity Method Investments Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Schedule of Total Net Product Revenues Based on Patient Location Disaggregation of Revenue [Table Text Block] Hedging Designation Hedging Designation [Axis] Schedule Of Interest Expenses [Table] Schedule Of Interest Expenses [Table] Schedule of interest expenses table. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Stock-based compensation expense capitalized to inventory Share-based Payment Arrangement, Amount Capitalized Long-term Debt, Type Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Repurchase of common stock Stock Repurchased During Period, Value Principal repayments of financing leases Proceeds from (Payments for) Other Financing Activities Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Derivatives Designated As Hedging Instruments Designated as Hedging Instrument [Member] Cover page. Cover [Abstract] Base Rate Base Rate [Member] NQDC Plan assets Nonqualified Deferred Compensation Plan Assets [Member] Nonqualified deferred compensation plan assets. Clinical and Post Marketing Services Clinical And Post Marketing Services [Member] Clinical and post marketing services. Company Stock Held By NQDC Deferred Compensation, Share-based Payments [Member] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Axis] Goodwill [Line Items] Goodwill [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Leases Lessee, Operating Leases [Text Block] Investment in convertible note Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Amortization of premium (accretion of discount) on investments Accretion (Amortization) of Discounts and Premiums, Investments Financial assets remeasured Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Other current assets Increase (Decrease) in Other Current Assets Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Lease Cost Lease, Cost [Abstract] Aggregate Fair Value Debt Securities, Available-for-sale Total operating expenses Operating expenses as reported Costs and Expenses Equity Components Equity Components [Axis] Unvested restricted stock units Unvested RSUs Restricted Stock [Member] Finished goods Inventory, Finished Goods, Net of Reserves Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] Minimum Minimum [Member] Balance Sheet Location Balance Sheet Location [Domain] Land Land [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Operating, current Operating Lease, Liability, Current Customer Two Customer B Customer Two [Member] Customer 2 Europe Europe [Member] Financing leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Asset-backed securities Asset-backed Securities [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Gain on sale of nonfinancial assets Gain (loss) on disposition of other assets Gain (Loss) on Disposition of Other Assets Entity Interactive Data Current Entity Interactive Data Current United States UNITED STATES Fair Value Carrying Amount of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] REVENUES: Revenues [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Accounts Receivable Accounts Receivable [Member] Fair value of other current assets Other Assets Current Fair Value Disclosure Other assets current fair value disclosure. Assets: Lease Right Of Use Assets [Abstract] Lease right of use assets. Common stock potentially issuable for ESPP purchases Common Stock Issuable To Employee Stock Purchase Plan [Member] Common stock issuable for employee Stock Purchase Plan [Member] Customer Customer [Domain] Impact of change in accounting principles Cumulative Effect, Period of Adoption, Adjustment [Member] Land improvements Land Improvements [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Vimizim Product Four [Member] Product 4 [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones. Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. Non-cash changes in the fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Research and development Research and Development Expense [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Programs No Longer Being Developed Programs No Longer Being Developed [Member] Programs No Longer Being Developed. Schedule of Other Information Lessee Operating And Finance Leases Other Information Table [Text Block] Lessee operating and finance leases other information. Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Cash Cash Goodwill Goodwill Net current-period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 2023 Operating And Finance Lease Liability Payments Due Year Three Operating and finance lease liability payments due year three. Document Transition Report Document Transition Report Naglazyme Product Two [Member] Product 2 [Member] Derivative asset, fair value Derivative Asset, Fair Value, Gross Asset Retirement of treasury stock Stock Repurchased and Retired During Period, Value Thereafter Operating And Finance Lease Liability Payments Due After Year Four Operating and finance lease liability payments due after year five. Debt face amount Debt Instrument, Face Amount Level 2: Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Cash payment Disposal Group, Including Discontinued Operation, Consideration Sell Short [Member] Building and improvements Building and Building Improvements [Member] Other current assets Other Assets, Current Document Quarterly Report Document Quarterly Report Asset Class Asset Class [Domain] Equity [Abstract] Equity [Abstract] Fair value of financial assets, Total Assets, Fair Value Disclosure BASIS OF PRESENTATION Basis of Accounting [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Lease liabilities Contract with Customer, Liability, Current Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Debt instrument, convertible, conversion price, per share (in dollars per share) Debt Instrument, Convertible, Conversion Price Derivative Contract Derivative Contract [Domain] Weighted average common shares outstanding, diluted (in shares) Weighted-average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Palynziq Product Seven [Member] Product 7 [Member] NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) Net Income (Loss) per common share, basic (in dollars per share) Earnings Per Share, Basic Number of operating business segment Number of Operating Segments Entity File Number Entity File Number Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating leases Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Inventory, Current [Table] Inventory, Current [Table] Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Total stock-based compensation expense Share-based Payment Arrangement, Expense Kuvan Product Three [Member] Product 3 [Member] Unrealized Gains (Losses) on Available for-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Other Information Other Information Lease Liability [Abstract] Other information lease liability. Balance Sheet Location Balance Sheet Location [Axis] Common stock, $0.001 par value: 500,000,000 shares authorized; 181,492,344 and 179,838,114 shares issued and outstanding, respectively. Common Stock, Value, Issued Disposal Group Name [Axis] Disposal Group Name [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Concentration Risk And Geographic Information [Abstract] Concentration Risk And Geographic Information [Abstract] Concentration risk and geographic information. Document Fiscal Year Focus Document Fiscal Year Focus Tax effect Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Proceeds from issuance of notes Proceeds from Issuance of Secured Debt Issuances under equity incentive plans, net of tax Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Stock issued during period value new issues net excess tax benefit tax deficiency. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Commercial paper Commercial Paper [Member] Noncurrent assets: Assets, Noncurrent [Abstract] Entity Current Reporting Status Entity Current Reporting Status 2024 Finance Lease, Liability, to be Paid, Year Four Changes in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Intangible asset amortization and contingent consideration Intangible Asset Amortization And Contingent Consideration The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period. Position Position [Axis] Concentration Risk And Geographic Information [Table] Concentration Risk And Geographic Information [Table] Concentration risk and geographic information. Accrued rebates payable Accrued Government And Other Rebates Accrued Government And Other Rebates Purchases of available-for-sale securities Payments to Acquire Debt Securities, Available-for-sale Other Accumulated Gain Loss From Other [Member] Accumulated gain (loss) from other. Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Weighted-average fair value per RSU granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Forward contracts Foreign Exchange Forward [Member] Common stock issuable under the 2024 notes Convertible Senior Notes Due Two Thousand Twenty Four [Member] Present value of lease liabilities Operating Lease, Liability Pre-Launch Valoctocogene Roxaparvovec Pre-Launch Valoctocogene Roxaparvovec [Member] Pre-Launch Valoctocogene Roxaparvovec [Member] Firdapse Firdapse [Member] Firdapse Accounts receivable, net Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent NATURE OF OPERATIONS Nature of Operations [Text Block] Concentration Risk Type Concentration Risk Type [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] The 2018 Credit Facility Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member] Senior unsecured revolving two thousand eighteen credit facility. Entity Address, City or Town Entity Address, City or Town Schedule of Net Product Revenue Concentrations Attributed to Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Cash used in financing activities: Cash Flow, Financing Activities, Lessee [Abstract] Accrued compensation expense Employee-related Liabilities, Current Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Purchase of intangible assets Payments to Acquire Intangible Assets Operating Operating Lease, Cost Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Total number of potentially issuable shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Additional leases not yet commenced (undiscounted): Lessee, Operating Lease, Not yet Commenced, Description [Abstract] Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Financing leases Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other Other Noncash Income (Expense) Net product revenues Total net product revenues Product [Member] Equity Component Equity Component [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] NQDC Plan liability Nonqualified Deferred Compensation Plan Liability [Member] Nonqualified deferred compensation plan liability. Remainder of 2020 Operating And Finance Lease Liability Payments Remainder Of Fiscal Year Operating and finance lease liability payments remainder of fiscal year. Other assets Increase (Decrease) in Other Noncurrent Assets Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net Construction-in-progress Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] NET INCOME (LOSS) Net income (loss) Net Income (Loss) Attributable to Parent Financing, noncurrent Finance Lease, Liability, Noncurrent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Brineura Product Six [Member] Product six. Remainder of 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year LIBOR Rate London Interbank Offered Rate (LIBOR) [Member] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Leases [Abstract] Leases [Abstract] Long-term Debt, Type Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Earnings Per Share [Abstract] Earnings Per Share [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Present value of lease liabilities Finance Lease, Liability Unrealized foreign exchange loss Foreign Currency Transaction Gain (Loss), Unrealized Measurement period Debt Instrument, Convertible, Weighted Average Measurement Period Debt Instrument, Convertible, Weighted Average Measurement Period Base percentage of annual target ceiling Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Less: net gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Disposal Group Name [Domain] Disposal Group Name [Domain] Maturity of derivatives Derivative, Remaining Maturity Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Total convertible debt, net Convertible Debt Net Income (Loss), diluted Net Income (Loss) Available to Common Stockholders, Diluted SUPPLEMENTAL CASH FLOW DISCLOSURES: Supplemental Cash Flow Information [Abstract] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Entity Filer Category Entity Filer Category Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service Product and Service [Domain] Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Inventory [Domain] Inventory [Domain] Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Convertible Senior Notes Convertible Debt [Member] Financing leases Finance Lease, Weighted Average Discount Rate, Percent Schedule of Property Plant and Equipment Net Property, Plant and Equipment [Table Text Block] Other Commitments Other Commitments [Axis] Other Commitments Other Commitments [Domain] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings per share line Items. Leasehold improvements Leasehold Improvements [Member] Finite-lived intangible assets Finite-Lived Intangible Assets, Gross Net Product Revenue Revenue Benchmark [Member] Foreign exchange remeasurement of Euro denominated contingent acquisition consideration Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Convertible notes stated rate Debt Instrument, Interest Rate, Stated Percentage Intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Money market instruments Money Market Funds [Member] Common stock held by the NQDC Share-based Payment Arrangement [Member] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Repayments of convertible debt Repayments of Convertible Debt Financing Finance Lease, Right-of-Use Asset, after Accumulated Amortization Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Options to purchase common stock Options to purchase common stock Share-based Payment Arrangement, Option [Member] Deferred revenue Accrued Lease Liabilities Current Accrued lease liabilities current. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, basic (in shares) Weighted average number of shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Debt instrument interest rate percentage Debt Instrument, Basis Spread on Variable Rate Fair value of other non-current liabilities Other Liabilities Noncurrent Fair Value Disclosure Other liabilities noncurrent fair value disclosure. OPERATING EXPENSES: Costs and Expenses [Abstract] Number of investments Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Operating leases expected to commence in remainder of year Operating Leases, Not Yet Commenced, Expected To Commence By End Of Fiscal Year Operating Leases, Not Yet Commenced, Expected To Commence By End Of Fiscal Year Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target [Member] Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Gain on sale of nonfinancial assets Gain (Loss) on Disposition of Intangible Assets Common stock held by the NQDC Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Strategic investments fair value Equity Securities without Readily Determinable Fair Value, Amount Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Remainder of 2020 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of ROU Assets and Lease Liabilities Schedule Of Lessee Lease Assets And Liabilities Table [Text Block] Schedule of Lessee lease assets and liabilities. Benefit from income taxes Income Tax Expense (Benefit) Beginning of period End of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.25% Senior Subordinated Convertible Notes Due in May 2027 1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member] 1.25% Senior Subordinated Convertible Notes Due in May 2027 Fair value of financial liabilities, Total Financial and Nonfinancial Liabilities, Fair Value Disclosure NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) Net Income (Loss) per common share, diluted (in dollars per share) Earnings Per Share, Diluted Financing, current Finance Lease, Liability, Current Local Phone Number Local Phone Number Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Derivative [Line Items] Derivative [Line Items] Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Carrying value of equity component Convertible Notes Long-term Debt, Gross Depreciation expense Depreciation 2024 Operating And Finance Lease Liability Payments Due Year Four Operating and finance lease liability payments due year four. Entity Address, Address Line One Entity Address, Address Line One Entity Emerging Growth Company Entity Emerging Growth Company Deferred income taxes Deferred Income Tax Expense (Benefit) Derivative liability, fair value Derivative Liability, Fair Value, Gross Liability Senior Subordinated Notes Senior Subordinated Notes [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Accumulated amortization Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Amortization of debt issuance costs Amortization of Debt Issuance Costs Maximum Maximum [Member] Accumulated Deficit Retained Earnings [Member] Payment of contingent acquisition consideration Payment for Contingent Consideration Liability, Financing Activities Summary of Interest Expense on Debt Interest Income and Interest Expense Disclosure [Table Text Block] Short term marketable securities maturity period Short Term Marketable Securities Maturity Period Short-term marketable securities maturity period. Aldurazyme Product One [Member] Product 1 [Member] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Equity Award Award Type [Domain] Investments Investments [Domain] Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Accounts payable and accrued operating expenses Accounts Payable and Other Accrued Liabilities, Current Corporate debt securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule of cash, cash equivalents and available-for-sale securities. Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Other comprehensive income (loss) before      reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Disposal Group Classification [Domain] Disposal Group Classification [Domain] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Percentage of commitment fees payable on undrawn amount Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Proceeds from exercises of awards under equity incentive plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised NET INCOME (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Manufacturing and laboratory equipment Equipment [Member] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Fair Value, Measurements, Recurring Fair Value, Recurring [Member] 2022 Finance Lease, Liability, to be Paid, Year Two Income Tax Contingency [Table] Income Tax Contingency [Table] Customer C Customer Three [Member] Customer 3 New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 9 bmrn-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 bmrn-20200930_htm.xml IDEA: XBRL DOCUMENT 0001048477 2020-01-01 2020-09-30 0001048477 2020-10-23 0001048477 2020-09-30 0001048477 2019-12-31 0001048477 us-gaap:ProductMember 2020-07-01 2020-09-30 0001048477 us-gaap:ProductMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember 2020-01-01 2020-09-30 0001048477 us-gaap:ProductMember 2019-01-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2020-07-01 2020-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-07-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2020-01-01 2020-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-01-01 2019-09-30 0001048477 2020-07-01 2020-09-30 0001048477 2019-07-01 2019-09-30 0001048477 2019-01-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2020-06-30 0001048477 us-gaap:CommonStockMember 2019-06-30 0001048477 us-gaap:CommonStockMember 2019-12-31 0001048477 us-gaap:CommonStockMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001048477 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001048477 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2020-09-30 0001048477 us-gaap:CommonStockMember 2019-09-30 0001048477 2020-06-30 0001048477 2019-06-30 0001048477 2018-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001048477 us-gaap:TreasuryStockMember 2020-06-30 0001048477 us-gaap:TreasuryStockMember 2019-06-30 0001048477 us-gaap:TreasuryStockMember 2019-12-31 0001048477 us-gaap:TreasuryStockMember 2018-12-31 0001048477 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001048477 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0001048477 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:TreasuryStockMember 2020-09-30 0001048477 us-gaap:TreasuryStockMember 2019-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-07-01 2020-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-07-01 2019-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-01-01 2020-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2020-06-30 0001048477 us-gaap:RetainedEarningsMember 2019-06-30 0001048477 us-gaap:RetainedEarningsMember 2019-12-31 0001048477 us-gaap:RetainedEarningsMember 2018-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-06-30 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-06-30 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001048477 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001048477 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2020-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-09-30 0001048477 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001048477 srt:MaximumMember 2020-01-01 2020-09-30 0001048477 srt:MaximumMember 2019-01-01 2019-12-31 0001048477 srt:MinimumMember 2019-01-01 2019-12-31 0001048477 srt:MinimumMember 2020-01-01 2020-09-30 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-01-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-01-01 2020-03-31 0001048477 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember bmrn:FirdapseMember 2020-03-31 0001048477 2019-04-01 2019-06-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2020-09-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001048477 us-gaap:EquipmentMember 2020-09-30 0001048477 us-gaap:EquipmentMember 2019-12-31 0001048477 us-gaap:ComputerEquipmentMember 2020-09-30 0001048477 us-gaap:ComputerEquipmentMember 2019-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001048477 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001048477 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001048477 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001048477 us-gaap:LandImprovementsMember 2020-09-30 0001048477 us-gaap:LandImprovementsMember 2019-12-31 0001048477 us-gaap:LandMember 2020-09-30 0001048477 us-gaap:LandMember 2019-12-31 0001048477 us-gaap:ConstructionInProgressMember 2020-09-30 0001048477 us-gaap:ConstructionInProgressMember 2019-12-31 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2020-09-30 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2020-07-01 2020-09-30 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2020-01-01 2020-09-30 0001048477 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001048477 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001048477 bmrn:ContingentPaymentMember 2019-12-31 0001048477 bmrn:ContingentPaymentMember 2020-01-01 2020-09-30 0001048477 bmrn:ContingentPaymentMember 2020-09-30 0001048477 us-gaap:NondesignatedMember 2020-01-01 2020-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2020-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2020-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2020-09-30 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2020-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-12-31 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2020-07-01 2020-09-30 0001048477 us-gaap:NondesignatedMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-01-01 2019-09-30 0001048477 us-gaap:OperatingExpenseMember 2020-07-01 2020-09-30 0001048477 us-gaap:OperatingExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:OperatingExpenseMember 2020-01-01 2020-09-30 0001048477 us-gaap:OperatingExpenseMember 2019-01-01 2019-09-30 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member 2020-09-30 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member 2019-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2019-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2020-09-30 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2019-12-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2020-09-30 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember us-gaap:SubsequentEventMember 2020-10-15 2020-10-15 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember us-gaap:SeniorSubordinatedNotesMember us-gaap:SubsequentEventMember 2020-10-15 0001048477 us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001048477 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member us-gaap:SeniorSubordinatedNotesMember 2020-05-31 0001048477 bmrn:A125SeniorSubordinatedConvertibleNotesDueInMay2027Member us-gaap:SeniorSubordinatedNotesMember 2020-05-01 2020-05-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2020-09-30 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2019-12-31 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-07-01 2020-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-07-01 2020-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2020-01-01 2020-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-01-01 2019-09-30 0001048477 country:US 2020-07-01 2020-09-30 0001048477 country:US 2019-07-01 2019-09-30 0001048477 country:US 2020-01-01 2020-09-30 0001048477 country:US 2019-01-01 2019-09-30 0001048477 srt:EuropeMember 2020-07-01 2020-09-30 0001048477 srt:EuropeMember 2019-07-01 2019-09-30 0001048477 srt:EuropeMember 2020-01-01 2020-09-30 0001048477 srt:EuropeMember 2019-01-01 2019-09-30 0001048477 srt:LatinAmericaMember 2020-07-01 2020-09-30 0001048477 srt:LatinAmericaMember 2019-07-01 2019-09-30 0001048477 srt:LatinAmericaMember 2020-01-01 2020-09-30 0001048477 srt:LatinAmericaMember 2019-01-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2020-07-01 2020-09-30 0001048477 bmrn:RestOfWorldMember 2019-07-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2020-01-01 2020-09-30 0001048477 bmrn:RestOfWorldMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductFourMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductThreeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductTwoMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductSevenMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductSixMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductFiveMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-07-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0001048477 bmrn:CustomersMember 2020-09-30 0001048477 bmrn:CustomersMember 2019-12-31 0001048477 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0001048477 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001048477 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0001048477 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-01 2020-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-01 2020-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2020-03-01 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember 2020-03-01 2020-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember 2020-03-01 2020-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember 2020-03-01 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember 2020-03-31 0001048477 bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember 2020-03-01 2020-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember 2020-03-01 2020-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember 2020-03-01 2020-03-31 0001048477 country:IE 2020-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2020-07-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2020-01-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2020-07-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2020-01-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2020-07-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2020-01-01 2020-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentySevenMember 2019-01-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001048477 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001048477 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2020-07-01 2020-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2020-07-01 2020-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-07-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2020-01-01 2020-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2020-09-30 0001048477 bmrn:ThirdPartyMember bmrn:EarlyStageDevelopmentProgramMember 2020-04-01 2020-06-30 0001048477 bmrn:ThirdPartyMember 2020-01-01 2020-09-30 0001048477 bmrn:ThirdPartyMember bmrn:ProgramsNoLongerBeingDevelopedMember 2020-01-01 2020-09-30 0001048477 bmrn:ClinicalAndPostMarketingServicesMember 2020-09-30 shares iso4217:USD iso4217:USD shares bmrn:investment pure bmrn:lease utr:D bmrn:Segment false 2020 Q3 0001048477 --12-31 P1Y P1Y P2Y6M us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent 10-Q true true 2020-09-30 false false 000-26727 BioMarin Pharmaceutical Inc DE DE 68-0397820 68-0397820 770 Lindaro Street 770 Lindaro Street San Rafael San Rafael CA CA 94901 94901 415 506-6700 Common Stock, par value $0.001 Common Stock, par value $0.001 BMRN BMRN NASDAQ NASDAQ Yes Yes Large Accelerated Filer Large Accelerated Filer false false false false false 181529667 1015675000 437446000 489998000 316361000 411712000 377404000 700847000 680275000 120747000 130657000 2738979000 1942143000 265122000 411978000 1015062000 1010868000 427172000 456580000 196199000 197039000 1396547000 549422000 119009000 122009000 6158090000 4690039000 480403000 570621000 374290000 361882000 854693000 932503000 1074164000 486238000 54103000 50793000 121237000 98124000 2104197000 1567658000 0.001 0.001 500000000 500000000 181492344 181492344 179838114 179838114 181000 180000 4937791000 4832707000 10756000 9961000 10385000 20164000 -883708000 -1720709000 4053893000 3122381000 6158090000 4690039000 460741000 450900000 1368816000 1224458000 16043000 10197000 39522000 25147000 476784000 461097000 1408338000 1249605000 188793000 96949000 398134000 263567000 147053000 172963000 471449000 542195000 179450000 170112000 542157000 493024000 17429000 17063000 48018000 57114000 0 0 59495000 15000000 532725000 457087000 1400263000 1340900000 -55941000 4010000 8075000 -91295000 -921000 -551000 -1077000 -780000 4004000 5340000 13539000 17537000 9597000 2937000 24560000 16530000 1239000 3960000 1886000 6038000 -61216000 9822000 -2137000 -85030000 -846019000 -45214000 -839138000 -46158000 784803000 55036000 837001000 -38872000 4.33 0.31 4.63 -0.22 4.01 0.30 4.39 -0.22 181142000 179289000 180592000 178873000 197674000 185924000 194959000 178873000 765138000 74600000 827222000 -7140000 181148000 179433000 179838000 178253000 344000 171000 2172000 1351000 0 0 518000 0 181492000 179604000 181492000 179604000 3236679000 2960954000 3122381000 2967940000 181000 179000 180000 178000 0 1000 1000 2000 181000 180000 181000 180000 4885637000 4744316000 4832707000 4669926000 7319000 -1294000 17601000 -19183000 44757000 40144000 136688000 122212000 0 0 50000000 0 -78000 250000 -795000 692000 0 0 0 10653000 4937791000 4782916000 4937791000 4782916000 0 0 0 0 0 0 50000000 0 0 0 -50000000 0 0 0 0 0 -10678000 -10211000 -9961000 -13301000 78000 -250000 795000 -692000 0 0 0 2648000 -10756000 -9961000 -10756000 -9961000 30050000 17439000 20164000 5271000 -19665000 19564000 -9779000 31732000 10385000 37003000 10385000 37003000 -1668511000 -1790769000 -1720709000 -1694134000 0 0 0 -2727000 784803000 55036000 837001000 -38872000 -883708000 -1735733000 -883708000 -1735733000 4053893000 3074405000 4053893000 3074405000 837001000 -38872000 77814000 79510000 14766000 9395000 -175000 1897000 142125000 121763000 59495000 15000000 75609000 0 -854199000 -59780000 -9082000 -784000 1352000 5646000 -388000 18000 32915000 61803000 73310000 52571000 -32848000 13259000 5543000 7112000 -76174000 21747000 9225000 2386000 98749000 -9081000 83286000 94241000 345224000 635678000 369942000 528497000 67159000 15000000 14369000 8323000 8709000 0 725000 1747000 -64648000 17870000 60268000 21768000 42667000 40951000 0 57508000 50000000 0 585752000 0 -6080000 -2025000 547273000 -78716000 -3145000 -835000 578229000 -70762000 437446000 493982000 1015675000 423220000 4355000 6088000 5615000 5777000 -13281000 -5801000 -3043000 2053000 NATURE OF OPERATIONS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div> BASIS OF PRESENTATION<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div> The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.</span> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2020, as compared to the significant accounting policies disclosed in Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span> RECENT ACCOUNTING PRONOUNCEMENTS<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as described in Note 2 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the nine months ended September 30, 2020, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that the Company believes are of significance or potential significance to the Company.</span> FINANCIAL INSTRUMENTS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All marketable securities were classified as available-for-sale at September 30, 2020 and December 31, 2019.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385,075 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,392,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763,780 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,770,795 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,998 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,785 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The Company’s short-term marketable securities mature in one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    The Company’s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk2YjQ0YzZlOGM0MTQzNDg4MGM4NDg4M2FkYjg1YmFiL3NlYzo5NmI0NGM2ZThjNDE0MzQ4ODBjODQ4ODNhZGI4NWJhYl80Ni9mcmFnOjBlMDAxZGI4NWQxNDRjMGViNmYwNzg4Mzc3N2M2ZmFiL3RleHRyZWdpb246MGUwMDFkYjg1ZDE0NGMwZWI2ZjA3ODgzNzc3YzZmYWJfNDEy_32d245a7-3aed-4420-8c3e-ad393ed5ced0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk2YjQ0YzZlOGM0MTQzNDg4MGM4NDg4M2FkYjg1YmFiL3NlYzo5NmI0NGM2ZThjNDE0MzQ4ODBjODQ4ODNhZGI4NWJhYl80Ni9mcmFnOjBlMDAxZGI4NWQxNDRjMGViNmYwNzg4Mzc3N2M2ZmFiL3RleHRyZWdpb246MGUwMDFkYjg1ZDE0NGMwZWI2ZjA3ODgzNzc3YzZmYWJfNDEy_4ce81418-200f-4622-8353-10684bf99a36">one</span></span> and five years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.</span></div>The Company has three investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of September 30, 2020 and December 31, 2019, the fair value of the Company’s strategic investments was $8.0 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Condensed Consolidated Balance Sheets. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,385,075 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,392,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763,780 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,770,795 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489,998 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901,805 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,161,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,785 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The Company’s short-term marketable securities mature in one year or less.</span></div>(2)    The Company’s long-term marketable securities mature between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk2YjQ0YzZlOGM0MTQzNDg4MGM4NDg4M2FkYjg1YmFiL3NlYzo5NmI0NGM2ZThjNDE0MzQ4ODBjODQ4ODNhZGI4NWJhYl80Ni9mcmFnOjBlMDAxZGI4NWQxNDRjMGViNmYwNzg4Mzc3N2M2ZmFiL3RleHRyZWdpb246MGUwMDFkYjg1ZDE0NGMwZWI2ZjA3ODgzNzc3YzZmYWJfNDEy_32d245a7-3aed-4420-8c3e-ad393ed5ced0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk2YjQ0YzZlOGM0MTQzNDg4MGM4NDg4M2FkYjg1YmFiL3NlYzo5NmI0NGM2ZThjNDE0MzQ4ODBjODQ4ODNhZGI4NWJhYl80Ni9mcmFnOjBlMDAxZGI4NWQxNDRjMGViNmYwNzg4Mzc3N2M2ZmFiL3RleHRyZWdpb246MGUwMDFkYjg1ZDE0NGMwZWI2ZjA3ODgzNzc3YzZmYWJfNDEy_4ce81418-200f-4622-8353-10684bf99a36">one</span></span> and five years. 378705000 0 0 378705000 378705000 0 0 557006000 0 0 557006000 557006000 0 0 435954000 4558000 14000 440498000 0 280000000 160498000 361336000 2182000 1000 363517000 79964000 199559000 83994000 23430000 129000 0 23559000 0 3639000 19920000 6800000 0 0 6800000 0 6800000 0 549000 161000 0 710000 0 0 710000 1385075000 7030000 15000 1392090000 636970000 489998000 265122000 1763780000 7030000 15000 1770795000 1015675000 489998000 265122000 259347000 0 0 259347000 259347000 0 0 173100000 0 0 173100000 173100000 0 0 518523000 3575000 12000 522086000 0 233294000 288792000 209633000 993000 67000 210559000 4999000 83067000 122493000 549000 145000 1000 693000 0 0 693000 901805000 4713000 80000 906438000 178099000 316361000 411978000 1161152000 4713000 80000 1165785000 437446000 316361000 411978000 P1Y P1Y P5Y P5Y 3 8000000.0 6200000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211,296)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,154)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427,172 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. Additionally, the Company recognized a $0.8 million reduction to goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million, as a result of the sale of Firdapse. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the second quarter of 2019, the Company recorded $15.0 million of gain on sale of intangible assets, reported in Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Comprehensive Income (Loss), due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211,296)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,154)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427,172 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,580 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 638468000 652734000 211296000 196154000 427172000 456580000 67200000 59500000 -800000 32200000 31600000 15000000.0 PROPERTY, PLANT AND EQUIPMENT<div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725,906 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,187 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,238 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,749 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,206 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation capitalized into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725,906 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(549,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,062 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,187 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,238 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,749 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,206 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation capitalized into inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 756479000 725906000 402357000 366951000 187722000 167554000 90418000 90418000 52479000 51324000 39360000 38569000 7349000 7349000 92581000 111897000 1628745000 1559968000 613683000 549100000 1015062000 1010868000 22187000 24238000 65749000 67206000 10883000 9807000 34053000 24894000 SUPPLEMENTAL BALANCE SHEET INFORMATION<div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:71.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,857 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,442 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,978 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,305 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,855 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,847 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If the marketing application is rejected, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed to Research and Development (R&amp;D).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requested additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $81.2 million to Cost of Sales in the three and nine months ended September 30, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480,403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:71.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,857 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,442 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,978 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,305 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,855 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,847 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73857000 74442000 296685000 349978000 330305000 255855000 700847000 680275000 0 81200000 81200000 <div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,981 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value added taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480,403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 218021000 240981000 137415000 192467000 65999000 57163000 20426000 30797000 10930000 10700000 7222000 8395000 7774000 10448000 3240000 13037000 9376000 6633000 480403000 570621000 FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2020 and December 31, 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 12 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2020 or December 31, 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:52.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,639 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,639 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,755 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,554 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.928%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,465 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The restricted investments at September 30, 2020 and December 31, 2019 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no transfers between levels during the three and nine months ended September 30, 2020. The following table represents a roll forward of contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:82.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent acquisition consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2020 and December 31, 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 12 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2020 or December 31, 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:52.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,639 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,639 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,652 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,755 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,554 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.928%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQDC Plan liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,465 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The restricted investments at September 30, 2020 and December 31, 2019 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div> 0 0 0 0 1902000 0 1902000 17652000 0 17652000 2987000 0 2987000 20639000 0 20639000 22541000 0 22541000 1902000 0 1902000 17652000 0 17652000 0 54103000 54103000 17652000 54103000 71755000 19554000 54103000 73657000 1177000 0 1177000 16288000 0 16288000 3168000 0 3168000 19456000 0 19456000 20633000 0 20633000 1177000 0 1177000 16288000 0 16288000 0 50793000 50793000 16288000 50793000 67081000 17465000 50793000 68258000 The following table represents a roll forward of contingent consideration. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.281%"><tr><td style="width:1.0%"/><td style="width:82.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange remeasurement of Euro denominated contingent acquisition consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,103 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50793000 1352000 1958000 54103000 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as hedging instruments and have maturities up to two and a half years. The Company also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments and have maturities up to three months. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company’s derivatives designated as hedging instruments outstanding as of the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company’s derivatives not designated as hedging instruments outstanding as of the periods presented. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,180 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    For additional discussion of fair value measurements, see Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income (Loss) for the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company expected to reclassify unrealized gains of $4.8 million from Accumulated Other Comprehensive Income (AOCI) to earnings as the forecasted revenue and operating expense transactions occur over the next 12 months. For additional discussion of balances in AOCI see Note 13 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> P3M <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company’s derivatives designated as hedging instruments outstanding as of the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 729998000 820546000 163116000 212348000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the aggregate notional amounts for the Company’s derivatives not designated as hedging instruments outstanding as of the periods presented. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sell</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 41031000 77335000 30031000 30818000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability Derivatives - Level 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Derivatives Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,180 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    For additional discussion of fair value measurements, see Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div> 13537000 19584000 4621000 13539000 18158000 33123000 7704000 8184000 4406000 5493000 12110000 13677000 16000 469000 70000 2264000 18174000 33592000 12180000 15941000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income (Loss) for the periods presented.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:45pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues as reported</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses as reported</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (Losses) Recognized in Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 460741000 2693000 450900000 6196000 532725000 -815000 457087000 -1388000 4166000 -1286000 1368816000 17301000 1224458000 11171000 1400263000 -4274000 1340900000 -1885000 9600000 -5182000 4800000 LEASES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:24.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company’s leases were as follows: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,612 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,212 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    As of September 30, 2020, one operating lease is expected to commence in the fourth quarter of 2020.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> LEASES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:24.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company’s leases were as follows: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,612 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,212 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    As of September 30, 2020, one operating lease is expected to commence in the fourth quarter of 2020.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:24.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,434 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 45764000 49045000 12018000 10389000 57782000 59434000 7813000 7451000 3117000 3249000 40831000 44092000 4570000 6708000 56331000 61500000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,260 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,687 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,331 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 3460000 940000 4400000 9908000 3080000 12988000 9095000 2375000 11470000 8055000 1797000 9852000 6253000 48000 6301000 21714000 20000 21734000 58485000 8260000 66745000 9841000 573000 10414000 48644000 7687000 56331000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease costs associated with payments under the Company’s leases were as follows: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,612 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,212 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table> 3227000 3535000 8953000 9946000 841000 600000 2307000 1811000 111000 142000 352000 455000 4179000 4277000 11612000 12212000 The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table> P7Y1M6D P8Y P2Y9M18D P4Y2M12D 0.051 0.052 0.052 0.054 1 7007000 5918000 354000 454000 6080000 2027000 3299000 9268000 3941000 72000 DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.5 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586,499 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The 2020 Notes are classified as a current liability in the periods presented because they matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company’s convertible debt consisted of the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,209 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2027 Notes</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 13 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the Company’s convertible debt.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and earnings before interest, taxes, depreciation and amortization (EBITDA) for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount </span></div>range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021, at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2020, and December 31, 2019, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility. As of September 30, 2020, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants. 1500000000 The following table summarizes information regarding the Company’s convertible debt: <div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586,499 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487,665 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,290 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total convertible debt, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value of fixed rate convertible debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total fair value of fixed rate convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482,737 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,518 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The 2020 Notes are classified as a current liability in the periods presented because they matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.</span> 0.0125 0.0125 600000000 0 12792000 0 709000 0 586499000 0 0.00599 0.00599 495000000 495000000 5470000 6533000 1865000 2229000 487665000 486238000 0.0150 0.0150 374993000 374993000 649000 12078000 54000 1033000 374290000 361882000 1448454000 848120000 590010000 0 517730000 521839000 374997000 405679000 1482737000 927518000 375000000.0 0 94.15 25 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense on the Company’s convertible debt consisted of the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,860 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense on convertible debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,209 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4696000 4005000 13201000 11860000 4255000 2271000 9443000 6681000 535000 508000 1565000 1522000 9486000 6784000 24209000 20063000 600000000.0 0.0125 7.2743 137.47 585800000 13500000 700000 200000000.0 0.0100 0.0195 0.0000 0.0095 0.0015 0.0035 1000000.0 0 0 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statement of Comprehensive Income (Loss)<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,171 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,885)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain (loss) on cash flow hedges</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at June 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,087 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,094)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at June 30, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2019</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,779)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,917)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,431 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,256 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2019</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statement of Comprehensive Income (Loss)<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,693 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,301 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,171 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward contracts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(815)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,885)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gain (loss) on cash flow hedges</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2693000 6196000 17301000 17301000 11171000 11171000 815000 1388000 4274000 1885000 1878000 4808000 13027000 13027000 9286000 9286000 <div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at June 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,087 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">     reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,094)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: net gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at June 30, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,165 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2019</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,779)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,385 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on Cash<br/>Flow Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains<br/>(Losses) on<br/>Available for-Sale<br/>Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,917)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before<br/>     reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,431 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,256 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,684 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: gain (loss) reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI balance at September 30, 2019</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,346 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 22963000 7087000 0 30050000 -16094000 -2201000 0 -18295000 1878000 0 0 1878000 0 -508000 0 -508000 -17972000 -1693000 0 -19665000 4991000 5394000 0 10385000 14181000 3271000 -13000 17439000 23973000 522000 -3000 24492000 4808000 0 0 4808000 0 120000 0 120000 19165000 402000 -3000 19564000 33346000 3673000 -16000 37003000 16614000 3565000 -15000 20164000 1404000 2379000 15000 3798000 13027000 0 13027000 0 550000 0 550000 -11623000 1829000 15000 -9779000 4991000 5394000 0 10385000 7201000 -1917000 -13000 5271000 35431000 7256000 -3000 42684000 9286000 0 0 9286000 0 1666000 0 1666000 26145000 5590000 -3000 31732000 33346000 3673000 -16000 37003000 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues by geographic region:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">476,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461,097 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,408,338 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Net Product Revenues by product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,466 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Firdapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419,754 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,048 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,513 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a consolidated basis, two customers accounted for 33% and 15% of the September 30, 2020 accounts receivable balance, respectively, compared to December 31, 2019, when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of September 30, 2020, and December 31, 2019, the accounts receivable balance for Genzyme included $106.5 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outbreak of COVID-19 continues to affect economies and business around the world. The Company experienced a modest impact on its global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, in the three and nine months ended September 30, 2020 and the Company anticipates a continued impact on its financial results for the remainder of 2020 and into fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations. See the risk factor related to the impact of the coronavirus pandemic, “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A of this Quarterly Report, for additional details on the impact of the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</span></div> 1 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues by geographic region:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">476,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461,097 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,408,338 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 252948000 201874000 729672000 562217000 121158000 125485000 375453000 369585000 44064000 83799000 141852000 164132000 58614000 49939000 161361000 153671000 476784000 461097000 1408338000 1249605000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table disaggregates Net Product Revenues by product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues by product:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vimizim</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,466 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuvan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naglazyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palynziq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brineura</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Firdapse</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419,754 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,048 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,513 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 147891000 163466000 401789000 411953000 123993000 120524000 368604000 340771000 76323000 94408000 271585000 279462000 46092000 24142000 121354000 55250000 25455000 19840000 75223000 46815000 0 5668000 1316000 16262000 419754000 428048000 1239871000 1150513000 40987000 22852000 128945000 73945000 460741000 450900000 1368816000 1224458000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues marketed by the Company</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldurazyme net product revenues marketed by Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,741 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224,458 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 203892000 175127000 582734000 480330000 115548000 121363000 360718000 358041000 44064000 83799000 141852000 164132000 56250000 47759000 154567000 148010000 419754000 428048000 1239871000 1150513000 40987000 22852000 128945000 73945000 460741000 450900000 1368816000 1224458000 The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.16 0.16 0.15 0.17 0.14 0.13 0.14 0.12 0.11 0.10 0.12 0.11 0.01 0.12 0.03 0.06 0.42 0.51 0.44 0.46 0.33 0.15 0.24 0.16 106500000 60200000 STOCK-BASED COMPENSATION<div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,093 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,125 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,763 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation of $4.9 million and $14.9 million was capitalized into inventory for the three and nine months ended September 30, 2020, respectively. Stock-based compensation of $5.1 million and $13.2 million was capitalized into inventory for the three and nine months ended September 30, 2019, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards with Market Conditions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the Compensation Committee and Board approved the grant of 126,710 RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between 0% and 200% of the base TSR-RSUs, with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the 50th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of $112.12 per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Awards with Performance Conditions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year Non-GAAP income target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its current long-range financial plan and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year strategic goal target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its product candidate development pipeline and planned regulatory activity and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.</span></div> Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,093 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,125 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,763 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 10342000 4093000 20381000 12629000 15705000 14261000 45333000 43037000 24122000 20819000 76411000 66097000 50169000 39173000 142125000 121763000 4900000 14900000 5100000 13200000 126710 P3Y 0 2 1 0.50 112.12 63400 73.82 P3Y 0.50 2 63400 73.82 P3Y 0.50 2 INCOME TAXESIn the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s Ex-US regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Condensed Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of September 30, 2020. 835100000 NET INCOME (LOSS) PER COMMON SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s Employee Share Purchase Plan (ESPP), unvested RSUs, common stock held by the NQDC and contingent issuances of common stock related to the Company’s convertible debt.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (common shares in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss), diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,872)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss) per common share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss) per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.252%"><tr><td style="width:1.0%"/><td style="width:53.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The potential effect of the capped call transactions and potential shares issuable under the 2020 Notes were excluded from the calculation of diluted net income (loss) per share in the three and nine months ended September 30, 2020 and 2019, as the Company’s closing price on September 30, 2020 and 2019 did not exceed the conversion price of $94.15 per share. The Company’s 2020 Notes matured on October 15, 2020 and were settled in cash. T</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">he potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 30, 2020.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There is no similar capped call transaction associated with the 2024 Notes or the 2027 Notes. See Note 12 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for additional information on the Company’s 2020 Notes and 2027 Notes. Refer to Note 13 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the 2024 Notes and details of the capped call transaction.</span></div> The following table sets forth the computation of basic and diluted earnings per common share (common shares in <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss), basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">837,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Interest on convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss), diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,872)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2027 notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,373 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,873 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss) per common share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income (Loss) per common share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 784803000 55036000 837001000 -38872000 7070000 937000 18333000 0 791873000 55973000 855334000 -38872000 181142000 179289000 180592000 178873000 1731000 1560000 1728000 0 3983000 0 3983000 0 3970000 3970000 3970000 0 4365000 0 2373000 0 1926000 669000 1765000 0 346000 231000 337000 0 211000 205000 211000 0 197674000 185924000 194959000 178873000 4.33 0.31 4.63 -0.22 4.01 0.30 4.39 -0.22 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.252%"><tr><td style="width:1.0%"/><td style="width:53.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable under the 2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock potentially issuable for ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock held by the NQDC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,394 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5172000 5829000 5175000 7388000 0 3983000 0 3983000 0 0 0 3970000 2900000 3360000 3060000 4029000 193000 222000 204000 453000 0 0 0 205000 8265000 13394000 8439000 20028000 94.15 COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">are probable and reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contingent Payments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company was subject to contingent payments totaling approximately $622.4 million upon achievement of certain development, regulatory and commercial sales milestones, if they occur before certain dates in the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $70.3 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and $236.0 million related to programs that are no longer being developed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company recorded a total of $54.1 million of contingent liabilities on its Condensed</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated Balances Sheet. See Note 9 – </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into various firm purchase commitments primarily related to active</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pharmaceutical ingredients, certain inventory-related items and certain third-party R&amp;D services. As of September 30, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $150.3 million.</span></div> 622400000 235000000.0 70300000 236000000.0 54100000 150300000 December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020. The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the years ended December 31, 2019 and 2018, respectively, filed with the SEC on February 27, 2020. XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2020
Oct. 23, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 000-26727  
Entity Registrant Name BioMarin Pharmaceutical Inc  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 68-0397820  
Entity Address, Address Line One 770 Lindaro Street  
Entity Address, City or Town San Rafael  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94901  
City Area Code 415  
Local Phone Number 506-6700  
Title of 12(b) Security Common Stock, par value $0.001  
Trading Symbol BMRN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   181,529,667
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001048477  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
 [1]
Current assets:    
Cash and cash equivalents $ 1,015,675 $ 437,446
Short-term investments 489,998 316,361
Accounts receivable, net 411,712 377,404
Inventory 700,847 680,275
Other current assets 120,747 130,657
Total current assets 2,738,979 1,942,143
Noncurrent assets:    
Long-term investments 265,122 411,978
Property, plant and equipment, net 1,015,062 1,010,868
Intangible assets, net 427,172 456,580
Goodwill 196,199 197,039
Deferred tax assets 1,396,547 549,422
Other assets 119,009 122,009
Total assets 6,158,090 4,690,039
Current liabilities:    
Accounts payable and accrued liabilities 480,403 570,621
Short-term convertible debt, net 374,290 361,882
Total current liabilities 854,693 932,503
Noncurrent liabilities:    
Long-term convertible debt, net 1,074,164 486,238
Long-term contingent consideration 54,103 50,793
Other long-term liabilities 121,237 98,124
Total liabilities 2,104,197 1,567,658
Stockholders’ equity:    
Common stock, $0.001 par value: 500,000,000 shares authorized; 181,492,344 and 179,838,114 shares issued and outstanding, respectively. 181 180
Additional paid-in capital 4,937,791 4,832,707
Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) (10,756) (9,961)
Accumulated other comprehensive income 10,385 20,164
Accumulated deficit (883,708) (1,720,709)
Total stockholders’ equity 4,053,893 3,122,381 [2]
Total liabilities and stockholders’ equity $ 6,158,090 $ 4,690,039
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
[2] The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the years ended December 31, 2019 and 2018, respectively, filed with the SEC on February 27, 2020.
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 181,492,344 179,838,114
Common stock, shares outstanding (in shares) 181,492,344 179,838,114
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
REVENUES:        
Total revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
OPERATING EXPENSES:        
Cost of sales 188,793 96,949 398,134 263,567
Research and development 147,053 172,963 471,449 542,195
Selling, general and administrative 179,450 170,112 542,157 493,024
Intangible asset amortization and contingent consideration 17,429 17,063 48,018 57,114
Gain on sale of nonfinancial assets 0 0 (59,495) (15,000)
Total operating expenses 532,725 457,087 1,400,263 1,340,900
INCOME (LOSS) FROM OPERATIONS (55,941) 4,010 8,075 (91,295)
Equity in the loss of BioMarin/Genzyme LLC (921) (551) (1,077) (780)
Interest income 4,004 5,340 13,539 17,537
Interest expense (9,597) (2,937) (24,560) (16,530)
Other income, net 1,239 3,960 1,886 6,038
INCOME (LOSS) BEFORE INCOME TAXES (61,216) 9,822 (2,137) (85,030)
Benefit from income taxes (846,019) (45,214) (839,138) (46,158)
NET INCOME (LOSS) $ 784,803 $ 55,036 $ 837,001 $ (38,872)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) $ 4.33 $ 0.31 $ 4.63 $ (0.22)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) $ 4.01 $ 0.30 $ 4.39 $ (0.22)
Weighted average common shares outstanding, basic (in shares) 181,142 179,289 180,592 178,873
Weighted average common shares outstanding, diluted (in shares) 197,674 185,924 194,959 178,873
COMPREHENSIVE INCOME (LOSS) $ 765,138 $ 74,600 $ 827,222 $ (7,140)
Net product revenues        
REVENUES:        
Total revenues 460,741 450,900 1,368,816 1,224,458
Royalty and other revenues        
REVENUES:        
Total revenues $ 16,043 $ 10,197 $ 39,522 $ 25,147
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Company Stock Held By NQDC
Accumulated other comprehensive income (loss)
Accumulated Deficit
Accumulated Deficit
Impact of change in accounting principles
Beginning balance (in shares) at Dec. 31, 2018 [1]   178,253            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans (in shares)   1,351            
Repurchase of common stock (in shares)   0            
Ending balance (in shares) at Sep. 30, 2019   179,604            
Beginning balance at Dec. 31, 2018 $ 2,967,940 [1] $ 178 [1] $ 4,669,926 [1] $ 0 [1] $ (13,301) [1] $ 5,271 [1] $ (1,694,134) [1] $ (2,727)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans, net of tax   2 (19,183)          
Stock-based compensation     122,212          
Repurchase of common stock     0 0        
Common stock held by the NQDC     (692)   692      
Retirement of treasury stock       0        
Accounting impact of NQDC Plan change     10,653   2,648      
Other comprehensive income (loss)           31,732    
Net income (loss) (38,872)           (38,872)  
Ending balance at Sep. 30, 2019 3,074,405 $ 180 4,782,916 0 (9,961) 37,003 (1,735,733)  
Beginning balance (in shares) at Jun. 30, 2019 [1]   179,433            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans (in shares)   171            
Repurchase of common stock (in shares)   0            
Ending balance (in shares) at Sep. 30, 2019   179,604            
Beginning balance at Jun. 30, 2019 2,960,954 [1] $ 179 [1] 4,744,316 [1] 0 [1] (10,211) [1] 17,439 [1] (1,790,769) [1] 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans, net of tax   1 (1,294)          
Stock-based compensation     40,144          
Repurchase of common stock     0 0        
Common stock held by the NQDC     (250)   250      
Retirement of treasury stock       0        
Accounting impact of NQDC Plan change     0   0      
Other comprehensive income (loss)           19,564    
Net income (loss) 55,036           55,036  
Ending balance at Sep. 30, 2019 3,074,405 $ 180 4,782,916 0 (9,961) 37,003 (1,735,733)  
Beginning balance (in shares) at Dec. 31, 2019 [1]   179,838            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans (in shares)   2,172            
Repurchase of common stock (in shares)   (518)            
Ending balance (in shares) at Sep. 30, 2020   181,492            
Beginning balance at Dec. 31, 2019 3,122,381 [1],[2] $ 180 [1] 4,832,707 [1] 0 [1] (9,961) [1] 20,164 [1] (1,720,709) [1] 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans, net of tax   1 17,601          
Stock-based compensation     136,688          
Repurchase of common stock     (50,000) (50,000)        
Common stock held by the NQDC     795   (795)      
Retirement of treasury stock       50,000        
Accounting impact of NQDC Plan change     0   0      
Other comprehensive income (loss)           (9,779)    
Net income (loss) 837,001           837,001  
Ending balance at Sep. 30, 2020 4,053,893 $ 181 4,937,791 0 (10,756) 10,385 (883,708)  
Beginning balance (in shares) at Jun. 30, 2020 [1]   181,148            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans (in shares)   344            
Repurchase of common stock (in shares)   0            
Ending balance (in shares) at Sep. 30, 2020   181,492            
Beginning balance at Jun. 30, 2020 3,236,679 [1] $ 181 [1] 4,885,637 [1] 0 [1] (10,678) [1] 30,050 [1] (1,668,511) [1] $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuances under equity incentive plans, net of tax   0 7,319          
Stock-based compensation     44,757          
Repurchase of common stock     0 0        
Common stock held by the NQDC     78   (78)      
Retirement of treasury stock       0        
Accounting impact of NQDC Plan change     0   0      
Other comprehensive income (loss)           (19,665)    
Net income (loss) 784,803           784,803  
Ending balance at Sep. 30, 2020 $ 4,053,893 $ 181 $ 4,937,791 $ 0 $ (10,756) $ 10,385 $ (883,708)  
[1] The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the years ended December 31, 2019 and 2018, respectively, filed with the SEC on February 27, 2020.
[2] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 837,001 $ (38,872)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 77,814 79,510
Non-cash interest expense 14,766 9,395
Amortization of premium (accretion of discount) on investments 175 (1,897)
Stock-based compensation 142,125 121,763
Gain on sale of nonfinancial assets (59,495) (15,000)
Inventory write-off, net of stock-based compensation 75,609 0
Deferred income taxes (854,199) (59,780)
Unrealized foreign exchange loss 9,082 784
Non-cash changes in the fair value of contingent consideration 1,352 5,646
Other 388 (18)
Changes in operating assets and liabilities:    
Accounts receivable, net (32,915) (61,803)
Inventory (73,310) (52,571)
Other current assets 32,848 (13,259)
Other assets (5,543) (7,112)
Accounts payable and accrued liabilities (76,174) 21,747
Other long-term liabilities 9,225 2,386
Net cash provided by (used in) operating activities 98,749 (9,081)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (83,286) (94,241)
Maturities and sales of investments 345,224 635,678
Purchases of available-for-sale securities (369,942) (528,497)
Proceeds from sale of nonfinancial assets 67,159 15,000
Purchase of intangible assets (14,369) (8,323)
Investment in convertible note (8,709) 0
Other (725) (1,747)
Net cash provided by (used in) investing activities (64,648) 17,870
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercises of awards under equity incentive plans 60,268 21,768
Taxes paid related to net share settlement of equity awards (42,667) (40,951)
Payment of contingent acquisition consideration 0 (57,508)
Repurchase of common stock (50,000) 0
Proceeds from convertible senior subordinated note offering, net 585,752 0
Principal repayments of financing leases (6,080) (2,025)
Net cash provided by (used in) financing activities 547,273 (78,716)
Effect of exchange rate changes on cash (3,145) (835)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 578,229 (70,762)
Cash and cash equivalents:    
Beginning of period 437,446 493,982
End of period 1,015,675 423,220
SUPPLEMENTAL CASH FLOW DISCLOSURES:    
Cash paid for income taxes 4,355 6,088
Cash paid for interest 5,615 5,777
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Decrease in accounts payable and accrued liabilities related to fixed assets (13,281) (5,801)
Increase (decrease) in accounts payable and accrued liabilities related to intangible assets $ (3,043) $ 2,053
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
NATURE OF OPERATIONS
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
NATURE OF OPERATIONS NATURE OF OPERATIONS
BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.
On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - Debt, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThere have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2020, as compared to the significant accounting policies disclosed in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2
RECENT ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTSExcept as described in Note 2 – Basis of Presentation, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the nine months ended September 30, 2020, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that the Company believes are of significance or potential significance to the Company.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
All marketable securities were classified as available-for-sale at September 30, 2020 and December 31, 2019.
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:
September 30, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$378,705 $— $— $378,705 $378,705 $— $— 
Level 2:
Money market instruments557,006 — — 557,006 557,006 — — 
Corporate debt securities435,954 4,558 (14)440,498 — 280,000 160,498 
U.S. government agency securities361,336 2,182 (1)363,517 79,964 199,559 83,994 
Asset-backed securities23,430 129 — 23,559 — 3,639 19,920 
Commercial paper6,800 — — 6,800 — 6,800 — 
Foreign and other549 161 — 710 — — 710 
Subtotal1,385,075 7,030 (15)1,392,090 636,970 489,998 265,122 
Total$1,763,780 $7,030 $(15)$1,770,795 $1,015,675 $489,998 $265,122 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments173,100 — — 173,100 173,100 — — 
Corporate debt securities518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other549 145 (1)693 — — 693 
Subtotal901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)    The Company’s short-term marketable securities mature in one year or less.
(2)    The Company’s long-term marketable securities mature between one and five years.
As of September 30, 2020, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.
The Company has three investments in non-marketable equity securities, measured using unobservable valuation inputs remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of September 30, 2020 and December 31, 2019, the fair value of the Company’s strategic investments was $8.0 million and $6.2 million, respectively. These investments were recorded in Other Assets in the Company’s Condensed Consolidated Balance Sheets.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Intangible assets consisted of the following:
September 30,
2020		December 31,
2019
Intangible assets:
Finite-lived intangible assets$638,468 $652,734 
Accumulated amortization(211,296)(196,154)
Net carrying value$427,172 $456,580 
In January 2020, the Company completed the sale of worldwide rights to Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome, to a third party in exchange for a one-time cash payment of $67.2 million plus residual royalties. Under the terms of the agreement, the Company agreed to provide certain transition services to the third-party purchaser, such as customer sales and support, for up to 12 months after the closing of the transaction. During the first quarter of 2020, the Company recognized a before-tax net gain of $59.5 million related to the sale of the Firdapse intellectual property (IP) and existing inventory. Additionally, the Company recognized a $0.8 million reduction to goodwill and disposed of $32.2 million in intangible assets, including related accumulated amortization of $31.6 million, as a result of the sale of Firdapse.
During the second quarter of 2019, the Company recorded $15.0 million of gain on sale of intangible assets, reported in Gain on Sale of Nonfinancial Assets in the Consolidated Statements of Comprehensive Income (Loss), due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY, PLANT AND EQUIPMENT
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, net consisted of the following: 
September 30,
2020		December 31,
2019
Building and improvements$756,479 $725,906 
Manufacturing and laboratory equipment402,357 366,951 
Computer hardware and software187,722 167,554 
Land90,418 90,418 
Leasehold improvements52,479 51,324 
Furniture and equipment39,360 38,569 
Land improvements7,349 7,349 
Construction-in-progress92,581 111,897 
1,628,745 1,559,968 
Accumulated depreciation(613,683)(549,100)
Total property, plant and equipment, net$1,015,062 $1,010,868 
The construction-in-progress balance primarily included costs related to significant in-progress projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.

Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Depreciation expense$22,187 $24,238 $65,749 $67,206 
Depreciation capitalized into inventory$10,883 $9,807 $34,053 $24,894 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
SUPPLEMENTAL BALANCE SHEET INFORMATION
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventory consisted of the following:
September 30,
2020		December 31,
2019
Raw materials$73,857 $74,442 
Work-in-process296,685 349,978 
Finished goods330,305 255,855 
Total inventory$700,847 $680,275 
Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the second quarter of 2019, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale had been significantly reduced and included the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec in inventory. A number of factors were taken into consideration based on the information available at the time, including the status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If the marketing application is rejected, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed to Research and Development (R&D).
In the third quarter of 2020, the Company unexpectedly received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) and a Joint Assessment Report from the European Medicines Agency (EMA) respectively, both indicating that the Company’s regulatory applications for valoctocogene roxaparvovec could not be approved in their present form and requested additional safety and efficacy data from the ongoing Phase 3 study. The Company evaluated the impact of the new requirement for Phase 3 data that is currently unknown and determined the value of the pre-launch inventory was no longer recoverable due to delays in anticipated regulatory approvals. As a result, the Company adjusted the pre-launch inventory to zero, its net realizable value, and recorded $81.2 million to Cost of Sales in the three and nine months ended September 30, 2020.
Accounts Payable and Accrued Liabilities consisted of the following:
September 30,
2020		December 31,
2019
Accounts payable and accrued operating expenses$218,021 $240,981 
Accrued compensation expense137,415 192,467 
Accrued rebates payable65,999 57,163 
Accrued royalties payable20,426 30,797 
Lease liabilities10,930 10,700 
Value added taxes payable7,222 8,395 
Forward foreign currency exchange contracts7,774 10,448 
Deferred revenue3,240 13,037 
Other9,376 6,633 
Total accounts payable and accrued liabilities$480,403 $570,621 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2020 and December 31, 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 12 – Debt, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2020 or December 31, 2019.
Fair Value Measurements at September 30, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,902 $— $1,902 
Other assets:
NQDC Plan assets17,652 — 17,652 
Restricted investments (1)
2,987 — 2,987 
Total other assets20,639 — 20,639 
Total assets$22,541 $— $22,541 
Liabilities:
Current liabilities:
NQDC Plan liability$1,902 $— $1,902 
Other long-term liabilities:
NQDC Plan liability17,652 — 17,652 
Contingent consideration— 54,103 54,103 
Total other long-term liabilities17,652 54,103 71,755 
Total liabilities$19,554 $54,103 $73,657 
Fair Value Measurements at December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)    The restricted investments at September 30, 2020 and December 31, 2019 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
There were no transfers between levels during the three and nine months ended September 30, 2020. The following table represents a roll forward of contingent consideration.
Contingent consideration at December 31, 2019$50,793 
Changes in fair value of contingent consideration1,352 
Foreign exchange remeasurement of Euro denominated contingent acquisition consideration1,958 
Contingent consideration at September 30, 2020$54,103 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as hedging instruments and have maturities up to two and a half years. The Company also enters into forward contracts that are considered to be economic hedges that are not designated as hedging instruments and have maturities up to three months. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from product revenues, royalty revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
The following table summarizes the aggregate notional amounts for the Company’s derivatives designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$729,998 $820,546 
Purchase$163,116 $212,348 
The following table summarizes the aggregate notional amounts for the Company’s derivatives not designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$41,031 $77,335 
Purchase$30,031 $30,818 
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationSeptember 30, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$13,537 $19,584 
Other assets4,621 13,539 
Subtotal$18,158 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$7,704 $8,184 
Other long-term liabilities4,406 5,493 
Subtotal$12,110 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$16 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$70 $2,264 
Total Derivatives Assets$18,174 $33,592 
Total Derivatives Liabilities$12,180 $15,941 
(1)    For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income (Loss) for the periods presented.
Three Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$460,741 $2,693 $450,900 $6,196 
Operating expenses as reported$532,725 $(815)$457,087 $(1,388)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$4,166 $(1,286)

Nine Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,368,816 $17,301 $1,224,458 $11,171 
Operating expenses as reported$1,400,263 $(4,274)$1,340,900 $(1,885)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$9,600 $(5,182)
As of September 30, 2020, the Company expected to reclassify unrealized gains of $4.8 million from Accumulated Other Comprehensive Income (AOCI) to earnings as the forecasted revenue and operating expense transactions occur over the next 12 months. For additional discussion of balances in AOCI see Note 13 – Accumulated Other Comprehensive Income.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Leases LEASES
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020: 
Lease ClassificationClassificationSeptember 30,
2020		December 31,
2019
Assets:
OperatingOther Assets$45,764 $49,045 
FinancingOther Assets12,018 10,389 
Total ROU assets$57,782 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$7,813 $7,451 
FinancingAccounts payable and accrued liabilities3,117 3,249 
Noncurrent:
OperatingOther long-term liabilities40,831 44,092 
FinancingOther long-term liabilities4,570 6,708 
Total lease liabilities$56,331 $61,500 
Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
Remainder of 2020$3,460 $940 $4,400 
20219,908 3,080 12,988 
20229,095 2,375 11,470 
20238,055 1,797 9,852 
20246,253 48 6,301 
Thereafter21,714 20 21,734 
Total lease payments58,485 8,260 66,745 
Less: Interest(9,841)(573)(10,414)
Present value of lease liabilities$48,644 $7,687 $56,331 

Lease costs associated with payments under the Company’s leases were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
Lease CostClassification2020201920202019
Operating (1)
Operating Expenses$3,227 $3,535 $8,953 $9,946 
Financing:
AmortizationOperating Expenses841 600 2,307 1,811 
Interest expenseOperating Expenses111 142 352 455 
Total lease costs$4,179 $4,277 $11,612 $12,212 
 (1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Other InformationSeptember 30,
2020		September 30,
2019
Weighted average remaining lease term (in years):
Operating leases7.18.0
Financing leases2.84.2
Weighted average discount rate:
Operating leases5.1 %5.2 %
Financing leases5.2 %5.4 %
    As of September 30, 2020, one operating lease is expected to commence in the fourth quarter of 2020.
Nine Months Ended September 30,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$7,007 $5,918 
Financing leases$354 $454 
Cash used in financing activities:
Financing leases$6,080 $2,027 
ROU assets obtained in exchange for lease obligations:
Operating leases$3,299 $9,268 
Financing leases$3,941 $72 
Leases LEASES
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020: 
Lease ClassificationClassificationSeptember 30,
2020		December 31,
2019
Assets:
OperatingOther Assets$45,764 $49,045 
FinancingOther Assets12,018 10,389 
Total ROU assets$57,782 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$7,813 $7,451 
FinancingAccounts payable and accrued liabilities3,117 3,249 
Noncurrent:
OperatingOther long-term liabilities40,831 44,092 
FinancingOther long-term liabilities4,570 6,708 
Total lease liabilities$56,331 $61,500 
Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
Remainder of 2020$3,460 $940 $4,400 
20219,908 3,080 12,988 
20229,095 2,375 11,470 
20238,055 1,797 9,852 
20246,253 48 6,301 
Thereafter21,714 20 21,734 
Total lease payments58,485 8,260 66,745 
Less: Interest(9,841)(573)(10,414)
Present value of lease liabilities$48,644 $7,687 $56,331 

Lease costs associated with payments under the Company’s leases were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
Lease CostClassification2020201920202019
Operating (1)
Operating Expenses$3,227 $3,535 $8,953 $9,946 
Financing:
AmortizationOperating Expenses841 600 2,307 1,811 
Interest expenseOperating Expenses111 142 352 455 
Total lease costs$4,179 $4,277 $11,612 $12,212 
 (1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Other InformationSeptember 30,
2020		September 30,
2019
Weighted average remaining lease term (in years):
Operating leases7.18.0
Financing leases2.84.2
Weighted average discount rate:
Operating leases5.1 %5.2 %
Financing leases5.2 %5.4 %
    As of September 30, 2020, one operating lease is expected to commence in the fourth quarter of 2020.
Nine Months Ended September 30,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$7,007 $5,918 
Financing leases$354 $454 
Cash used in financing activities:
Financing leases$6,080 $2,027 
ROU assets obtained in exchange for lease obligations:
Operating leases$3,299 $9,268 
Financing leases$3,941 $72 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
DEBT DEBT
Convertible Notes
As of September 30, 2020, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.5 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
September 30,
2020		December 31,
2019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,792)— 
Unamortized deferred offering costs(709)— 
2027 Notes, net586,499 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,470)(6,533)
Unamortized deferred offering costs(1,865)(2,229)
2024 Notes, net487,665 486,238 
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993 374,993 
Unamortized discount(649)(12,078)
Unamortized deferred offering costs(54)(1,033)
2020 Notes, net (1)
374,290 361,882 
Total convertible debt, net$1,448,454 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$590,010 $— 
2024 Notes
517,730 521,839 
2020 Notes
374,997 405,679 
Total fair value of fixed rate convertible debt$1,482,737 $927,518 
(1)    The 2020 Notes are classified as a current liability in the periods presented because they matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
(2)    The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Interest expense on the Company’s convertible debt consisted of the following: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Accretion of discount on convertible notes$4,696 $4,005 $13,201 $11,860 
Coupon interest expense4,255 2,271 9,443 6,681 
Amortization of debt issuance costs535 508 1,565 1,522 
Total interest expense on convertible debt$9,486 $6,784 $24,209 $20,063 
 
2027 Notes
In May 2020, the Company issued $600.0 million in aggregate principal amount of senior subordinated unsecured convertible notes with a maturity date of May 15, 2027. The 2027 Notes were issued to the public at par value and bear interest at the rate of 1.25% per annum. Interest is payable semi-annually in cash in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The 2027 Notes are convertible, at the option of the holder into shares of the Company’s common stock. The initial conversion rate for the 2027 Notes is 7.2743 shares per $1,000 principal amount of the 2027 Notes, which represents a conversion price of approximately $137.47 per share, subject to adjustment under certain conditions. Following certain corporate transactions, the Company will, in certain circumstances, increase the conversion rate for a holder that elects to convert its 2027 Notes in connection with such corporate transactions by a number of additional shares of the Company’s common stock. A holder may convert fewer than all of such holder’s 2027 Notes so long as the amount of the 2027 Notes converted is an integral multiple of $1,000 principal amount. Net proceeds from the offering were $585.8 million. In connection with the issuance of the 2027 Notes, the Company recorded a discount on the 2027 Notes of $13.5 million, which will be accreted and recorded as additional interest expense over the life of the 2027 Notes. The Company also incurred $0.7 million of issuance costs, which were deferred and are being amortized over the life of the 2027 Notes and recorded as additional interest expense.
The 2027 Notes are senior subordinated, unsecured obligations, and rank (i) subordinated in right of payment to the prior payment in full of all of the Company’s existing and future senior debt, (ii) equal in right of payment with the Company’s existing and future senior subordinated debt, (iii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the notes, (vi) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, and (v) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Upon the occurrence of a “fundamental change,” as defined in the indenture governing the 2027 Notes, the holders may require the Company to repurchase all or a portion of such holder’s 2027 Notes for cash at 100% of the principal amount of the 2027 Notes being purchased, plus any accrued and unpaid interest.
The offer and sale of the 2027 Notes and the shares of the Company’s common stock issuable upon conversion of the 2027 Notes have not been registered under the Securities Act or any state securities laws and the 2027 Notes were offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act.
See Note 13 - Debt in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the Company’s convertible debt.
Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and earnings before interest, taxes, depreciation and amortization (EBITDA) for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount
range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021, at which time all outstanding amounts become due and payable. The Company incurred approximately $1.0 million of issuance costs, which are amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2020, and December 31, 2019, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility. As of September 30, 2020, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
ACCUMULATED OTHER COMPREHENSIVE INCOME
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019. 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification		Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Gains (losses) on cash flow hedges:
Forward contracts
Net product revenues$2,693 $6,196 $17,301 $11,171 
Forward contracts
Operating expenses(815)(1,388)(4,274)(1,885)
Total gain (loss) on cash flow hedges$1,878 $4,808 $13,027 $9,286 
The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2020 and 2019.
Three Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2020$22,963 $7,087 $— $30,050 
Other comprehensive income (loss) before
     reclassifications
(16,094)(2,201)— (18,295)
Less: net gain (loss) reclassified from AOCI1,878 — — 1,878 
Tax effect— 508 — 508 
Net current-period other comprehensive income (loss)(17,972)(1,693)— (19,665)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 
Three Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2019$14,181 $3,271 $(13)$17,439 
Other comprehensive income (loss) before
     reclassifications		23,973 522 (3)24,492 
Less: gain (loss) reclassified from AOCI4,808 — — 4,808 
Tax effect— (120)— (120)
Net current-period other comprehensive income (loss)19,165 402 (3)19,564 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 


Nine Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2019$16,614 $3,565 $(15)$20,164 
Other comprehensive income (loss) before
     reclassifications		1,404 2,379 15 3,798 
Less: gain (loss) reclassified from AOCI13,027 — 13,027 
Tax effect— (550)— (550)
Net current-period other comprehensive income (loss)(11,623)1,829 15 (9,779)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 

Nine Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
     reclassifications		35,431 7,256 (3)42,684 
Less: gain (loss) reclassified from AOCI9,286 — — 9,286 
Tax effect— (1,666)— (1,666)
Net current-period other comprehensive income (loss)26,145 5,590 (3)31,732 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2020
Concentration Risk And Geographic Information [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Total revenues by geographic region:
United States$252,948 $201,874 $729,672 $562,217 
Europe121,158 125,485 375,453 369,585 
Latin America44,064 83,799 141,852 164,132 
Rest of world58,614 49,939 161,361 153,671 
Total revenues$476,784 $461,097 $1,408,338 $1,249,605 

The following table disaggregates Net Product Revenues by product. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Net product revenues by product:
Vimizim$147,891 $163,466 $401,789 $411,953 
Kuvan123,993 120,524 368,604 340,771 
Naglazyme76,323 94,408 271,585 279,462 
Palynziq46,092 24,142 121,354 55,250 
Brineura25,455 19,840 75,223 46,815 
Firdapse— 5,668 1,316 16,262 
Total net product revenues marketed by the Company$419,754 $428,048 $1,239,871 $1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 $128,945 $73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
United States$203,892 $175,127 $582,734 $480,330 
Europe115,548 121,363 360,718 358,041 
Latin America44,064 83,799 141,852 164,132 
Rest of world56,250 47,759 154,567 148,010 
Total net product revenues marketed by the Company419,754 428,048 1,239,871 1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 128,945 73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Customer A16 %16 %15 %17 %
Customer B14 %13 %14 %12 %
Customer C11 %10 %12 %11 %
Customer D1 %12 %3 %6 %
Total42 %51 %44 %46 %

On a consolidated basis, two customers accounted for 33% and 15% of the September 30, 2020 accounts receivable balance, respectively, compared to December 31, 2019, when two customers accounted for 24% and 16% of the accounts receivable balance, respectively. As of September 30, 2020, and December 31, 2019, the accounts receivable balance for Genzyme included $106.5 million and $60.2 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The outbreak of COVID-19 continues to affect economies and business around the world. The Company experienced a modest impact on its global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, in the three and nine months ended September 30, 2020 and the Company anticipates a continued impact on its financial results for the remainder of 2020 and into fiscal year 2021. The extent and duration of such effects are highly uncertain and difficult to predict. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations. See the risk factor related to the impact of the coronavirus pandemic, “The coronavirus, or COVID-19, pandemic could materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A of this Quarterly Report, for additional details on the impact of the COVID-19 pandemic.
The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and other types of awards to its employees, officers and non-employee directors. Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Cost of sales$10,342 $4,093 $20,381 $12,629 
Research and development15,705 14,261 45,333 43,037 
Selling, general and administrative24,122 20,819 76,411 66,097 
Total stock-based compensation expense$50,169 $39,173 $142,125 $121,763 
Stock-based compensation of $4.9 million and $14.9 million was capitalized into inventory for the three and nine months ended September 30, 2020, respectively. Stock-based compensation of $5.1 million and $13.2 million was capitalized into inventory for the three and nine months ended September 30, 2019, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.
Restricted Stock Unit Awards with Market Conditions
In March 2020, the Compensation Committee and Board approved the grant of 126,710 RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between 0% and 200% of the base TSR-RSUs, with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the 50th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of $112.12 per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.
Restricted Stock Unit Awards with Performance Conditions
In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year Non-GAAP income target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its current long-range financial plan and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.
In March 2020, the Compensation Committee and Board approved the grant of 63,400 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $73.82 per RSU. This award is contingent upon the achievement of a three-year strategic goal target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the target in the context of its product candidate development pipeline and planned regulatory activity and determined that attainment of the target was probable for accounting purposes commencing in the first quarter of 2020. The number of shares that may be earned range between 50% and 200% of the base RSUs.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESIn the third quarter of 2020, the Company completed an intra-entity transfer of certain intellectual property rights to an Irish subsidiary where the Company’s Ex-US regional headquarters are located and has significant manufacturing and commercial operations, to better align ownership of intellectual property rights with how the business operates. The transaction did not result in a taxable gain; however, the Company’s Irish subsidiary recognized a deferred tax asset for the book and tax basis difference of the transferred intellectual property rights. As a result, the Company recognized a deferred tax asset of $835.1 million and related tax benefit on its Condensed Consolidated Financial Statements based on the fair value of the transferred intellectual property rights. The tax deductions related to the amortization of these intangible assets will be recognized in the future and any amortization not deducted for tax purposes will be carried forward indefinitely under Irish tax laws. The Company expects to be able to realize the deferred tax asset resulting from this transaction and has not recorded a valuation allowance as of September 30, 2020.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER COMMON SHARE
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER COMMON SHARE NET INCOME (LOSS) PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s Employee Share Purchase Plan (ESPP), unvested RSUs, common stock held by the NQDC and contingent issuances of common stock related to the Company’s convertible debt.
The following table sets forth the computation of basic and diluted earnings per common share (common shares in
thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Numerator:
Net Income (Loss), basic$784,803 $55,036 $837,001 $(38,872)
Add: Interest on convertible notes7,070 937 18,333 — 
Net Income (Loss), diluted$791,873 $55,973 $855,334 $(38,872)
Denominator:
Weighted-average common shares outstanding, basic181,142 179,289 180,592 178,873 
Effect of dilutive securities:
Options to purchase common stock1,731 1,560 1,728 — 
Common stock issuable under the 2020 notes3,983 — 3,983 — 
Common stock issuable under the 2024 notes3,970 3,970 3,970 — 
Common stock issuable under the 2027 notes4,365 — 2,373 — 
Unvested RSUs1,926 669 1,765 — 
Common stock potentially issuable for ESPP purchases346 231 337 — 
Common shares held by the NQDC211 205 211 — 
Weighted-average common shares outstanding, diluted197,674 185,924 194,959 178,873 
Net Income (Loss) per common share, basic$4.33 $0.31 4.63 (0.22)
Net Income (Loss) per common share, diluted$4.01 $0.30 4.39 (0.22)
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Options to purchase common stock5,172 5,829 5,175 7,388 
Common stock issuable under the 2020 Notes— 3,983 — 3,983 
Common stock issuable under the 2024 Notes— — — 3,970 
Unvested RSUs2,900 3,360 3,060 4,029 
Common stock potentially issuable for ESPP purchases193 222 204 453 
Common stock held by the NQDC— — — 205 
Total number of potentially issuable shares8,265 13,394 8,439 20,028 
The potential effect of the capped call transactions and potential shares issuable under the 2020 Notes were excluded from the calculation of diluted net income (loss) per share in the three and nine months ended September 30, 2020 and 2019, as the Company’s closing price on September 30, 2020 and 2019 did not exceed the conversion price of $94.15 per share. The Company’s 2020 Notes matured on October 15, 2020 and were settled in cash. The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net income (loss) per share as of September 30, 2020.There is no similar capped call transaction associated with the 2024 Notes or the 2027 Notes. See Note 12 – Debt for additional information on the Company’s 2020 Notes and 2027 Notes. Refer to Note 13 - Debt to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for additional information related to the 2024 Notes and details of the capped call transaction.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of
resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these
matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general
practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses
are probable and reasonably estimable.
Contingent Payments
As of September 30, 2020, the Company was subject to contingent payments totaling approximately $622.4 million upon achievement of certain development, regulatory and commercial sales milestones, if they occur before certain dates in the future. Of this amount, $235.0 million related to an early stage development programs licensed from a third party in the second quarter of 2020, $70.3 million related to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and $236.0 million related to programs that are no longer being developed.
As of September 30, 2020, the Company recorded a total of $54.1 million of contingent liabilities on its Condensed
Consolidated Balances Sheet. See Note 9 – Fair Value Measurements to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
In the normal course of business, the Company enters into various firm purchase commitments primarily related to active
pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services. As of September 30, 2020, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $150.3 million.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2
BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that, except for the maturity and settlement of our convertible debt discussed in Note 12 - Debt, there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.
New Accounting Pronouncements On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:
September 30, 2020
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$378,705 $— $— $378,705 $378,705 $— $— 
Level 2:
Money market instruments557,006 — — 557,006 557,006 — — 
Corporate debt securities435,954 4,558 (14)440,498 — 280,000 160,498 
U.S. government agency securities361,336 2,182 (1)363,517 79,964 199,559 83,994 
Asset-backed securities23,430 129 — 23,559 — 3,639 19,920 
Commercial paper6,800 — — 6,800 — 6,800 — 
Foreign and other549 161 — 710 — — 710 
Subtotal1,385,075 7,030 (15)1,392,090 636,970 489,998 265,122 
Total$1,763,780 $7,030 $(15)$1,770,795 $1,015,675 $489,998 $265,122 


December 31, 2019
Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Aggregate Fair ValueCash and Cash Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:
Cash$259,347 $— $— $259,347 $259,347 $— $— 
Level 2:
Money market instruments173,100 — — 173,100 173,100 — — 
Corporate debt securities518,523 3,575 (12)522,086 — 233,294 288,792 
U.S. government agency securities209,633 993 (67)210,559 4,999 83,067 122,493 
Foreign and other549 145 (1)693 — — 693 
Subtotal901,805 4,713 (80)906,438 178,099 316,361 411,978 
Total$1,161,152 $4,713 $(80)$1,165,785 $437,446 $316,361 $411,978 
(1)    The Company’s short-term marketable securities mature in one year or less.
(2)    The Company’s long-term marketable securities mature between one and five years.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
September 30,
2020		December 31,
2019
Intangible assets:
Finite-lived intangible assets$638,468 $652,734 
Accumulated amortization(211,296)(196,154)
Net carrying value$427,172 $456,580 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY, PLANT AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Schedule of Property Plant and Equipment Net
Property, plant and equipment, net consisted of the following: 
September 30,
2020		December 31,
2019
Building and improvements$756,479 $725,906 
Manufacturing and laboratory equipment402,357 366,951 
Computer hardware and software187,722 167,554 
Land90,418 90,418 
Leasehold improvements52,479 51,324 
Furniture and equipment39,360 38,569 
Land improvements7,349 7,349 
Construction-in-progress92,581 111,897 
1,628,745 1,559,968 
Accumulated depreciation(613,683)(549,100)
Total property, plant and equipment, net$1,015,062 $1,010,868 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Depreciation expense$22,187 $24,238 $65,749 $67,206 
Depreciation capitalized into inventory$10,883 $9,807 $34,053 $24,894 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Inventory consisted of the following:
September 30,
2020		December 31,
2019
Raw materials$73,857 $74,442 
Work-in-process296,685 349,978 
Finished goods330,305 255,855 
Total inventory$700,847 $680,275 
Schedule of Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities consisted of the following:
September 30,
2020		December 31,
2019
Accounts payable and accrued operating expenses$218,021 $240,981 
Accrued compensation expense137,415 192,467 
Accrued rebates payable65,999 57,163 
Accrued royalties payable20,426 30,797 
Lease liabilities10,930 10,700 
Value added taxes payable7,222 8,395 
Forward foreign currency exchange contracts7,774 10,448 
Deferred revenue3,240 13,037 
Other9,376 6,633 
Total accounts payable and accrued liabilities$480,403 $570,621 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2020 and December 31, 2019. Other than the Company’s fixed-rate convertible debt disclosed in Note 12 – Debt, there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2020 or December 31, 2019.
Fair Value Measurements at September 30, 2020
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,902 $— $1,902 
Other assets:
NQDC Plan assets17,652 — 17,652 
Restricted investments (1)
2,987 — 2,987 
Total other assets20,639 — 20,639 
Total assets$22,541 $— $22,541 
Liabilities:
Current liabilities:
NQDC Plan liability$1,902 $— $1,902 
Other long-term liabilities:
NQDC Plan liability17,652 — 17,652 
Contingent consideration— 54,103 54,103 
Total other long-term liabilities17,652 54,103 71,755 
Total liabilities$19,554 $54,103 $73,657 
Fair Value Measurements at December 31, 2019
Significant Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Other current assets:
NQDC Plan assets$1,177 $— $1,177 
Other assets:
NQDC Plan assets16,288 — 16,288 
Restricted investments (1)
3,168 — 3,168 
Total other assets19,456 — 19,456 
Total assets$20,633 $— $20,633 
Liabilities:
Current liabilities:
NQDC Plan liability$1,177 $— $1,177 
Other long-term liabilities:
NQDC Plan liability16,288 — 16,288 
Contingent consideration— 50,793 50,793 
Total other long-term liabilities16,288 50,793 67,081 
Total liabilities$17,465 $50,793 $68,258 
(1)    The restricted investments at September 30, 2020 and December 31, 2019 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs The following table represents a roll forward of contingent consideration.
Contingent consideration at December 31, 2019$50,793 
Changes in fair value of contingent consideration1,352 
Foreign exchange remeasurement of Euro denominated contingent acquisition consideration1,958 
Contingent consideration at September 30, 2020$54,103 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)
 9 Months Ended
Sep. 30, 2020
Derivative [Line Items]  
Fair Value Carrying Amount of Derivatives
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet LocationSeptember 30, 2020December 31, 2019
Derivatives designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$13,537 $19,584 
Other assets4,621 13,539 
Subtotal$18,158 $33,123 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$7,704 $8,184 
Other long-term liabilities4,406 5,493 
Subtotal$12,110 $13,677 
Derivatives not designated as hedging instruments:
Asset Derivatives - Level 2 (1)
Other current assets$16 $469 
Liability Derivatives - Level 2 (1)
Accounts payable and accrued liabilities$70 $2,264 
Total Derivatives Assets$18,174 $33,592 
Total Derivatives Liabilities$12,180 $15,941 
(1)    For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income (Loss) for the periods presented.
Three Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$460,741 $2,693 $450,900 $6,196 
Operating expenses as reported$532,725 $(815)$457,087 $(1,388)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$4,166 $(1,286)

Nine Months Ended
September 30, 2020September 30, 2019
Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses)
Reclassified into Earnings		Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
Net product revenues as reported$1,368,816 $17,301 $1,224,458 $11,171 
Operating expenses as reported$1,400,263 $(4,274)$1,340,900 $(1,885)
Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in Earnings
Operating expenses$9,600 $(5,182)
Derivatives Designated As Hedging Instruments  
Derivative [Line Items]  
Summary of Derivatives Designated as Hedging Instruments Outstanding
The following table summarizes the aggregate notional amounts for the Company’s derivatives designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$729,998 $820,546 
Purchase$163,116 $212,348 
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Summary of Derivatives Designated as Hedging Instruments Outstanding
The following table summarizes the aggregate notional amounts for the Company’s derivatives not designated as hedging instruments outstanding as of the periods presented.
Foreign Exchange ContractsSeptember 30, 2020December 31, 2019
Sell$41,031 $77,335 
Purchase$30,031 $30,818 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2
LEASES (Tables)
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Schedule of ROU Assets and Lease Liabilities
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2020: 
Lease ClassificationClassificationSeptember 30,
2020		December 31,
2019
Assets:
OperatingOther Assets$45,764 $49,045 
FinancingOther Assets12,018 10,389 
Total ROU assets$57,782 $59,434 
Liabilities:
Current:
OperatingAccounts payable and accrued liabilities$7,813 $7,451 
FinancingAccounts payable and accrued liabilities3,117 3,249 
Noncurrent:
OperatingOther long-term liabilities40,831 44,092 
FinancingOther long-term liabilities4,570 6,708 
Total lease liabilities$56,331 $61,500 
Schedule of Maturities of Operating Lease Liabilities
Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
Remainder of 2020$3,460 $940 $4,400 
20219,908 3,080 12,988 
20229,095 2,375 11,470 
20238,055 1,797 9,852 
20246,253 48 6,301 
Thereafter21,714 20 21,734 
Total lease payments58,485 8,260 66,745 
Less: Interest(9,841)(573)(10,414)
Present value of lease liabilities$48,644 $7,687 $56,331 
Schedule of Maturities of Finance Lease Liabilities
Maturities of lease liabilities as of September 30, 2020 by fiscal year were as follows: 
Maturity of Lease LiabilitiesOperatingFinancingTotal
Remainder of 2020$3,460 $940 $4,400 
20219,908 3,080 12,988 
20229,095 2,375 11,470 
20238,055 1,797 9,852 
20246,253 48 6,301 
Thereafter21,714 20 21,734 
Total lease payments58,485 8,260 66,745 
Less: Interest(9,841)(573)(10,414)
Present value of lease liabilities$48,644 $7,687 $56,331 
Schedule of Lease Cost
Lease costs associated with payments under the Company’s leases were as follows:

Three Months Ended
September 30,		Nine Months Ended
September 30,
Lease CostClassification2020201920202019
Operating (1)
Operating Expenses$3,227 $3,535 $8,953 $9,946 
Financing:
AmortizationOperating Expenses841 600 2,307 1,811 
Interest expenseOperating Expenses111 142 352 455 
Total lease costs$4,179 $4,277 $11,612 $12,212 
 (1)    Includes short-term leases and variable lease costs, both of which were not material in the periods presented.
Nine Months Ended September 30,
Supplemental Cash Flow Information20202019
Cash paid for amounts included in the measurement of lease liabilities:
Cash used in operating activities:
Operating leases$7,007 $5,918 
Financing leases$354 $454 
Cash used in financing activities:
Financing leases$6,080 $2,027 
ROU assets obtained in exchange for lease obligations:
Operating leases$3,299 $9,268 
Financing leases$3,941 $72 
Schedule of Other Information The following table includes the weighted average remaining lease terms and the weighted average discount rate used to calculate the present value of the Company’s lease liabilities:
Other InformationSeptember 30,
2020		September 30,
2019
Weighted average remaining lease term (in years):
Operating leases7.18.0
Financing leases2.84.2
Weighted average discount rate:
Operating leases5.1 %5.2 %
Financing leases5.2 %5.4 %
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2
DEBT (Tables)
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Summary of Convertible Debt The following table summarizes information regarding the Company’s convertible debt: 
September 30,
2020		December 31,
2019
1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)
$600,000 $— 
Unamortized discount(12,792)— 
Unamortized deferred offering costs(709)— 
2027 Notes, net586,499 — 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000 495,000 
Unamortized discount(5,470)(6,533)
Unamortized deferred offering costs(1,865)(2,229)
2024 Notes, net487,665 486,238 
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993 374,993 
Unamortized discount(649)(12,078)
Unamortized deferred offering costs(54)(1,033)
2020 Notes, net (1)
374,290 361,882 
Total convertible debt, net$1,448,454 $848,120 
Fair value of fixed rate convertible debt (2):
2027 Notes
$590,010 $— 
2024 Notes
517,730 521,839 
2020 Notes
374,997 405,679 
Total fair value of fixed rate convertible debt$1,482,737 $927,518 
(1)    The 2020 Notes are classified as a current liability in the periods presented because they matured on October 15, 2020 and were settled in cash for approximately $375.0 million. No shares were issued in connection with the settlement as the Company’s share price did not exceed the conversion price of $94.15, as measured over a 25-day averaging period, and the capped call transaction entered into concurrently with the issuance of notes was not triggered. The Company incurred no gain or loss upon the extinguishment of the 2020 Notes.
(2)    The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Summary of Interest Expense on Debt
Interest expense on the Company’s convertible debt consisted of the following: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Accretion of discount on convertible notes$4,696 $4,005 $13,201 $11,860 
Coupon interest expense4,255 2,271 9,443 6,681 
Amortization of debt issuance costs535 508 1,565 1,522 
Total interest expense on convertible debt$9,486 $6,784 $24,209 $20,063 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019. 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification		Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Gains (losses) on cash flow hedges:
Forward contracts
Net product revenues$2,693 $6,196 $17,301 $11,171 
Forward contracts
Operating expenses(815)(1,388)(4,274)(1,885)
Total gain (loss) on cash flow hedges$1,878 $4,808 $13,027 $9,286 
Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI
The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2020 and 2019.
Three Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2020$22,963 $7,087 $— $30,050 
Other comprehensive income (loss) before
     reclassifications
(16,094)(2,201)— (18,295)
Less: net gain (loss) reclassified from AOCI1,878 — — 1,878 
Tax effect— 508 — 508 
Net current-period other comprehensive income (loss)(17,972)(1,693)— (19,665)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 
Three Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at June 30, 2019$14,181 $3,271 $(13)$17,439 
Other comprehensive income (loss) before
     reclassifications		23,973 522 (3)24,492 
Less: gain (loss) reclassified from AOCI4,808 — — 4,808 
Tax effect— (120)— (120)
Net current-period other comprehensive income (loss)19,165 402 (3)19,564 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 


Nine Months Ended September 30, 2020
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2019$16,614 $3,565 $(15)$20,164 
Other comprehensive income (loss) before
     reclassifications		1,404 2,379 15 3,798 
Less: gain (loss) reclassified from AOCI13,027 — 13,027 
Tax effect— (550)— (550)
Net current-period other comprehensive income (loss)(11,623)1,829 15 (9,779)
AOCI balance at September 30, 2020$4,991 $5,394 $— $10,385 

Nine Months Ended September 30, 2019
Unrealized Gains
(Losses) on Cash
Flow Hedges		Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities		OtherTotal
AOCI balance at December 31, 2018$7,201 $(1,917)$(13)$5,271 
Other comprehensive income (loss) before
     reclassifications		35,431 7,256 (3)42,684 
Less: gain (loss) reclassified from AOCI9,286 — — 9,286 
Tax effect— (1,666)— (1,666)
Net current-period other comprehensive income (loss)26,145 5,590 (3)31,732 
AOCI balance at September 30, 2019$33,346 $3,673 $(16)$37,003 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2020
Concentration Risk And Geographic Information [Abstract]  
Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Total revenues by geographic region:
United States$252,948 $201,874 $729,672 $562,217 
Europe121,158 125,485 375,453 369,585 
Latin America44,064 83,799 141,852 164,132 
Rest of world58,614 49,939 161,361 153,671 
Total revenues$476,784 $461,097 $1,408,338 $1,249,605 
Schedule of Net Product Revenues by Product
The following table disaggregates Net Product Revenues by product. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Net product revenues by product:
Vimizim$147,891 $163,466 $401,789 $411,953 
Kuvan123,993 120,524 368,604 340,771 
Naglazyme76,323 94,408 271,585 279,462 
Palynziq46,092 24,142 121,354 55,250 
Brineura25,455 19,840 75,223 46,815 
Firdapse— 5,668 1,316 16,262 
Total net product revenues marketed by the Company$419,754 $428,048 $1,239,871 $1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 $128,945 $73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
Schedule of Total Net Product Revenues Based on Patient Location
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
United States$203,892 $175,127 $582,734 $480,330 
Europe115,548 121,363 360,718 358,041 
Latin America44,064 83,799 141,852 164,132 
Rest of world56,250 47,759 154,567 148,010 
Total net product revenues marketed by the Company419,754 428,048 1,239,871 1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 128,945 73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Customer A16 %16 %15 %17 %
Customer B14 %13 %14 %12 %
Customer C11 %10 %12 %11 %
Customer D1 %12 %3 %6 %
Total42 %51 %44 %46 %
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Cost of sales$10,342 $4,093 $20,381 $12,629 
Research and development15,705 14,261 45,333 43,037 
Selling, general and administrative24,122 20,819 76,411 66,097 
Total stock-based compensation expense$50,169 $39,173 $142,125 $121,763 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share The following table sets forth the computation of basic and diluted earnings per common share (common shares in
thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Numerator:
Net Income (Loss), basic$784,803 $55,036 $837,001 $(38,872)
Add: Interest on convertible notes7,070 937 18,333 — 
Net Income (Loss), diluted$791,873 $55,973 $855,334 $(38,872)
Denominator:
Weighted-average common shares outstanding, basic181,142 179,289 180,592 178,873 
Effect of dilutive securities:
Options to purchase common stock1,731 1,560 1,728 — 
Common stock issuable under the 2020 notes3,983 — 3,983 — 
Common stock issuable under the 2024 notes3,970 3,970 3,970 — 
Common stock issuable under the 2027 notes4,365 — 2,373 — 
Unvested RSUs1,926 669 1,765 — 
Common stock potentially issuable for ESPP purchases346 231 337 — 
Common shares held by the NQDC211 205 211 — 
Weighted-average common shares outstanding, diluted197,674 185,924 194,959 178,873 
Net Income (Loss) per common share, basic$4.33 $0.31 4.63 (0.22)
Net Income (Loss) per common share, diluted$4.01 $0.30 4.39 (0.22)
Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Options to purchase common stock5,172 5,829 5,175 7,388 
Common stock issuable under the 2020 Notes— 3,983 — 3,983 
Common stock issuable under the 2024 Notes— — — 3,970 
Unvested RSUs2,900 3,360 3,060 4,029 
Common stock potentially issuable for ESPP purchases193 222 204 453 
Common stock held by the NQDC— — — 205 
Total number of potentially issuable shares8,265 13,394 8,439 20,028 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 1,763,780 $ 1,161,152
Gross Unrealized Gains 7,030 4,713
Gross Unrealized Losses (15) (80)
Aggregate Fair Value 1,770,795 1,165,785
Cash and Cash Equivalents 1,015,675 437,446 [1]
Short-term Marketable Securities 489,998 316,361 [1]
Long-term Marketable Securities 265,122 411,978 [1]
Level 1: | Cash    
Schedule of Available-for-sale Securities [Line Items]    
Cash 378,705 259,347
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Aggregate Fair Value 378,705 259,347
Cash and Cash Equivalents 378,705 259,347
Short-term Marketable Securities 0 0
Long-term Marketable Securities 0 0
Level 2:    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 1,385,075 901,805
Gross Unrealized Gains 7,030 4,713
Gross Unrealized Losses (15) (80)
Aggregate Fair Value 1,392,090 906,438
Cash and Cash Equivalents 636,970 178,099
Short-term Marketable Securities 489,998 316,361
Long-term Marketable Securities 265,122 411,978
Level 2: | Money market instruments    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 557,006 173,100
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Aggregate Fair Value 557,006 173,100
Cash and Cash Equivalents 557,006 173,100
Short-term Marketable Securities 0 0
Long-term Marketable Securities 0 0
Level 2: | Corporate debt securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 435,954 518,523
Gross Unrealized Gains 4,558 3,575
Gross Unrealized Losses (14) (12)
Aggregate Fair Value 440,498 522,086
Cash and Cash Equivalents 0 0
Short-term Marketable Securities 280,000 233,294
Long-term Marketable Securities 160,498 288,792
Level 2: | U.S. government agency securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 361,336 209,633
Gross Unrealized Gains 2,182 993
Gross Unrealized Losses (1) (67)
Aggregate Fair Value 363,517 210,559
Cash and Cash Equivalents 79,964 4,999
Short-term Marketable Securities 199,559 83,067
Long-term Marketable Securities 83,994 122,493
Level 2: | Asset-backed securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 23,430  
Gross Unrealized Gains 129  
Gross Unrealized Losses 0  
Aggregate Fair Value 23,559  
Cash and Cash Equivalents 0  
Short-term Marketable Securities 3,639  
Long-term Marketable Securities 19,920  
Level 2: | Commercial paper    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 6,800  
Gross Unrealized Gains 0  
Gross Unrealized Losses 0  
Aggregate Fair Value 6,800  
Cash and Cash Equivalents 0  
Short-term Marketable Securities 6,800  
Long-term Marketable Securities 0  
Level 2: | Foreign and other    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 549 549
Gross Unrealized Gains 161 145
Gross Unrealized Losses 0 (1)
Aggregate Fair Value 710 693
Cash and Cash Equivalents 0 0
Short-term Marketable Securities 0 0
Long-term Marketable Securities $ 710 $ 693
Minimum    
Schedule of Available-for-sale Securities [Line Items]    
Long term marketable securities maturity period 1 year 1 year
Maximum    
Schedule of Available-for-sale Securities [Line Items]    
Short term marketable securities maturity period 1 year 1 year
Long term marketable securities maturity period 5 years 5 years
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Additional Information (Detail) - Fair Value, Measurements, Recurring
$ in Millions
Sep. 30, 2020
USD ($)
investment
Dec. 31, 2019
USD ($)
Schedule of Available-for-sale Securities [Line Items]    
Number of investments | investment 3  
Strategic Investment    
Schedule of Available-for-sale Securities [Line Items]    
Strategic investments fair value | $ $ 8.0 $ 6.2
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Intangible assets:    
Finite-lived intangible assets $ 638,468 $ 652,734
Accumulated amortization (211,296) (196,154)
Net carrying value $ 427,172 $ 456,580 [1]
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Jan. 31, 2020
Dec. 31, 2019
Goodwill [Line Items]            
Gain (loss) on disposition of other assets     $ 59,495 $ 15,000    
Finite-lived intangible assets     638,468     $ 652,734
Accumulated amortization     $ 211,296     $ 196,154
Gain on sale of nonfinancial assets   $ 15,000        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Firdapse            
Goodwill [Line Items]            
Cash payment         $ 67,200  
Gain (loss) on disposition of other assets $ 59,500          
Increase (decrease) in goodwill (800)          
Finite-lived intangible assets 32,200          
Accumulated amortization $ 31,600          
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 1,628,745 $ 1,559,968
Accumulated depreciation (613,683) (549,100)
Total property, plant and equipment, net 1,015,062 1,010,868 [1]
Building and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 756,479 725,906
Manufacturing and laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 402,357 366,951
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 187,722 167,554
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 7,349 7,349
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 90,418 90,418
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 52,479 51,324
Land improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 39,360 38,569
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 92,581 $ 111,897
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 22,187 $ 24,238 $ 65,749 $ 67,206
Depreciation capitalized into inventory $ 10,883 $ 9,807 $ 34,053 $ 24,894
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Inventory [Line Items]          
Raw materials $ 73,857,000   $ 73,857,000   $ 74,442,000
Work-in-process 296,685,000   296,685,000   349,978,000
Finished goods 330,305,000   330,305,000   255,855,000
Total inventory 700,847,000   700,847,000   $ 680,275,000 [1]
Cost of sales 188,793,000 $ 96,949,000 398,134,000 $ 263,567,000  
Pre-Launch Valoctocogene Roxaparvovec          
Inventory [Line Items]          
Total inventory 0   0    
Cost of sales $ 81,200,000   $ 81,200,000    
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable and accrued operating expenses $ 218,021 $ 240,981
Accrued compensation expense 137,415 192,467
Accrued rebates payable 65,999 57,163
Accrued royalties payable 20,426 30,797
Lease liabilities 10,930 10,700
Value added taxes payable 7,222 8,395
Forward foreign currency exchange contracts 7,774 10,448
Deferred revenue 3,240 13,037
Other 9,376 6,633
Total accounts payable and accrued liabilities $ 480,403 $ 570,621 [1]
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets remeasured $ 0 $ 0
Liabilities remeasured 0 0
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 20,639,000 19,456,000
Fair value of financial assets, Total 22,541,000 20,633,000
Fair value of other non-current liabilities 71,755,000 67,081,000
Fair value of financial liabilities, Total 73,657,000 68,258,000
Fair Value, Measurements, Recurring | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 1,902,000 1,177,000
Fair value of other non-current liabilities 17,652,000 16,288,000
Fair Value, Measurements, Recurring | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 54,103,000 50,793,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 20,639,000 19,456,000
Fair value of financial assets, Total 22,541,000 20,633,000
Fair value of other non-current liabilities 17,652,000 16,288,000
Fair value of financial liabilities, Total 19,554,000 17,465,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 1,902,000 1,177,000
Fair value of other non-current liabilities 17,652,000 16,288,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 0 0
Fair value of financial assets, Total 0 0
Fair value of other non-current liabilities 54,103,000 50,793,000
Fair value of financial liabilities, Total 54,103,000 50,793,000
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 0 0
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current liabilities 54,103,000 50,793,000
Fair Value, Measurements, Recurring | NQDC Plan assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 1,902,000 1,177,000
Fair value of other non-current assets 17,652,000 16,288,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 1,902,000 1,177,000
Fair value of other non-current assets 17,652,000 16,288,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 0 0
Fair value of other non-current assets 0 0
Fair Value, Measurements, Recurring | Restricted Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 2,987,000 3,168,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets 2,987,000 3,168,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets $ 0 $ 0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) - Contingent Payment
$ in Thousands
 9 Months Ended
Sep. 30, 2020
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Contingent consideration at December 31, 2019 $ 50,793
Changes in fair value of contingent consideration 1,352
Foreign exchange remeasurement of Euro denominated contingent acquisition consideration 1,958
Contingent consideration at September 30, 2020 $ 54,103
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Strategies - Additional Information (Detail)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
Derivative [Line Items]  
Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions $ 4.8
Derivatives Designated As Hedging Instruments  
Derivative [Line Items]  
Maturity of derivatives 2 years 6 months
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Maturity of derivatives 3 months
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) - Derivatives Designated As Hedging Instruments - Foreign exchange contracts - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sell    
Derivative [Line Items]    
Notional amount $ 729,998 $ 820,546
Purchase    
Derivative [Line Items]    
Notional amount $ 163,116 $ 212,348
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) - Not Designated as Hedging Instrument - Foreign exchange contracts - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sell    
Derivative [Line Items]    
Notional amount $ 41,031 $ 77,335
Purchase    
Derivative [Line Items]    
Notional amount $ 30,031 $ 30,818
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Derivative [Line Items]    
Derivative asset, fair value $ 18,174 $ 33,592
Derivative liability, fair value 12,180 15,941
Level 2: | Derivatives Designated As Hedging Instruments    
Derivative [Line Items]    
Derivative asset, fair value 18,158 33,123
Derivative liability, fair value 12,110 13,677
Level 2: | Derivatives Designated As Hedging Instruments | Other current assets    
Derivative [Line Items]    
Derivative asset, fair value 13,537 19,584
Level 2: | Derivatives Designated As Hedging Instruments | Other assets    
Derivative [Line Items]    
Derivative asset, fair value 4,621 13,539
Level 2: | Derivatives Designated As Hedging Instruments | Accounts payable and accrued liabilities    
Derivative [Line Items]    
Derivative liability, fair value 7,704 8,184
Level 2: | Derivatives Designated As Hedging Instruments | Other long-term liabilities    
Derivative [Line Items]    
Derivative liability, fair value 4,406 5,493
Level 2: | Not Designated as Hedging Instrument | Other current assets    
Derivative [Line Items]    
Derivative asset, fair value 16 469
Level 2: | Not Designated as Hedging Instrument | Accounts payable and accrued liabilities    
Derivative [Line Items]    
Derivative liability, fair value $ 70 $ 2,264
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Net product revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
Operating expenses as reported 532,725 457,087 1,400,263 1,340,900
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (Losses) Recognized in Earnings 4,166 (1,286) 9,600 (5,182)
Operating expenses as reported | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash Flow Hedging Gains (Losses) Reclassified into Earnings (815) (1,388) (4,274) (1,885)
Net product revenues        
Derivative Instruments, Gain (Loss) [Line Items]        
Net product revenues 460,741 450,900 1,368,816 1,224,458
Net product revenues | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash Flow Hedging Gains (Losses) Reclassified into Earnings $ 2,693 $ 6,196 $ 17,301 $ 11,171
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Schedule of ROU Assets and Lease Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Assets:    
Operating $ 45,764 $ 49,045
Financing 12,018 10,389
Total ROU assets 57,782 59,434
Liabilities:    
Operating, current 7,813 7,451
Financing, current 3,117 3,249
Operating, noncurrent 40,831 44,092
Financing, noncurrent 4,570 6,708
Total lease liabilities $ 56,331 $ 61,500
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Schedule of Maturities of Lease Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Operating    
Remainder of 2020 $ 3,460  
2021 9,908  
2022 9,095  
2023 8,055  
2024 6,253  
Thereafter 21,714  
Total lease payments 58,485  
Less: Interest (9,841)  
Present value of lease liabilities 48,644  
Financing    
Remainder of 2020 940  
2021 3,080  
2022 2,375  
2023 1,797  
2024 48  
Thereafter 20  
Total lease payments 8,260  
Less: Interest (573)  
Present value of lease liabilities 7,687  
Total    
Remainder of 2020 4,400  
2021 12,988  
2022 11,470  
2023 9,852  
2024 6,301  
Thereafter 21,734  
Total lease payments 66,745  
Less: Interest (10,414)  
Present value of lease liabilities $ 56,331 $ 61,500
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Schedule of Lease Cost (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Lease Cost        
Total lease costs $ 4,179 $ 4,277 $ 11,612 $ 12,212
Operating Expenses        
Lease Cost        
Operating 3,227 3,535 8,953 9,946
Amortization 841 600 2,307 1,811
Interest expense $ 111 $ 142 $ 352 $ 455
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Schedule of Other Information (Detail) - lease
Sep. 30, 2020
Sep. 30, 2019
Weighted average remaining lease term (in years):    
Operating leases 7 years 1 month 6 days 8 years
Financing leases 2 years 9 months 18 days 4 years 2 months 12 days
Weighted average discount rate:    
Operating leases 5.10% 5.20%
Financing leases 5.20% 5.40%
Additional leases not yet commenced (undiscounted):    
Operating leases expected to commence in remainder of year 1  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Schedule of Supplemental Cash Flow Information (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash used in operating activities:    
Operating leases $ 7,007 $ 5,918
Financing leases 354 454
Cash used in financing activities:    
Financing leases 6,080 2,027
ROU assets obtained in exchange for lease obligations:    
Operating leases 3,299 9,268
Financing leases $ 3,941 $ 72
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Additional Information (Detail)
 1 Months Ended
May 31, 2020
USD ($)
$ / shares
Oct. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]        
Carrying value of equity component     $ 1,500,000,000  
1.25% Senior Subordinated Convertible Notes Due in May 2027        
Debt Instrument [Line Items]        
Carrying value of equity component     $ 600,000,000 $ 0
Convertible notes stated rate     1.25% 1.25%
Debt discount     $ 12,792,000 $ 0
1.25% Senior Subordinated Convertible Notes Due in May 2027 | Senior Subordinated Notes        
Debt Instrument [Line Items]        
Debt face amount $ 600,000,000.0      
Convertible notes stated rate 1.25%      
Debt instrument, conversion ratio 7.2743      
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares $ 137.47      
Proceeds from issuance of notes $ 585,800,000      
Debt discount 13,500,000      
Debt issuance costs $ 700,000      
The 2018 Credit Facility        
Debt Instrument [Line Items]        
Debt issuance costs   $ 1,000,000.0    
Maximum borrowing capacity   $ 200,000,000.0    
Outstanding amount     0 0
The 2018 Credit Facility | Minimum        
Debt Instrument [Line Items]        
Percentage of commitment fees payable on undrawn amount   0.15%    
The 2018 Credit Facility | Minimum | LIBOR Rate        
Debt Instrument [Line Items]        
Debt instrument interest rate percentage   1.00%    
The 2018 Credit Facility | Minimum | Base Rate        
Debt Instrument [Line Items]        
Debt instrument interest rate percentage   0.00%    
The 2018 Credit Facility | Maximum        
Debt Instrument [Line Items]        
Percentage of commitment fees payable on undrawn amount   0.35%    
The 2018 Credit Facility | Maximum | LIBOR Rate        
Debt Instrument [Line Items]        
Debt instrument interest rate percentage   1.95%    
The 2018 Credit Facility | Maximum | Base Rate        
Debt Instrument [Line Items]        
Debt instrument interest rate percentage   0.95%    
1.50% Senior Subordinated Convertible Notes Due in October 2020        
Debt Instrument [Line Items]        
Carrying value of equity component     $ 374,993,000 $ 374,993,000
Convertible notes stated rate     1.50% 1.50%
Debt discount     $ 649,000 $ 12,078,000
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Summary of Convertible Debt (Detail)
$ / shares in Units, $ in Thousands
Oct. 15, 2020
USD ($)
d
$ / shares
shares
Sep. 30, 2020
USD ($)
May 31, 2020
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]        
Convertible Notes   $ 1,500,000    
Convertible Notes, net of unamortized discount and deferred offering costs   1,074,164   $ 486,238 [1]
Short-term convertible debt, net   374,290   361,882 [1]
Total convertible debt, net   1,448,454   848,120
Total fair value of fixed rate convertible debt   $ 1,482,737   $ 927,518
1.25% Senior Subordinated Convertible Notes Due in May 2027        
Debt Instrument [Line Items]        
Convertible notes stated rate   1.25%   1.25%
Convertible Notes   $ 600,000   $ 0
Convertible debt, unamortized discount   (12,792)   0
Convertible debt, Unamortized deferred offering costs   (709)   0
Convertible Notes, net of unamortized discount and deferred offering costs   586,499   0
Total fair value of fixed rate convertible debt   $ 590,010   $ 0
1.25% Senior Subordinated Convertible Notes Due in May 2027 | Senior Subordinated Notes        
Debt Instrument [Line Items]        
Convertible notes stated rate     1.25%  
Convertible debt, unamortized discount     $ (13,500)  
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares     $ 137.47  
0.599% Senior Subordinated Convertible Notes Due in August 2024        
Debt Instrument [Line Items]        
Convertible notes stated rate   0.599%   0.599%
Convertible Notes   $ 495,000   $ 495,000
Convertible debt, unamortized discount   (5,470)   (6,533)
Convertible debt, Unamortized deferred offering costs   (1,865)   (2,229)
Convertible Notes, net of unamortized discount and deferred offering costs   487,665   486,238
Total fair value of fixed rate convertible debt   $ 517,730   $ 521,839
1.50% Senior Subordinated Convertible Notes Due in October 2020        
Debt Instrument [Line Items]        
Convertible notes stated rate   1.50%   1.50%
Convertible Notes   $ 374,993   $ 374,993
Convertible debt, unamortized discount   (649)   (12,078)
Convertible debt, Unamortized deferred offering costs   (54)   (1,033)
Short-term convertible debt, net   374,290   361,882
Total fair value of fixed rate convertible debt   $ 374,997   $ 405,679
1.50% Senior Subordinated Convertible Notes Due in October 2020 | Subsequent Event        
Debt Instrument [Line Items]        
Repayments of convertible debt $ 375,000      
Shares issued (in shares) | shares 0      
Measurement period | d 25      
1.50% Senior Subordinated Convertible Notes Due in October 2020 | Subsequent Event | Senior Subordinated Notes        
Debt Instrument [Line Items]        
Debt instrument, convertible, conversion price, per share (in dollars per share) | $ / shares $ 94.15      
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Summary of Interest Expense on Convertible Debt (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Schedule Of Interest Expenses [Line Items]        
Total interest expense on convertible debt $ 9,597 $ 2,937 $ 24,560 $ 16,530
Convertible Senior Notes        
Schedule Of Interest Expenses [Line Items]        
Accretion of discount on convertible notes 4,696 4,005 13,201 11,860
Coupon interest expense 4,255 2,271 9,443 6,681
Amortization of debt issuance costs 535 508 1,565 1,522
Total interest expense on convertible debt $ 9,486 $ 6,784 $ 24,209 $ 20,063
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
INCOME (LOSS) FROM OPERATIONS (55,941) 4,010 8,075 (91,295)
Net product revenues        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues 460,741 450,900 1,368,816 1,224,458
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
INCOME (LOSS) FROM OPERATIONS 1,878 4,808 13,027 9,286
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Operating expenses (815) (1,388) (4,274) (1,885)
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Net product revenues | Forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues $ 2,693 $ 6,196 $ 17,301 $ 11,171
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance [1] $ 3,236,679 $ 2,960,954 $ 3,122,381 [2] $ 2,967,940
Other comprehensive income (loss) before      reclassifications (18,295) 24,492 3,798 42,684
Less: net gain (loss) reclassified from AOCI 1,878 4,808 13,027 9,286
Tax effect 508 (120) (550) (1,666)
Net current-period other comprehensive income (loss) (19,665) 19,564 (9,779) 31,732
Ending balance 4,053,893 3,074,405 4,053,893 3,074,405
Unrealized Gains (Losses) on Cash Flow Hedges        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 22,963 14,181 16,614 7,201
Other comprehensive income (loss) before      reclassifications (16,094) 23,973 1,404 35,431
Less: net gain (loss) reclassified from AOCI 1,878 4,808 13,027 9,286
Tax effect 0 0 0 0
Net current-period other comprehensive income (loss) (17,972) 19,165 (11,623) 26,145
Ending balance 4,991 33,346 4,991 33,346
Unrealized Gains (Losses) on Available for-Sale Debt Securities        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 7,087 3,271 3,565 (1,917)
Other comprehensive income (loss) before      reclassifications (2,201) 522 2,379 7,256
Less: net gain (loss) reclassified from AOCI 0 0 0
Tax effect 508 (120) (550) (1,666)
Net current-period other comprehensive income (loss) (1,693) 402 1,829 5,590
Ending balance 5,394 3,673 5,394 3,673
Other        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 0 (13) (15) (13)
Other comprehensive income (loss) before      reclassifications 0 (3) 15 (3)
Less: net gain (loss) reclassified from AOCI 0 0 0 0
Tax effect 0 0 0 0
Net current-period other comprehensive income (loss) 0 (3) 15 (3)
Ending balance 0 (16) 0 (16)
Total        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance [1] 30,050 17,439 20,164 5,271
Ending balance $ 10,385 $ 37,003 $ 10,385 $ 37,003
[1] The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the years ended December 31, 2019 and 2018, respectively, filed with the SEC on February 27, 2020.
[2] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Concentration Risk And Geographic Information [Line Items]    
Number of operating business segment | Segment 1  
Accounts receivable, net $ 411,712 $ 377,404 [1]
Customers    
Concentration Risk And Geographic Information [Line Items]    
Accounts receivable, net $ 106,500 $ 60,200
Credit Concentration Risk | Accounts Receivable | Customer One    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 33.00% 24.00%
Credit Concentration Risk | Accounts Receivable | Customer Two    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 15.00% 16.00%
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from External Customer [Line Items]        
Total revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
United States        
Revenue from External Customer [Line Items]        
Total revenues 252,948 201,874 729,672 562,217
Europe        
Revenue from External Customer [Line Items]        
Total revenues 121,158 125,485 375,453 369,585
Latin America        
Revenue from External Customer [Line Items]        
Total revenues 44,064 83,799 141,852 164,132
Rest of world        
Revenue from External Customer [Line Items]        
Total revenues $ 58,614 $ 49,939 $ 161,361 $ 153,671
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from External Customer [Line Items]        
Net product revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
Vimizim | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 147,891 163,466 401,789 411,953
Kuvan | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 123,993 120,524 368,604 340,771
Naglazyme | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 76,323 94,408 271,585 279,462
Palynziq | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 46,092 24,142 121,354 55,250
Brineura | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 25,455 19,840 75,223 46,815
Firdapse | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 0 5,668 1,316 16,262
Total net product revenues        
Revenue from External Customer [Line Items]        
Net product revenues 460,741 450,900 1,368,816 1,224,458
Total net product revenues | Marketed by Company        
Revenue from External Customer [Line Items]        
Net product revenues 419,754 428,048 1,239,871 1,150,513
Aldurazyme | Marketed by Genzyme        
Revenue from External Customer [Line Items]        
Net product revenues $ 40,987 $ 22,852 $ 128,945 $ 73,945
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Net product revenues $ 476,784 $ 461,097 $ 1,408,338 $ 1,249,605
United States        
Disaggregation of Revenue [Line Items]        
Net product revenues 252,948 201,874 729,672 562,217
Europe        
Disaggregation of Revenue [Line Items]        
Net product revenues 121,158 125,485 375,453 369,585
Latin America        
Disaggregation of Revenue [Line Items]        
Net product revenues 44,064 83,799 141,852 164,132
Rest of world        
Disaggregation of Revenue [Line Items]        
Net product revenues 58,614 49,939 161,361 153,671
Total net product revenues        
Disaggregation of Revenue [Line Items]        
Net product revenues 460,741 450,900 1,368,816 1,224,458
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim        
Disaggregation of Revenue [Line Items]        
Net product revenues 419,754 428,048 1,239,871 1,150,513
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | United States        
Disaggregation of Revenue [Line Items]        
Net product revenues 203,892 175,127 582,734 480,330
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe        
Disaggregation of Revenue [Line Items]        
Net product revenues 115,548 121,363 360,718 358,041
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America        
Disaggregation of Revenue [Line Items]        
Net product revenues 44,064 83,799 141,852 164,132
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world        
Disaggregation of Revenue [Line Items]        
Net product revenues 56,250 47,759 154,567 148,010
Marketed by Company | Total net product revenues        
Disaggregation of Revenue [Line Items]        
Net product revenues 419,754 428,048 1,239,871 1,150,513
Marketed by Genzyme | Aldurazyme        
Disaggregation of Revenue [Line Items]        
Net product revenues $ 40,987 $ 22,852 $ 128,945 $ 73,945
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) - Customer Concentration Risk - Net Product Revenue
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Concentration Risk [Line Items]        
Concentration risk, percentage 42.00% 51.00% 44.00% 46.00%
Customer A        
Concentration Risk [Line Items]        
Concentration risk, percentage 16.00% 16.00% 15.00% 17.00%
Customer B        
Concentration Risk [Line Items]        
Concentration risk, percentage 14.00% 13.00% 14.00% 12.00%
Customer C        
Concentration Risk [Line Items]        
Concentration risk, percentage 11.00% 10.00% 12.00% 11.00%
Customer D        
Concentration Risk [Line Items]        
Concentration risk, percentage 1.00% 12.00% 3.00% 6.00%
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation - Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 50,169 $ 39,173 $ 142,125 $ 121,763
Cost of sales        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 10,342 4,093 20,381 12,629
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 15,705 14,261 45,333 43,037
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 24,122 $ 20,819 $ 76,411 $ 66,097
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Stock Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense capitalized to inventory   $ 4.9 $ 5.1 $ 14.9 $ 13.2
Restricted Stock Unit Awards With Market Conditions          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Granted restricted stock units (in shares) 126,710        
Award vesting service period 3 years        
Base percentage of annual target ceiling 100.00%        
Weighted-average fair value per RSU granted (in dollars per share) $ 112.12        
Restricted Stock Unit Awards With Market Conditions | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 0.00%        
Percentage of Annual TSR multiplier on absolute basis 50.00%        
Restricted Stock Unit Awards With Market Conditions | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 200.00%        
Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Granted restricted stock units (in shares) 63,400        
Award vesting service period 3 years        
Weighted-average fair value per RSU granted (in dollars per share) $ 73.82        
Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 50.00%        
Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 200.00%        
Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Granted restricted stock units (in shares) 63,400        
Award vesting service period 3 years        
Weighted-average fair value per RSU granted (in dollars per share) $ 73.82        
Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 50.00%        
Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Annual percentage of shares earned, performance metric 200.00%        
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.20.2
INCOME TAXES (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
 [1]
Income Tax Contingency [Line Items]    
Deferred tax assets $ 1,396,547 $ 549,422
IRELAND    
Income Tax Contingency [Line Items]    
Deferred tax assets $ 835,100  
[1] December 31, 2019 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020.
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Numerator:        
Net Income (Loss), basic $ 784,803 $ 55,036 $ 837,001 $ (38,872)
Add: Interest on convertible notes 7,070 937 18,333 0
Net Income (Loss), diluted $ 791,873 $ 55,973 $ 855,334 $ (38,872)
Denominator:        
Weighted average number of shares outstanding, basic 181,142 179,289 180,592 178,873
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Weighted-average common shares outstanding, diluted 197,674 185,924 194,959 178,873
Net Income (Loss) per common share, basic (in dollars per share) $ 4.33 $ 0.31 $ 4.63 $ (0.22)
Net Income (Loss) per common share, diluted (in dollars per share) $ 4.01 $ 0.30 $ 4.39 $ (0.22)
Options to purchase common stock        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 1,731 1,560 1,728 0
Common stock issuable under the 2020 notes        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 3,983 0 3,983 0
Common stock issuable under the 2024 notes        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 3,970 3,970 3,970 0
Common stock issuable under the 2027 Notes        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 4,365 0 2,373 0
Unvested restricted stock units        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 1,926 669 1,765 0
Common stock potentially issuable for ESPP purchases        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 346 231 337 0
Common stock held by the NQDC        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 211 205 211 0
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 8,265 13,394 8,439 20,028
Options to purchase common stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 5,172 5,829 5,175 7,388
Common stock issuable under the 2020 notes        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 3,983 0 3,983
Common stock issuable under the 2024 notes        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 0 0 3,970
Unvested RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 2,900 3,360 3,060 4,029
Common stock potentially issuable for ESPP purchases        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 193 222 204 453
Common stock held by the NQDC        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 0 0 205
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.20.2
NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail)
Sep. 30, 2020
$ / shares
Convertible Notes due 2020  
Earnings Per Share [Line Items]  
Debt instrument, convertible, conversion price, per share (in dollars per share) $ 94.15
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2020
Sep. 30, 2020
Commitments And Contingencies [Line Items]    
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   $ 622.4
Contingent liabilities   54.1
Clinical and Post Marketing Services    
Commitments And Contingencies [Line Items]    
Purchase commitments and other minimum contractual obligations   150.3
Third Party    
Commitments And Contingencies [Line Items]    
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   70.3
Early Stage Development Program | Third Party    
Commitments And Contingencies [Line Items]    
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones $ 235.0  
Programs No Longer Being Developed | Third Party    
Commitments And Contingencies [Line Items]    
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones   $ 236.0
EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 417 388 1 true 105 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.bmrn.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - NATURE OF OPERATIONS Sheet http://www.bmrn.com/role/NATUREOFOPERATIONS NATURE OF OPERATIONS Notes 7 false false R8.htm 2102102 - Disclosure - BASIS OF PRESENTATION Sheet http://www.bmrn.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 8 false false R9.htm 2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2105104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 10 false false R11.htm 2106105 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 11 false false R12.htm 2110106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 12 false false R13.htm 2114107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 2118108 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION Notes 14 false false R15.htm 2122109 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 2126110 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Notes 16 false false R17.htm 2133111 - Disclosure - LEASES Sheet http://www.bmrn.com/role/LEASES LEASES Notes 17 false false R18.htm 2140112 - Disclosure - DEBT Sheet http://www.bmrn.com/role/DEBT DEBT Notes 18 false false R19.htm 2145113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 19 false false R20.htm 2149114 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Notes 20 false false R21.htm 2156115 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.bmrn.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 21 false false R22.htm 2160116 - Disclosure - INCOME TAXES Sheet http://www.bmrn.com/role/INCOMETAXES INCOME TAXES Notes 22 false false R23.htm 2162117 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE NET INCOME (LOSS) PER COMMON SHARE Notes 23 false false R24.htm 2167118 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 2203201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 25 false false R26.htm 2307301 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.bmrn.com/role/FINANCIALINSTRUMENTS 26 false false R27.htm 2311302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS 27 false false R28.htm 2315303 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT 28 false false R29.htm 2319304 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Sheet http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Tables http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION 29 false false R30.htm 2323305 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS 30 false false R31.htm 2327306 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Tables http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES 31 false false R32.htm 2334307 - Disclosure - LEASES (Tables) Sheet http://www.bmrn.com/role/LEASESTables LEASES (Tables) Tables http://www.bmrn.com/role/LEASES 32 false false R33.htm 2341308 - Disclosure - DEBT (Tables) Sheet http://www.bmrn.com/role/DEBTTables DEBT (Tables) Tables http://www.bmrn.com/role/DEBT 33 false false R34.htm 2346309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME 34 false false R35.htm 2350310 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Tables http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION 35 false false R36.htm 2357311 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.bmrn.com/role/STOCKBASEDCOMPENSATION 36 false false R37.htm 2363312 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables NET INCOME (LOSS) PER COMMON SHARE (Tables) Tables http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE 37 false false R38.htm 2408401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Sheet http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Details 38 false false R39.htm 2409402 - Disclosure - Financial Instruments - Additional Information (Detail) Sheet http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail Financial Instruments - Additional Information (Detail) Details 39 false false R40.htm 2412403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail) Details 40 false false R41.htm 2413404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 41 false false R42.htm 2416405 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) Sheet http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) Details 42 false false R43.htm 2417406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details) Sheet http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetails PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details) Details 43 false false R44.htm 2420407 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Details 44 false false R45.htm 2421408 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) Details 45 false false R46.htm 2424409 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) Sheet http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) Details 46 false false R47.htm 2425410 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) Sheet http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) Details 47 false false R48.htm 2428411 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail Derivative Instruments and Hedging Strategies - Additional Information (Detail) Details 48 false false R49.htm 2429412 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) Details 49 false false R50.htm 2430413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) Details 50 false false R51.htm 2431414 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) Details 51 false false R52.htm 2432415 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) Details 52 false false R53.htm 2435416 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail Leases - Schedule of ROU Assets and Lease Liabilities (Detail) Details 53 false false R54.htm 2436417 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail Leases - Schedule of Maturities of Lease Liabilities (Detail) Details 54 false false R55.htm 2437418 - Disclosure - Leases - Schedule of Lease Cost (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail Leases - Schedule of Lease Cost (Detail) Details 55 false false R56.htm 2438419 - Disclosure - Leases - Schedule of Other Information (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail Leases - Schedule of Other Information (Detail) Details 56 false false R57.htm 2439420 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail Leases - Schedule of Supplemental Cash Flow Information (Detail) Details 57 false false R58.htm 2442421 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.bmrn.com/role/DebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 58 false false R59.htm 2443422 - Disclosure - Debt - Summary of Convertible Debt (Detail) Sheet http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail Debt - Summary of Convertible Debt (Detail) Details 59 false false R60.htm 2444423 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail) Sheet http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail Debt - Summary of Interest Expense on Convertible Debt (Detail) Details 60 false false R61.htm 2447424 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Details 61 false false R62.htm 2448425 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Details 62 false false R63.htm 2451426 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) Details 63 false false R64.htm 2452427 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Details 64 false false R65.htm 2453428 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) Details 65 false false R66.htm 2454429 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Details 66 false false R67.htm 2455430 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Details 67 false false R68.htm 2458431 - Disclosure - Stock-Based Compensation - Expense (Detail) Sheet http://www.bmrn.com/role/StockBasedCompensationExpenseDetail Stock-Based Compensation - Expense (Detail) Details 68 false false R69.htm 2459432 - Disclosure - Stock Based Compensation - Additional Information (Detail) Sheet http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail Stock Based Compensation - Additional Information (Detail) Details 69 false false R70.htm 2461433 - Disclosure - INCOME TAXES (Details) Sheet http://www.bmrn.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.bmrn.com/role/INCOMETAXES 70 false false R71.htm 2464434 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 71 false false R72.htm 2465435 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 72 false false R73.htm 2466436 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) Sheet http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail) Details http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables 73 false false R74.htm 2468437 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 74 false false All Reports Book All Reports bmrn-20200930.htm bmrn-20200930.xsd bmrn-20200930_cal.xml bmrn-20200930_def.xml bmrn-20200930_lab.xml bmrn-20200930_pre.xml exhibit311-30sep20x10q.htm exhibit312-30sep20x10q.htm exhibit321-30sep20x10q.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bmrn-20200930.htm": { "axisCustom": 0, "axisStandard": 33, "contextCount": 417, "dts": { "calculationLink": { "local": [ "bmrn-20200930_cal.xml" ] }, "definitionLink": { "local": [ "bmrn-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bmrn-20200930.htm" ] }, "labelLink": { "local": [ "bmrn-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bmrn-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bmrn-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 600, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 13, "http://www.bmrn.com/20200930": 2, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 20 }, "keyCustom": 43, "keyStandard": 345, "memberCustom": 40, "memberStandard": 64, "nsprefix": "bmrn", "nsuri": "http://www.bmrn.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.bmrn.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106105 - Disclosure - FINANCIAL INSTRUMENTS", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114107 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118108 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122109 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126110 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133111 - Disclosure - LEASES", "role": "http://www.bmrn.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140112 - Disclosure - DEBT", "role": "http://www.bmrn.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149114 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156115 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160116 - Disclosure - INCOME TAXES", "role": "http://www.bmrn.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162117 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE", "shortName": "NET INCOME (LOSS) PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2167118 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - BASIS OF PRESENTATION (Policies)", "role": "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "role": "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334307 - Disclosure - LEASES (Tables)", "role": "http://www.bmrn.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - DEBT (Tables)", "role": "http://www.bmrn.com/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357311 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2363312 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE (Tables)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables", "shortName": "NET INCOME (LOSS) PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "role": "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "shortName": "Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i80ddf7505a48495c82fb1deef8c8721a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Financial Instruments - Additional Information (Detail)", "role": "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail", "shortName": "Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i80ddf7505a48495c82fb1deef8c8721a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfOtherAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "role": "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i5b35fa03b67b45d8b17263f8c9093234_D20190401-20190630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail)", "role": "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail", "shortName": "Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417406 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details)", "role": "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420407 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail)", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i7e31e441d99e4c25a6be89e741a2107e_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421408 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i91603aa7acf54adc8057aa85dfbbf550_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424409 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)", "role": "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i91603aa7acf54adc8057aa85dfbbf550_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ie184dc425e944f80b72aaaab7a9bbed0_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425410 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)", "role": "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail", "shortName": "Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ie184dc425e944f80b72aaaab7a9bbed0_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428411 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "shortName": "Derivative Instruments and Hedging Strategies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i2090fb46ec0d47f19bad068f1f5ca4d7_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429412 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i2090fb46ec0d47f19bad068f1f5ca4d7_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0f5c91fd577347158d8d30ef21f7e193_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0f5c91fd577347158d8d30ef21f7e193_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i549cb7dda0d2411bb40ffe95076e16fd_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430413 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i549cb7dda0d2411bb40ffe95076e16fd_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "shortName": "Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i5f3e6c756bbb47098c06f08d7786cf79_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of ROU Assets and Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436417 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437418 - Disclosure - Leases - Schedule of Lease Cost (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail", "shortName": "Leases - Schedule of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438419 - Disclosure - Leases - Schedule of Other Information (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail", "shortName": "Leases - Schedule of Other Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail", "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442421 - Disclosure - Debt - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ic042cbe63d594a9b87590a0c34f6a66c_I20200531", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443422 - Disclosure - Debt - Summary of Convertible Debt (Detail)", "role": "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "shortName": "Debt - Summary of Convertible Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444423 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail)", "role": "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail", "shortName": "Debt - Summary of Interest Expense on Convertible Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ia3b4f61fea9c4318bf496d0b25bd45e9_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447424 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "shortName": "Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i31b857c7fcbd4f3ab2e9276bf848c152_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ib83eb42a76de474390c4176b809ea237_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "shortName": "Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451426 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452427 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453428 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "ia8a450fe232d4f9989077c1319322fe0_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i6e7ab25d6d834704b91cadd116b9ce20_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i200339a7c4c44f22b201081d0108abcf_D20200701-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455430 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i200339a7c4c44f22b201081d0108abcf_D20200701-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458431 - Disclosure - Stock-Based Compensation - Expense (Detail)", "role": "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459432 - Disclosure - Stock Based Compensation - Additional Information (Detail)", "role": "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - NATURE OF OPERATIONS", "role": "http://www.bmrn.com/role/NATUREOFOPERATIONS", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i3a04fd8a218840abb8335add44a265c2_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461433 - Disclosure - INCOME TAXES (Details)", "role": "http://www.bmrn.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "if87f86f2f229480e9994985dbd5c6c67_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464434 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Schedule of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465435 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i0a23484c72e340f1ad5c18fa4a756277_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i79dc56076cca4e9687ef5f611ab36112_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466436 - Disclosure - NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail)", "role": "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail", "shortName": "NET INCOME (LOSS) PER COMMON SHARE - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i79dc56076cca4e9687ef5f611ab36112_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "bmrn:ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468437 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "bmrn:ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - BASIS OF PRESENTATION", "role": "http://www.bmrn.com/role/BASISOFPRESENTATION", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-20200930.htm", "contextRef": "i266dccab895f456590672e7c98ad4b52_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 105, "tag": { "bmrn_A125SeniorSubordinatedConvertibleNotesDueInMay2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.25% Senior Subordinated Convertible Notes Due in May 2027", "label": "1.25% Senior Subordinated Convertible Notes Due in May 2027 [Member]", "terseLabel": "1.25% Senior Subordinated Convertible Notes Due in May 2027" } } }, "localname": "A125SeniorSubordinatedConvertibleNotesDueInMay2027Member", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "bmrn_AccruedGovernmentAndOtherRebates": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Government And Other Rebates", "label": "Accrued Government And Other Rebates", "terseLabel": "Accrued rebates payable" } } }, "localname": "AccruedGovernmentAndOtherRebates", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_AccruedLeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued lease liabilities current.", "label": "Accrued Lease Liabilities Current", "terseLabel": "Deferred revenue" } } }, "localname": "AccruedLeaseLiabilitiesCurrent", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_AccumulatedGainLossFromOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated gain (loss) from other.", "label": "Accumulated Gain Loss From Other [Member]", "terseLabel": "Other" } } }, "localname": "AccumulatedGainLossFromOtherMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "label": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "terseLabel": "Accounting impact of NQDC Plan change" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "negatedTerseLabel": "Common stock held by the NQDC" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "label": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "terseLabel": "Percentage of Annual TSR multiplier on absolute basis" } } }, "localname": "AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities abstract.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ClinicalAndPostMarketingServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical and post marketing services.", "label": "Clinical And Post Marketing Services [Member]", "terseLabel": "Clinical and Post Marketing Services" } } }, "localname": "ClinicalAndPostMarketingServicesMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock issuable for employee Stock Purchase Plan [Member]", "label": "Common Stock Issuable To Employee Stock Purchase Plan [Member]", "terseLabel": "Common stock potentially issuable for ESPP purchases" } } }, "localname": "CommonStockIssuableToEmployeeStockPurchasePlanMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Abstract]", "terseLabel": "Concentration Risk And Geographic Information [Abstract]" } } }, "localname": "ConcentrationRiskAndGeographicInformationAbstract", "nsuri": "http://www.bmrn.com/20200930", "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Line Items]", "terseLabel": "Concentration Risk And Geographic Information [Line Items]" } } }, "localname": "ConcentrationRiskAndGeographicInformationLineItems", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Table]", "terseLabel": "Concentration Risk And Geographic Information [Table]" } } }, "localname": "ConcentrationRiskAndGeographicInformationTable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and segment reporting disclosure.", "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]", "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION" } } }, "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION" ], "xbrltype": "textBlockItemType" }, "bmrn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentLiabilityAccrualSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Liability Accrual Sales And Licensing Milestones", "label": "Contingent Liability Accrual Sales And Licensing Milestones", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilityAccrualSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Payment", "label": "Contingent Payment [Member]", "terseLabel": "Contingent Payment" } } }, "localname": "ContingentPaymentMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ConvertibleSeniorNotesDueTwentyTwentyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible senior notes due twenty twenty.", "label": "Convertible Senior Notes Due Twenty Twenty [Member]", "terseLabel": "Convertible Notes due 2020", "verboseLabel": "Common stock issuable under the 2020 notes" } } }, "localname": "ConvertibleSeniorNotesDueTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Convertible Senior Notes Due Two Thousand Twenty Four [Member]", "verboseLabel": "Common stock issuable under the 2024 notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Senior Notes Due Two Thousand Twenty Seven", "label": "Convertible Senior Notes Due Two Thousand Twenty Seven [Member]", "terseLabel": "Common stock issuable under the 2027 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandTwentySevenMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "bmrn_CustomerFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 4", "label": "Customer Four [Member]", "terseLabel": "Customer D" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 1", "label": "Customer One [Member]", "terseLabel": "Customer A", "verboseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 3", "label": "Customer Three [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 2", "label": "Customer Two [Member]", "terseLabel": "Customer B", "verboseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customers.", "label": "Customers [Member]", "terseLabel": "Customers" } } }, "localname": "CustomersMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_DebtInstrumentConvertibleWeightedAverageMeasurementPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Weighted Average Measurement Period", "label": "Debt Instrument, Convertible, Weighted Average Measurement Period", "terseLabel": "Measurement period" } } }, "localname": "DebtInstrumentConvertibleWeightedAverageMeasurementPeriod", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "integerItemType" }, "bmrn_DepreciationExpenseCapitalizedIntoInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation expense capitalized into inventory during the reporting period.", "label": "Depreciation Expense Capitalized Into Inventory", "terseLabel": "Depreciation capitalized into inventory" } } }, "localname": "DepreciationExpenseCapitalizedIntoInventory", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "bmrn_EarlyStageDevelopmentProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Early Stage Development Program", "label": "Early Stage Development Program [Member]", "terseLabel": "Early Stage Development Program" } } }, "localname": "EarlyStageDevelopmentProgramMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share line Items.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement", "verboseLabel": "Foreign exchange remeasurement of Euro denominated contingent acquisition consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liability, to be Paid, After Year Four", "label": "Finance Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FirdapseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Firdapse", "label": "Firdapse [Member]", "terseLabel": "Firdapse" } } }, "localname": "FirdapseMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign government and other debt securities.", "label": "Foreign Government And Other Debt Securities [Member]", "terseLabel": "Foreign and other" } } }, "localname": "ForeignGovernmentAndOtherDebtSecuritiesMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "bmrn_IntangibleAssetAmortizationAndContingentConsideration": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.", "label": "Intangible Asset Amortization And Contingent Consideration", "terseLabel": "Intangible asset amortization and contingent consideration" } } }, "localname": "IntangibleAssetAmortizationAndContingentConsideration", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "bmrn_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease liabilities.", "label": "Lease Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LeaseRightOfUseAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease right of use assets.", "label": "Lease Right Of Use Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "LeaseRightOfUseAssetsAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee operating and finance leases other information.", "label": "Lessee Operating And Finance Leases Other Information Table [Text Block]", "terseLabel": "Schedule of Other Information" } } }, "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "bmrn_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_LongTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term marketable securities maturity period.", "label": "Long Term Marketable Securities Maturity Period", "terseLabel": "Long term marketable securities maturity period" } } }, "localname": "LongTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_MaturityOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturity of lease liabilities.", "label": "Maturity Of Lease Liabilities [Abstract]", "terseLabel": "Maturity of Lease Liabilities" } } }, "localname": "MaturityOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nonqualified deferred compensation plan assets.", "label": "Nonqualified Deferred Compensation Plan Assets [Member]", "terseLabel": "NQDC Plan assets" } } }, "localname": "NonqualifiedDeferredCompensationPlanAssetsMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nonqualified deferred compensation plan liability.", "label": "Nonqualified Deferred Compensation Plan Liability [Member]", "terseLabel": "NQDC Plan liability" } } }, "localname": "NonqualifiedDeferredCompensationPlanLiabilityMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One point five zero percent senior subordinated convertible notes due in October twenty twenty.", "label": "One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member]", "terseLabel": "1.50% Senior Subordinated Convertible Notes Due in October 2020" } } }, "localname": "OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liabilities payments due.", "label": "Operating And Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Total" } } }, "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_OperatingAndFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability.", "label": "Operating And Finance Lease Liability", "totalLabel": "Total lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiability", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail", "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due.", "label": "Operating And Finance Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due after year five.", "label": "Operating And Finance Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year four.", "label": "Operating And Finance Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating And Finance Lease Liability Payments Due Year One", "label": "Operating And Finance Lease Liability Payments Due Year One", "terseLabel": "2021" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year three.", "label": "Operating And Finance Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 6.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year two.", "label": "Operating And Finance Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 5.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments remainder of fiscal year.", "label": "Operating And Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability undiscounted excess amount.", "label": "Operating And Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease right of use asset.", "label": "Operating And Finance Lease Right Of Use Asset", "totalLabel": "Total ROU assets" } } }, "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingLeasesNotYetCommencedExpectedToCommenceByEndOfFiscalYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Leases, Not Yet Commenced, Expected To Commence By End Of Fiscal Year", "label": "Operating Leases, Not Yet Commenced, Expected To Commence By End Of Fiscal Year", "terseLabel": "Operating leases expected to commence in remainder of year" } } }, "localname": "OperatingLeasesNotYetCommencedExpectedToCommenceByEndOfFiscalYear", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "integerItemType" }, "bmrn_OtherAssetsCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other assets current fair value disclosure.", "label": "Other Assets Current Fair Value Disclosure", "verboseLabel": "Fair value of other current assets" } } }, "localname": "OtherAssetsCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherAssetsNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other assets noncurrent fair value disclosure.", "label": "Other Assets Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current assets" } } }, "localname": "OtherAssetsNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherInformationLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other information lease liability.", "label": "Other Information Lease Liability [Abstract]", "terseLabel": "Other Information" } } }, "localname": "OtherInformationLeaseLiabilityAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other liabilities current fair value disclosure.", "label": "Other Liabilities Current Fair Value Disclosure", "verboseLabel": "Fair value of other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other liabilities noncurrent fair value disclosure.", "label": "Other Liabilities Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable", "label": "Payments To Acquire Debt Securities, Available-For-Sale, Non-Marketable", "negatedTerseLabel": "Investment in convertible note" } } }, "localname": "PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_PreLaunchValoctocogeneRoxaparvovecMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "label": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "terseLabel": "Pre-Launch Valoctocogene Roxaparvovec" } } }, "localname": "PreLaunchValoctocogeneRoxaparvovecMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProceedsFromSaleOfNonfinancialAssets": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Sale Of Nonfinancial Assets", "label": "Proceeds From Sale Of Nonfinancial Assets", "terseLabel": "Proceeds from sale of nonfinancial assets" } } }, "localname": "ProceedsFromSaleOfNonfinancialAssets", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_ProductFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 5 [Member]", "label": "Product Five [Member]", "terseLabel": "Firdapse" } } }, "localname": "ProductFiveMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 4 [Member]", "label": "Product Four [Member]", "terseLabel": "Vimizim" } } }, "localname": "ProductFourMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 1 [Member]", "label": "Product One [Member]", "terseLabel": "Aldurazyme" } } }, "localname": "ProductOneMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 7 [Member]", "label": "Product Seven [Member]", "terseLabel": "Palynziq" } } }, "localname": "ProductSevenMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product six.", "label": "Product Six [Member]", "terseLabel": "Brineura" } } }, "localname": "ProductSixMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 3 [Member]", "label": "Product Three [Member]", "terseLabel": "Kuvan" } } }, "localname": "ProductThreeMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 2 [Member]", "label": "Product Two [Member]", "terseLabel": "Naglazyme" } } }, "localname": "ProductTwoMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductsExcludingProductOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Products excluding product one.", "label": "Products Excluding Product One [Member]", "terseLabel": "Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim" } } }, "localname": "ProductsExcludingProductOneMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProgramsNoLongerBeingDevelopedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Programs No Longer Being Developed.", "label": "Programs No Longer Being Developed [Member]", "terseLabel": "Programs No Longer Being Developed" } } }, "localname": "ProgramsNoLongerBeingDevelopedMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rest of world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of world" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestrictedInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted investments.", "label": "Restricted Investments [Member]", "terseLabel": "Restricted Investments" } } }, "localname": "RestrictedInvestmentsMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right of use assets obtained in exchange for lease obligations abstract.", "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_RoyaltyAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty and other.", "label": "Royalty And Other [Member]", "terseLabel": "Royalty and other revenues" } } }, "localname": "RoyaltyAndOtherMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "domainItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]", "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfInterestExpensesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of interest expenses.", "label": "Schedule Of Interest Expenses [Line Items]", "terseLabel": "Schedule Of Interest Expenses [Line Items]" } } }, "localname": "ScheduleOfInterestExpensesLineItems", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfInterestExpensesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of interest expenses table.", "label": "Schedule Of Interest Expenses [Table]", "terseLabel": "Schedule Of Interest Expenses [Table]" } } }, "localname": "ScheduleOfInterestExpensesTable", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Lessee lease assets and liabilities.", "label": "Schedule Of Lessee Lease Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of ROU Assets and Lease Liabilities" } } }, "localname": "ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior unsecured revolving two thousand eighteen credit facility.", "label": "Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]", "terseLabel": "The 2018 Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "terseLabel": "Annual percentage of shares earned, performance metric" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "label": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "terseLabel": "Base percentage of annual target ceiling" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term marketable securities maturity period.", "label": "Short Term Marketable Securities Maturity Period", "terseLabel": "Short term marketable securities maturity period" } } }, "localname": "ShortTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency", "verboseLabel": "Issuances under equity incentive plans, net of tax" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares", "terseLabel": "Issuances under equity incentive plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "bmrn_StrategicInvestmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Strategic investment.", "label": "Strategic Investment [Member]", "terseLabel": "Strategic Investment" } } }, "localname": "StrategicInvestmentMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets", "terseLabel": "Decrease in accounts payable and accrued liabilities related to fixed assets" } } }, "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets", "terseLabel": "Increase (decrease) in accounts payable and accrued liabilities related to intangible assets" } } }, "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bmrn_SupplementalCashFlowLeaseInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental cash flow lease information.", "label": "Supplemental Cash Flow Lease Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowLeaseInformationAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ThirdPartyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third party.", "label": "Third Party [Member]", "terseLabel": "Third Party" } } }, "localname": "ThirdPartyMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Conditions", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Market Conditions [Member]", "terseLabel": "Restricted Stock Unit Awards With Market Conditions" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithMarketConditionsMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target [Member]", "terseLabel": "Restricted Stock Unit Awards With Performance Conditions, Non-GAAP Income Target" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsNonGAAPIncomeTargetMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target", "label": "Two Thousand Twenty Base Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target [Member]", "terseLabel": "Restricted Stock Unit Awards With Performance Conditions, Strategic Goal Target" } } }, "localname": "TwoThousandTwentyBaseRestrictedStockUnitAwardsWithPerformanceConditionsStrategicGoalTargetMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate abstract.", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted average discount rate:" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term abstract.", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term (in years):" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.", "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]", "terseLabel": "0.599% Senior Subordinated Convertible Notes Due in August 2024" } } }, "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20200930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "IRELAND", "terseLabel": "IRELAND" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r514" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r516" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r120", "r129", "r203", "r291", "r292", "r293", "r312", "r313" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "verboseLabel": "Impact of change in accounting principles" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r120", "r129", "r203", "r291", "r292", "r293", "r312", "r313" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r120", "r129", "r203", "r291", "r292", "r293", "r312", "r313" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r187", "r250", "r254", "r468" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r274", "r276", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r465", "r469" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r274", "r276", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r465", "r469" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r187", "r250", "r254", "r468" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r183", "r250", "r252", "r426", "r464", "r466" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r183", "r250", "r252", "r426", "r464", "r466" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r264", "r274", "r276", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r465", "r469" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r264", "r274", "r276", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r465", "r469" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r184", "r185", "r250", "r253", "r467", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESDetails", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r184", "r185", "r250", "r253", "r467", "r497", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESDetails", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts\u00a0payable\u00a0and accrued\u00a0liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued operating expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r20", "r188", "r189" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premium (accretion of discount) on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r9", "r41" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r224" ], "calculation": { "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r62", "r71", "r336" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent", "verboseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r56", "r57", "r58", "r62", "r64" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Available for-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r60", "r61", "r62", "r453", "r474", "r477" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r383", "r384", "r385", "r386", "r387", "r389" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r62", "r64", "r117", "r118", "r119", "r337", "r470", "r471" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r117", "r118", "r119", "r291", "r292", "r293" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r277", "r279", "r297", "r298" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r279", "r287", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r84", "r105", "r392" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": { "order": 3.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of discount on convertible notes" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r79", "r105", "r394" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r105", "r394" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total number of potentially issuable shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r198", "r265" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r172", "r175", "r181", "r202", "r334", "r338", "r379", "r433", "r450" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Lease Classification" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r51", "r112", "r202", "r334", "r338", "r379" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r365" ], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Fair value of financial assets, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r196" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r197" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r194", "r206" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r191", "r195", "r206", "r438" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r193", "r206" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term Marketable Securities", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r193", "r206" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term Marketable Securities", "verboseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r280", "r289" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r346", "r351" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r273", "r275" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r273", "r275", "r327", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r104", "r331" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Non-cash changes in the fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r329", "r330" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r33", "r480", "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r33", "r107" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r100", "r107", "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r100", "r382" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Financing Activities, Lessee [Abstract]", "terseLabel": "Cash used in financing activities:" } } }, "localname": "CashFlowFinancingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash used in operating activities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r229", "r230", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockIssuedEmployeeStockTrust": { "auth_ref": [ "r263" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.", "label": "Common Stock Issued, Employee Stock Trust", "negatedLabel": "Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)" } } }, "localname": "CommonStockIssuedEmployeeStockTrust", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r117", "r118" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r239" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; 181,492,344 and 179,838,114 shares issued and outstanding, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r77", "r443", "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r76", "r86", "r442", "r459" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r160", "r161", "r187", "r376", "r377" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r160", "r161", "r187", "r376", "r377", "r479" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r160", "r161", "r187", "r376", "r377", "r479" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r160", "r161", "r187", "r376", "r377" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r158", "r160", "r161", "r162", "r376", "r378" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r160", "r161", "r187", "r376", "r377" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r247", "r248", "r251" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Lease liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r250", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r250", "r258" ], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r16", "r435", "r451" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Total convertible debt, net" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Short-term convertible debt, net", "totalLabel": "Short-term convertible debt, net" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Total fair value of fixed rate convertible debt" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Long-term convertible debt, net", "totalLabel": "Convertible Notes, net of unamortized discount and deferred offering costs" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of Convertible Debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r265", "r272", "r478" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r81", "r112", "r202", "r379" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r80" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Operating expenses as reported" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r159", "r187" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r434", "r435", "r449" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument interest rate percentage" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r236", "r435", "r449" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Convertible Notes", "verboseLabel": "Carrying value of equity component" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price, per share (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r44", "r240", "r241", "r243" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Debt instrument, conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r393", "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Convertible notes stated rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r114", "r240", "r242", "r243", "r244", "r392", "r393", "r395", "r448" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r392", "r395" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Convertible debt, unamortized discount", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r199", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of investments" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.", "label": "Deferred Compensation, Share-based Payments [Member]", "terseLabel": "Company Stock Held By NQDC" } } }, "localname": "DeferredCompensationShareBasedPaymentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r301", "r302" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r113", "r310", "r319", "r320", "r321" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r50", "r210" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "negatedLabel": "Convertible debt, Unamortized deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r105", "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r105", "r169" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r52", "r54", "r349", "r424" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative asset, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r52", "r54", "r349", "r424" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative liability, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gains (Losses) Recognized in Earnings" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r347", "r350", "r354", "r357" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r344", "r347", "r354", "r357", "r358", "r361", "r362" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Forward foreign currency exchange contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r341", "r343" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeRemainingMaturity1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Remaining Maturity", "terseLabel": "Maturity of derivatives" } } }, "localname": "DerivativeRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r340", "r342", "r343", "r344", "r345", "r352", "r354", "r359", "r360", "r362" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated As Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Total Net Product Revenues Based on Patient Location" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r221", "r227" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Cash payment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r273", "r275" ], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r78", "r127", "r128", "r129", "r130", "r131", "r138", "r141", "r147", "r148", "r149", "r153", "r154", "r444", "r461" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net Income (Loss) per common share, basic (in dollars per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r78", "r127", "r128", "r129", "r130", "r131", "r141", "r147", "r148", "r149", "r153", "r154", "r444", "r461" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Income (Loss) per common share, diluted (in dollars per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r382" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation expense" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation expense capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Manufacturing and laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r117", "r118", "r119", "r124", "r132", "r134", "r156", "r203", "r239", "r245", "r291", "r292", "r293", "r312", "r313", "r383", "r384", "r385", "r386", "r387", "r389", "r470", "r471", "r472" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Strategic investments fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r365", "r366", "r367", "r373" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r365", "r373" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r365", "r375" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r366", "r415", "r416", "r417" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r372", "r373" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r365", "r366", "r368", "r369", "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r265", "r266", "r271", "r272", "r366", "r415" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1:", "verboseLabel": "Quoted\u00a0Price\u00a0in Active Markets For Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r265", "r266", "r271", "r272", "r366", "r416" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2:", "verboseLabel": "Significant\u00a0Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r366", "r417" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Financial assets remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Contingent consideration at September 30, 2020", "periodStartLabel": "Contingent consideration at December 31, 2019", "terseLabel": "Liabilities remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredatFairValueonRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r415", "r416", "r417" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r372", "r374" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r399", "r404", "r412" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r401", "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r397", "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Financing, noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r400", "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r396" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r399", "r404", "r412" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r409", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r408", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r219" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r219", "r430" ], "calculation": { "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r106", "r380", "r381" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r265", "r355" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Forward\u00a0contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r105" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of nonfinancial assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "terseLabel": "Gain on sale of nonfinancial assets" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r105" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Gain on sale of nonfinancial assets", "terseLabel": "Gain (loss) on disposition of other assets" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r211", "r212", "r432" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r344", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r73", "r172", "r174", "r177", "r180", "r182", "r431", "r440", "r446", "r462" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r74", "r105", "r170", "r201", "r439", "r457" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in the loss of BioMarin/Genzyme LLC" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r273", "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r305", "r306", "r308", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r304", "r307", "r309", "r317", "r322", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r133", "r134", "r171", "r303", "r318", "r323", "r463" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r102", "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r143", "r144", "r149" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Effect of dilutive securities" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r215", "r217" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Net carrying value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r72", "r168", "r391", "r394", "r445" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Total interest expense on convertible debt" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r85" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Coupon interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Summary of Interest Expense on Debt" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r140", "r142", "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The after-tax amount of interest recognized in the period associated with any convertible debt.", "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "Add: Interest on convertible notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r99", "r101", "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r27", "r209" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r49" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r29", "r209" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r28", "r209" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r208" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-off, net of stock-based compensation" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r83", "r167" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r410", "r412" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseNotYetCommencedDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Not yet Commenced, Description [Abstract]", "terseLabel": "Additional leases not yet commenced (undiscounted):" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r112", "r176", "r202", "r335", "r338", "r339", "r379" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r112", "r202", "r379", "r437", "r455" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r112", "r202", "r335", "r338", "r339", "r379" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r365" ], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Fair value of financial liabilities, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r16", "r435", "r449" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Percentage of commitment fees payable on undrawn amount" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR Rate" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Purchase" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r234" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail", "http://www.bmrn.com/role/DebtSummaryofInterestExpenseonConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market instruments" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r157", "r163" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NATUREOFOPERATIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r100", "r103", "r106" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r65", "r68", "r75", "r106", "r112", "r123", "r127", "r128", "r129", "r130", "r133", "r134", "r145", "r172", "r174", "r177", "r180", "r182", "r202", "r379", "r441", "r458" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "NET INCOME (LOSS)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r127", "r128", "r129", "r130", "r138", "r139", "r146", "r149", "r172", "r174", "r177", "r180", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss), basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r140", "r146", "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss), diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r121", "r122", "r125", "r126", "r135", "r136", "r137", "r204", "r205", "r259", "r260", "r261", "r262", "r294", "r314", "r315", "r316", "r427", "r428", "r429", "r473", "r474", "r475", "r476", "r477" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "verboseLabel": "Number of operating business segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r62" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before \u00a0\u00a0\u00a0\u00a0 reclassifications" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expenses as reported", "verboseLabel": "Operating Expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTerseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r172", "r174", "r177", "r180", "r182" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "INCOME (LOSS) FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r405", "r412" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r397" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r402", "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r396" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofROUAssetsandLeaseLiabilitiesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r409", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r408", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r60", "r63", "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Cash Flow Hedging Gains (Losses) Reclassified into Earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r66", "r69", "r71", "r76", "r239", "r383", "r388", "r389", "r442", "r459" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r66", "r69", "r332", "r333", "r336" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Net current-period other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r332", "r333", "r336" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Tax effect" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r346", "r361" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other\u00a0current\u00a0assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other\u00a0long-term\u00a0liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesFairValueCarryingAmountofDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of contingent acquisition consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r88", "r91", "r115" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r95" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r87", "r89", "r192" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r90" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r93" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible senior subordinated note offering, net" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from issuance of notes" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r92", "r290" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercises of awards under equity incentive plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r94", "r98", "r115" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Principal repayments of financing leases" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities and sales of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product revenues", "verboseLabel": "Total net product revenues" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r225" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r228", "r498", "r499", "r500" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r223" ], "calculation": { "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r225", "r456" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r225" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r223" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofInventoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r17", "r436", "r452" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase commitments and other minimum contractual obligations" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r62" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Less: net gain (loss) reclassified from AOCI" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Amount Reclassified from AOCI Gain (Loss)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "terseLabel": "Repayments of convertible debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r300", "r510" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock units", "verboseLabel": "Unvested RSUs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r245", "r295", "r454", "r473", "r477" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r117", "r118", "r119", "r124", "r132", "r134", "r203", "r291", "r292", "r293", "r312", "r313", "r470", "r472" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r165", "r166", "r173", "r178", "r179", "r183", "r184", "r187", "r249", "r250", "r426" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net product revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r407", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r407", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleofSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r9", "r37" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Value added taxes payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleofAccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Marketed by Company" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Marketed by Genzyme" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalNetProductRevenuesBasedonPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r160", "r187" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Product Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r62", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r347", "r354", "r358" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value Carrying Amount of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r279", "r286", "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofNetProductRevenuesbyProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsandGeographicInformationDisaggregatesofTotalRevenuesfromExternalCustomersandCollaborativePartnersbyGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Net Product Revenues by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r216", "r218" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Summary of Derivatives Designated as Hedging Instruments Outstanding" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r30", "r31", "r32" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r35", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r280", "r289" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r158", "r160", "r161", "r162", "r376", "r378" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Net Product Revenue Concentrations Attributed to Largest Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorSubordinatedNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A senior subordinated note is a bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior subordinated debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors. However senior subordinated notes are junior to Senior Notes and Senior bond holders.", "label": "Senior Subordinated Notes [Member]", "terseLabel": "Senior Subordinated Notes" } } }, "localname": "SeniorSubordinatedNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r104" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award vesting service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per RSU granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Granted restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r278", "r282" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesDesignatedasHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofDerivativesNotDesignatedasHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r117", "r118", "r119", "r124", "r132", "r134", "r156", "r203", "r239", "r245", "r291", "r292", "r293", "r312", "r313", "r383", "r384", "r385", "r386", "r387", "r389", "r470", "r471", "r472" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedoutofAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DerivativeInstrumentsandHedgingStrategiesSummaryofImpactofGainsandLossesfromDerivativesDesignatedasHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r117", "r118", "r119", "r156", "r426" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Common stock held by the NQDC" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleOfAntiDilutiveCommonStockExcludedFromComputationofDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r239", "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Retirement of treasury stock" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r239", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r239", "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r24", "r25", "r112", "r190", "r202", "r379" ], "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryofChangesinAccumulatedBalancesofAOCIIncludingCurrentPeriodOtherComprehensiveIncomeLossandReclassificationsOutofAOCIDetail", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r390", "r414" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r390", "r414" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r390", "r414" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryofConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/SUPPLEMENTALBALANCESHEETINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r246" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r265", "r447" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r140", "r149" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "verboseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r138", "r149" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding, basic", "verboseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bmrn.com/role/NETINCOMELOSSPERCOMMONSHAREScheduleofEarningsPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=75028277&loc=d3e19833-108362" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r513": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r514": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r515": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r516": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" } }, "version": "2.1" } ZIP 92 0001048477-20-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001048477-20-000029-xbrl.zip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Ó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end